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Abstract 
 
E-Adrenoceptors (E-ARs) mediate vasodilatation by activating various 
mechanisms that collectively contribute to vascular smooth muscle (VSM) 
relaxation. It has been shown that E2-AR stimulation in cultured cells 
results in activation of extracellular signal-regulated kinase (ERK). As the 
functional relevance of this was not known, the aim of the current 
investigation was determine the role of ERK in E-AR-mediated 
vasodilatation.  
 
Isoprenaline-induced relaxation of porcine coronary artery (PCA) segments 
pre-contracted with the thromboxane mimetic U46619 was significantly 
enhanced by inhibition of ERK activation. Relaxations to the E2-AR agonist 
salbutamol, but not those to the E1-AR agonist xamoterol or the adenylyl 
cyclase activator forskolin, were also enhanced. The intermediate-
conductance Ca2+-activated K+ (IKCa) channel blocker TRAM-34 prevented 
the enhancement of E2-AR-mediated responses.  
 
Taken together, the data indicate that ERK inhibits E2-AR-mediated 
vasodilatation by interacting with a cyclic ¶ ¶-adenosine monophosphate-
independent relaxation pathway involving K+ channels. This may occur 
through a direct regulatory action on the IKCa channel via phosphorylation.  
 
Furthermore, the finding that increased ERK activation in a rat model of 
Type II diabetes was associated with significantly impaired E-AR-mediated 
vasodilatation raises the possibility that ERK may represent a promising 
therapeutic target in the treatment of disease states characterised by 
abnormal vascular function.  
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1.1. VASODILATATION IN HEALTH AND DISEASE 
 
The regulation of vascular tone is a complex process involving the 
opposing actions of vasodilators and vasoconstrictors. Referring to the 
widening of blood vessels, vasodilatation is associated with increased blood 
flow and reduced vascular resistance, and occurs as a result of vascular 
smooth muscle (VSM) relaxation. VSM contraction causes vasoconstriction, 
which, in contrast, is associated with increased resistance and reduced 
blood flow.  
 
Factors known to regulate blood flow are diverse and include endogenous 
vasoactive substances, ischaemia and metabolic rate. Endogenous 
regulators of vascular tone include substances that activate cell-surface 
receptors and ultimately either increase or decrease VSM tone. For 
instance, the hormone adrenaline, when acting at E-adrenoceptors (E-ARs), 
relaxes VSM cells, causing vasodilatation. Similarly, thromboxane A2 
(TXA2), a product of the vascular endothelium, causes vasoconstriction by 
activating on thromboxane-prostanoid (TP) receptors on adjacent VSM 
cells.   
 
Impairment of vasodilatation is a characteristic feature of cardiovascular 
diseases such as hypertension and coronary artery disease. In fact, the 
actions of nicorandil and the nitrate drugs, indicated in the treatment of 
ischaemic heart disease, involve vasodilatation (Joint Formularly 
Committee, 2011). Effective treatment is critical in preventing the loss of 
structural integrity that accompanies vascular growth in cardiovascular 
disease states. A mediator of this complex process is the mitogen-
activated protein kinase ERK (extracellular signal-regulated kinase), which 
is also known to promote VSM contraction.    
14 
 
This investigation will attempt to reconcile the finding that E-AR agonists, 
which are known to induce vasodilatation, have been shown to activate 
ERK in cultured cells expressing E-ARs (Baker et al., 2003; Friedman et al., 
2002). 
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1.2. THE ROLE OF ERK IN THE REGULATION OF VASCULAR TONE 
 
1.2.1. Structure of blood vessels 
 
The vascular system is a collection of blood vessels that is responsible for 
transporting materials throughout the body and maintaining cellular 
homeostasis. Supported by a complex network of arterioles, capillaries and 
venules, arteries and veins are key components of the vascular system. As 
shown in Figure 1.1, they are broadly similar anatomically, possessing a 
characteristic three-layer structure composed of the intima, media and 
adventitia. 
 
Figure 1.1. Cross-sectional structures of an artery and a vein. The intima 
(innermost layer) is composed of a monolayer of endothelial cells and a 
subendothelial layer; smooth muscle cells and elastin fibres predominate 
the media; and the adventitia contains collagenous and elastic fibres. 
 
1.2.2. Vascular smooth muscle (VSM) contraction 
 
1.2.2.1. Intracellular Ca2+ 
 
A schematic representation of VSM contraction is shown in Figure 1.2. VSM 
contraction is dependent on intracellular calcium concentration ([Ca2+]i). 
The Ca2+-ATPase pump and the Na+/Ca2+ exchanger mediate the efflux of 
Ca2+ from the cytosol and are key in maintaining basal [Ca2+]i, which, at 
~100 nM, is roughly 10,000-fold lower than [Ca2+]e (Marin et al., 1999). 
16 
 
Increases in [Ca2+]i represent the primary means by which 
vasoconstrictors evoke contraction, though they may also act by increasing 
the sensitivity of contractile elements to Ca2+.  
 
 
 
Figure 1.2. A schematic representation of the main pathways involved in 
VSM contraction. Contraction depends on the phosphorylation state of 
myosin light chain (MLC20). Ca
2+ is sourced from the extracellular space 
and sarcoplasmic reticulum (SR) following activation of, for example, 
GDq/11-coupled receptors (left). The Ca2+-binding protein calmodulin (CaM) 
binds Ca2+, forming a complex capable of activating myosin light chain 
kinase (MLCK). MLCK phosphorylates MLC20, allowing it to interact with 
actin. Subsequent actomyosin ATPase activity results in contraction. 
Myosin phosphatase (MLCP) causes relaxation by dephosphorylating MLC20 
and is itself regulated by PKC-potentiated inhibitory protein (CPI-17). Rho-
associated kinase (RhoK) promotes contraction by activating CPI-17 and 
inactivating MLCP. ERK disinhibits actomyosin ATPase activity by 
phosphorylating and inactivating caldesmon. ERK may also directly 
phosphorylate MLC20. [Ca
2+]i is reduced by the plasma membrane Ca
2+ 
pump and Na+-Ca2+ exchanger. The sarco(endo)plasmic Ca2+ (SERCA) 
pump maintains Ca2+ in the SR and its activity is inhibited by 
phospholamban (PLB). PLC-E (phospholipase CE), IP3 (inositol-1,4,5-
triphosphate), VOCC (voltage-operated Ca2+ channel), PKA (protein kinase 
A) and DAG (diacyl glycerol) are also shown. Dashed lines with rounded 
tips indicate inhibition. 
 
The main source of Ca2+ is the extracellular solution, from which L-type 
Ca2+ channels conduct Ca2+ to the intracellular space. Opening of these 
17 
 
channels is voltage-sensitive and occurs under depolarised conditions, 
which arise in the presence of high [K+]e or following agonist-induced 
receptor activation (Ganitkevich et al., 1990; Matsuda et al., 1990; 
Shimoda et al., 2000).  
 
Under resting conditions, the vast majority of intracellular Ca2+ is 
sequestered in intracellular stores such as the sarcoplasmic reticulum (SR; 
Figure 1.2). Much of this is due to the action of the sarco(endo)plasmic 
Ca2+ (SERCA) pump, which accumulates Ca2+ in the SR (Orallo, 1996). 
However, stored Ca2+ can also be utilised. For instance, activation of 
GDq/11-coupled receptors causes a phospholipase CE (PLCE)-dependent 
increase in the levels of the second messenger inositol-1, 4, 5-triphosphate 
(IP3), which in turn activates IP3 receptors on the SR, causing Ca
2+ release. 
Stimulation of this signalling pathway also results in the activation of 
protein kinase C (PKC) via an additional second messenger known as 
diacylglycerol (DAG). PKC is involved in Ca2+-independent routes to 
contraction, discussed below.  
 
As shown in Figure 1.2, elevations of [Ca2+]i are detected by the Ca
2+-
binding protein calmodulin, which forms a complex with Ca2+. Ca2+-bound 
calmodulin interacts with the regulatory domain of myosin light chain 
kinase (MLCK), causing its activation. Phosphorylation at Ser19 of the 
regulatory, 20 kDa chain of myosin (MLC20) by activated MLCK triggers the 
binding of MLC20 to actin, accelerating actomyosin ATPase activity and 
cross bridge cycling (Somlyo et al., 1994).  
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1.2.2.2. Ca2+ sensitisation 
 
VSM contraction is enhanced by mechanisms which increase the Ca2+ 
sensitivity of the contractile elements. The phosphorylation state of MLC20 
is also regulated by myosin phosphatase (MLCP), which promotes 
relaxation by dephophosphorylating MLC20. However, the activity of MLCP 
itself is subject to regulation by Rho-associated kinase (RhoK), which 
promotes contraction by phosphorylating and inactivating MLCP. MLCP 
activity is also reduced via direct inhibition of its catalytic subunit by PKC-
potentiated inhibitory protein (CPI-17), which itself is activated by PKC and 
RhoK. These mechanisms are illustrated in Figure 1.2. 
 
1.2.2.3. The endothelium in VSM contraction 
 
1.2.2.3.1. Endothelin-1 
 
The peptide endothelin-1 (ET-1) is recognised as one of the most powerful 
endogenous vasoconstrictors. Formed in endothelial cells by endothelin-
converting enzyme (ECE), ET-1 induces Ca2+- and PKC-dependent 
vasoconstriction by activating the GDq/11-coupled ETA receptors on adjacent 
VSM cells (Griendling et al., 1989; Ohnaka et al., 1990; Takuwa et al., 
1990). ETB receptors are expressed on ECs, where they mediate relaxation 
responses via a nitric oxide (NO)-dependent mechanism (Hosoda et al., 
1991; Takayanagi et al., 1991).  
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1.2.2.3.2. Thromboxane-A2 (TXA2) 
 
TXA2 is a cyclooxygenase (COX)-derived arachidonic acid (AA) metabolite 
known to contribute to abnormalities in various cardiovascular diseases 
(Sellers et al., 2008). Its effects are mediated by GDq/11-coupled TP 
receptors, which, when activated on VSM, produce powerful 
vasoconstriction. The synthetic thromboxane mimetic U46619 has been 
shown to activate ERK in VSM (Miggin et al., 2002), suggesting that the 
reported effects of TXA2, such vasoconstriction and cell growth, may 
involve ERK.  
 
1.2.2.4. RAS 
 
The renin-angiotensin system (RAS) plays an important role in the 
regulation of cardiovascular and fluid homeostasis. Interactions between 
key the components of the RAS system are illustrated in Figure 1.3. Renin, 
secreted from juxtaglomerular kidney cells, converts liver-derived 
angiotensinogen to angiotensin I, which in turn is metabolised by 
angiotensin-converting enzyme (ACE) to form angiotensin II, the main 
effector peptide of the RAS. Angiotensin II produces its effects by 
activating AT1 and AT2 receptors and stimulates aldosterone release from 
the adrenal cortex.  
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Figure 1.3. Schematic diagram of the RAS. Angiotensin II, formed via the 
sequential actions of renin and ACE, acts at AT1 or AT2 receptors to 
constrict or dilate blood vessels. ACE also promotes the breakdown of 
bradykinin, a vasodilator, to inactive peptides.  
 
Although the systemic effects of circulating RAS have been well described, 
it has been shown that the components of the RAS are expressed in a wide 
range of tissues where they may perform important functions (Nguyen 
Dinh Cat et al., 2011). In blood vessels, for example, angiotensin II 
synthesised and released by endothelial cells may contribute to blood 
vessel tone by releasing vasoactive substances such as prostaglandins 
(Nguyen Dinh Cat et al., 2011). 
 
1.2.2.5. Mitogen-activated protein kinase (MAPK) 
 
The MAPK superfamily consists of distinct signalling enzymes that function 
to regulate a wide range of cellular processes in response to extracellular 
stimuli. Their physiological significance is underscored by their evolutionary 
conservation in eukaryotic organisms and expression in virtually all cell 
types. Six distinct subgroups of MAPKs have been described in mammalian 
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cells: ERKs 1 and 2, p38 MAPK, c-Jun NH2-terminal kinase (JNK), ERKs 3 
and 4, ERK 5 and ERKs 7 and 8 (Krishna et al., 2008). A wide range of 
stimuli are capable of activating MAPKs. Examples include cell-surface 
receptor activation by hormones, growth factors and cytokines; and 
physical and chemical stresses such as osmolarity, cold/heat shock, 
radiation and hypoxia/ischaemia.  
 
The activation of individual MAPK enzymes is mediated by a signal 
transduction cascade involving two upstream protein kinases. Thus MAPK 
signalling cascades are composed of a prototypical three-kinase module 
(Figure 1.4). Initially, an upstream MAP3K, or MAPK kinase kinase 
(MAPKKK), is activated by either small GTP-binding proteins or protein 
kinases. Thereafter, the activated MAP3K dual-phosphorylates its 
downstream signalling partner, a MAP2K (or MAPK kinase, MAPKK), 
allowing the MAP2K to activate the terminal MAPK by dual phosphorylation 
at threonine/tyrosine residues. Finally, the activated MAPK is able to 
regulate nuclear and cytosolic processes by phosphorylating a range of 
enzymes including transcription factors, protein kinases, phospholipases 
and phosphodiesterases.   
 
 
 
Figure 1.4. Schematic diagram of the MAPK signalling pathway. The 
cascade is composed of a three-kinase module in which each kinase is 
phosphorylated and activated in sequence. The ERK signalling cascade is 
shown as an example (in parentheses). 
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1.2.2.5.1. p38 MAPK 
 
The p38 MAPKs are so named as a result of the independent discovery of a 
38 kDa protein, later termed p38D, in four laboratories (Freshney et al., 
1994; Han et al., 1994; Lee et al., 1994; Rouse et al., 1994). Three 
further members of the p38 MAPK family have since been identified and 
characterised: p38E, p38G and p38J (Coulthard et al., 2009).  
 
The p38s regulate cellular processes in response to diverse external stimuli 
ranging from environmental stresses to inflammation. These stimuli are 
able to engage various mechanisms that stimulate the many MAP3Ks 
involved in p38 signalling. In turn, three dual-specificity MAP2Ks, namely 
MKK3, MKK4, MKK6, are activated and proceed to dual-phosphorylate p38 
MAPK at Thr180 and Tyr182 (Johnson et al., 2002). Downstream effectors 
of p38 MAPK include protein kinases such as MAPK-activated protein 
kinase-2 (MAPK-APK-2) (Manke et al., 2005) and MAPK-APK-5 (New et al., 
2003) and transcription factors such as p53 (Bulavin et al., 1999).  
 
The pyridinylimidazole SB 203580, a p38 inhibitor, has been instrumental 
in studies of p38 function, despite demonstrating non-specific effects on 
distinct signalling pathways (Clerk et al., 1998; Kalmes et al., 1999). More 
specific p38 inhibitors have demonstrated therapeutic potential and have 
reached clinical development in disease states characterised by chronic 
inflammation (Behr et al., 2003; Miwatashi et al., 2005).   
 
1.2.2.5.2. c-Jun NH2-terminal kinase (JNK) 
 
The JNK family of MAPKs includes three gene products, termed JNK1±3, 
which were initially characterised by their ability to phosphorylate the NH2-
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terminus of the transcription factor c-Jun (Davis, 2000). Activation of JNKs 
occurs primarily in response to cytokines and environmental stresses, the 
latter explaining why they are often called stress-activated protein kinases, 
or SAPKs. The components of the JNK signalling pathway, including various 
MAP3Ks, MAP2Ks and JNKs, are arranged into multi-protein complexes by 
the scaffold protein JNK-interacting protein (JIP) (Morrison et al., 2003).  
 
JNK regulates gene transcription predominantly by activating the 
transcription factor activator protein-1 (AP-1) (Davis, 2000). Studies of 
JNK function have employed the small molecule JNK inhibitor SP 600125  
(Han et al., 2001), which, however, has frequently been reported to 
produce effects independently of JNK inhibition (Ito et al., 2011; Kim et al., 
2010; Martial et al., 2008; Tanemura et al., 2009). Nonetheless, inhibitors 
of JNK activation represent promising tools in the treatment of 
degenerative disorders, as dysregulation of JNK signalling has been 
implicated in accelerated cell death (Cui et al., 2007). 
 
1.2.2.5.3. Extracellular signal-regulated kinase (ERK) 
 
This subgroup of the MAPK family consists of the 44 and 42 kDa proteins 
ERK1 and ERK2, alternatively known as p44- and p42-MAPK, respectively 
(Seger et al., 1995). Alternatively spliced variants of both ERK1 and ERK2, 
namely ERK1b (Yung et al., 2000), ERK1c (Aebersold et al., 2004) and 
ERK2b (Gonzalez et al., 1992), have also been described. The ERK 
signalling cascade involves the sequential activation of Raf (MAP3K), MEK 
(MAP2K) and, finally, ERK (MAPK) (Figure 1.4). Raf is typically activated by 
the small G-protein Ras and exists in three isoforms, namely A-Raf, B-Raf 
and C-Raf (or Raf-1), of which the latter two are more important activators 
of MEK (Shaul et al., 2009; Wellbrock et al., 2004). The MEK isoforms 
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MEK1 and MEK2 activate ERK1 and ERK2, respectively, by phosphorylation 
of Tyr-183 and Thr-185 residues (Robbins et al., 1993).   
 
As mentioned earlier, cell-surface receptors represent a means through 
which external stimuli activate ERK. Of these, two main receptor 
superfamilies have been particularly well studied with regard to ERK 
activation: receptor tyrosine kinases (RTKs) and G-protein-coupled 
receptors (GPCRs). Much of the current understanding of RTK structure 
and function stems from study of the epidermal growth factor receptor 
(EGFR), the first RTK to be discovered (Downward et al., 1984). RTKs, 
which include receptors for hormones, growth factors and cytokines, are 
characterised by an intracellular tyrosine kinase domain and 
autophosphorylation of activated receptor dimers. They activate ERK by 
triggering a recruitment of protein complexes to the cell membrane, 
resulting in the switching of membrane-bound Ras from its inactive GDP-
bound state to its active, GTP-bound state. In brief, activation of RTKs 
permits the docking to receptors of adapter proteins possessing Src 
Homology 2 (SH2) or phospho-tyrosine-binding (PTB) domains. Adaptor 
proteins also associate with the guanine nucleotide exchange factor son of 
sevenless (Sos), which is required for the activation of Ras. Finally, as 
mentioned above, Ras stimulates ERK by interacting with its upstream 
MAP3K Raf.  
 
Agonist occupancy of GPCRs triggers a series of events resulting in the 
regulation of the activity of associated effector proteins such as adenylyl 
F\FODVH$&ZKLFKLWVHOIDFWVWRLQFUHDVHLQWUDFHOOXODUOHYHOVRIF\FOLF¶¶-
adenosine monophosphate (cAMP). Such effector systems have been 
implicated in ERK phosphorylation following the activation of a wide variety 
of GPCRs. For instance, in human embryonic kidney (HEK) 293 cells 
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expressing E2-ARs, the E-AR agonist isoprenaline activated ERK via cAMP-
dependent protein kinase (PKA), the small G-protein Rap1 and B-Raf 
(Schmitt et al., 2000). An additional means by which GPCRs have been 
described to activate ERK involves transactivation of RTKs, a process in 
which intermediates of GPCR signalling release soluble ligands that are 
able to bind to RTKs (Liebmann, 2011). For example, GPCR-coupled 
stimulation of EGFR occurs via the release of heparin-binding EGF (HB-
EGF) (Prenzel et al., 1999). ERK activation subsequently occurs via Ras 
stimulation, as described above.  
 
The role of E-arrestin proteins in GPCR desensitisation and internalisation 
are well described (DeWire et al., 2007). E-arrestins are also known to 
facilitate ERK activation by acting as scaffolds for the various elements of 
ERK signalling. Furthermore, when acting in this capacity, E-arrestins may 
prevent the nuclear translocation of ERK, thereby directing ERK to 
phosphorylate cytosolic targets (Cervantes et al., 2010; Tohgo et al., 
2002). Regulation of the subcellular compartmentalisation of activated ERK 
is an important determinant of the cellular response produced by ERK 
activation.  
 
When activated, ERK acts by phosphorylating target proteins. The vast 
range of targets for ERK underscores its ability to influence numerous 
cellular processes. In the nucleus, for example, ERK has been shown to 
interact with transcription factors including elk-1 (Babu et al., 2000), c-fos 
(Murphy et al., 2002) and p53 (Milne et al., 1994). Cytosolic targets of 
ERK include phosphodiesterase (PDE) isoforms, which are phosphorylated 
to either reduce (Hoffmann et al., 1999) or increase (Liu et al., 1999) their 
activities. The phosphorylation of phospholipase enzymes by ERK has also 
been described (Lin et al., 1993). Further common cytosolic targets include 
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protein kinases such as p90 ribosomal S6 kinase (RSK), a MAPK-APK 
capable of activating transcription factors and exerting feedback inhibition 
on ERK signalling (Frodin et al., 1999). Such feedback regulation may 
explain the commonly observed transient nature of ERK activation (Santos 
et al., 2007). Equally, mechanisms of sustained ERK activation have also 
been proposed and include direct phosphorylation and activation of Raf-1 
by ERK (Balan et al., 2006). The temporal characteristics of ERK activation 
are thought to direct the cellular response evoked by activated ERK. For 
instance, sustained ERK activation in phaeochromocytoma 12 (PC12) cells 
is required for their differentiation into the post-mitotic phenotype, 
whereas transient activation promotes cell proliferation (Marshall, 1995; 
Yaka et al., 1998) . 
 
The development of inhibitors of ERK activation have not only provided 
useful research tools but have also given rise to clinical trials of agents 
with therapeutic potential in the treatment of cancers (Friday et al., 2008). 
The structurally dissimilar compounds PD98059 and U0126 (Figure 1.5) 
are the most commonly used MEK inhibitors, producing potent inhibition at 
low micromolar concentrations, whilst PD184952 (Figure 1.5), also 
structurally unrelated, inhibits MEK activity at high nanomolar 
concentrations (Mattingly et al., 2006). They inhibit ERK activation by 
preventing the activation of MEK, and their specificity stems from their low 
affinities for the ATP-binding site common to all protein kinases (Alessi et 
al., 1995; Davies et al., 2000; Favata et al., 1998).  
 
Figure 1.5. Chemical structures of MEK inhibitors. PD98059 (left), U0126 
(centre) and PD184352 are structurally dissimilar, non-competitive MEK 
inhibitors. 
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The high molecular weight (MW; 93 kDa) splice variant of the protein 
caldesmon is expressed solely in smooth muscle, whereas the low MW, 60 
kDa variant is ubiquitously expressed (Marston et al., 1991; Sobue et al., 
1991). By binding actin, caldesmon exerts an inhibitory influence on 
actomyosin ATPase activity and thus attenuates contraction (Wang, 2001). 
Phosphorylation of caldesmon by ERK has been proposed to disinhibit 
actomyosin ATPase activity, suggesting a role for ERK in smooth muscle 
contraction (D'Angelo et al., 2002; Gerthoffer et al., 1996; Gorenne et al., 
2004). Consistent with this proposal is the finding that ERK contributed to 
D2-AR-mediated vasoconstriction of porcine palmar lateral vein via a 
myosin phosphatase-independent pathway (Roberts, 2004). Furthermore, 
it has been suggested that ERK causes contraction by directly 
phosphorylating MLC20 at the same site as MLCK (D'Angelo et al., 2002; 
Roberts, 2004). These actions of ERK, along with other regulatory 
mechanisms of VSM contraction, are illustrated in Figure 1.2. 
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1.3. THE ROLE OF E-ADRENOCEPTORS IN THE REGULATION OF 
VASCULAR TONE 
 
The importance of E-ARs in the regulation of vascular tone has long been 
appreciated. Studies using subtype-selective compounds and knock-out 
animals have pointed to the E2-ARs as the more relevant subtypes involved 
in this process, though variations in the involvement of each subtype exist 
between blood vessels (Chruscinski et al., 1999; Osswald et al., 1983; 
Rohrer et al., 1999). In blood vessels, E-ARs are expressed on endothelial 
cells and smooth muscle cells (Guimaraes et al., 2001). Activation of 
vascular E-ARs relaxes smooth muscle cells via diverse mechanisms, 
thereby causing vasodilatation. The associated reduction in peripheral 
vascular resistance is particularly relevant during periods of physical 
activity, allowing increased blood flow to skeletal muscles. 
 
1.3.1. E-adrenoceptors 
 
E-ARs are GDs-coupled cell surface receptors which mediate the effects of 
the endogenous catecholamines of the sympathetic nervous system, 
adrenaline and noradrenaline. Ubiquitously expressed in peripheral tissues, 
they play central roles in the regulation of diverse physiological processes 
in numerous organ systems, most notably the cardiovascular and 
respiratory systems. For decades, this receptor group has been the subject 
of intense study, the fruits of which have led to a more comprehensive 
understanding of human physiology as well as to the development of 
effective drug treatments in many disease states (Emilien et al., 1998).  
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That the biological effects of adrenaline-like amines were mediated by two 
distinct receptor systems (D- and E-ARs) was a concept familiar to 
researchers as far back as the 1940s (Ahlquist, 1948). By the 1960s, the 
existence of multiple E-AR subtypes became evident and the E1- and E2-
ARs were identified (Lands et al., 1967). Evidence suggesting the existence 
of an atypical E-AR emerged in the 70s and 80s (Bojanic et al., 1985; 
Harms et al., 1977), and led to the characterisation of the E3-AR (Bylund et 
al., 1994). Recent reports of a putative E4-AR (Kaumann, 1997) are likely 
related to multiple conformational states of existing E-ARs as opposed to a 
novel receptor subtype per se (Kaumann et al., 2001). The endogenous 
catecholamine ligands adrenaline and noradrenaline differ in their relative 
potencies for the various E-AR subtypes. Specifically, they possess equal 
potency at the E1AR, whilst adrenaline is more potent at E2 and less potent 
at E3 (Bylund et al., 1994). Adrenaline has similar potency for D- and E-
ARs, whilst noradrenaline is considered D-adrenoceptor-selective.  The 
development of E-AR agonist ligands has been based on the molecular 
structures of these endogenous catecholamines, and initially led to the 
synthesis of isoprenaline in the 1940s (Ahlquist, 1948).  
 
Unlike its endogenous counterparts, isoprenaline exhibits marked 
selectivity for E-ARs over D-ARs due to presence of a relatively large 
isopropyl moiety at the terminal amine group (Ariens, 1967). Furthermore, 
isoprenaline possess greater potency at E1- and E2-ARs and is equipotent 
with noradrenaline at E3 (Bylund et al., 1994). Although isoprenaline was 
once the drug of choice in the treatment of asthma (Scott et al., 1961), it 
has since been replaced by more E2-selective compounds and remains 
relevant as a tool in the study of E-AR function. Other notable E-AR-
altering drugs include the bronchodilators salbutamol and salmeterol, 
short- and long-acting E2-AR agonists, respectively, which offer greater 
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selectivity than isoprenaline for the E2 subtype, the receptor implicated in 
asthma and chronic obstructive pulmonary disorder (COPD) (Waldeck, 
2002). Myocardial E1-ARs regulate heart rate and contractility and are 
targeted by antagonist compounds, often called E-blockers, in 
cardiovascular disease states including heart failure and hypertension 
(Joint Formularly Committee, 2011). Finally, the therapeutic potential of 
E3-AR agonists as anti-obesity and anti-diabetic drugs was suggested by 
the expression of this receptor in adipocytes and its role in lipolysis (de 
Souza et al., 2001).    
 
1.3.1.1. The E2-adrenoceptor 
 
GPCRs consist of seven transmembrane-spanning D-helical domains with 
three extracellular and three intracellular loops.  The human E2-AR is a 47 
kDa polypeptide composed of 413 amino acid residues (Kobilka et al., 
1987; Rybin et al., 2000). Of these, several have been identified as 
important sites in various aspects of receptor function, including ligand 
binding, G-protein coupling and receptor desensitisation (Liggett, 2002).   
 
The signal transduction events following ligand binding to GPCRs is well 
described (Rang et al., 2003). Briefly, ligand binding induces a 
conformational change in the receptor, allowing it to bind with the GTP-
bound D subunit of the G-protein, which also consists of E and J subunits. 
This in turn causes GTP to displace GDP from the D subunit. As a result, 
GTP-bound GD dissociates from both the receptor and EJ subunits in order 
to activate effector enzymes. E-ARs couple to AC via GDs which results in 
the accumulation of cAMP. In turn, cAMP is able to bind to, and therefore 
activate, a number of downstream proteins which possess cyclic nucleotide 
binding (CNB) domains. The most notable example is cAMP-dependent 
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protein kinase (PKA), though cAMP is also able to activate the related cyclic 
¶¶-guanosine monophosphate (cGMP)-dependent protein kinase (or 
protein kinase G, PKG), which shares significant sequence homology with 
PKA (Jiang et al., 1992). Also of note are Epac1 and Epac2 (exchange 
protein directly activated by cAMP) which act as guanine nucleotide 
exchange factors for the small GTPases Rap1 and Rap2, respectively (Bos, 
2006).  
 
Even at the time of its discovery, PKA was known to phosphorylate 
multiple intracellular proteins (Walsh et al., 1968).  It is capable of 
catalysing numerous cellular reactions by phosphorylating targets at 
serine/threonine residues. Its role in the regulation of ion channels is well 
described and relevant in various cell types (Ismailov et al., 1995; Levitan, 
1994). For example, in VSM cells, E-AR activation has been shown to 
increase ATP-sensitive K+ channel (KATP) activity in a PKA-dependent 
manner (Shi et al., 2007). PKA is also involved in the desensitisation of the 
E2-AR, a means by which responses mediated by the receptor are 
regulated. The phosphorylation of the receptor at serine/threonine residues 
within its third intracellular loop and cytoplasmic tail results in the binding 
of E-arrestin, which results in the uncoupling of the activated receptor from 
GDs. In addition, E-arrestin may recruit cAMP-specific PDE4, which 
catalyses the hydrolysis of cAMP. Furthermore, the genomic effects of the 
cAMP-PKA pathway are triggered by PKA-stimulated phosphorylation of the 
transcription factor cAMP response element-binding protein (CREB).  
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1.3.2. The AC-cAMP-PKA pathway in E-AR-mediated 
vasodilatation 
 
The mechanisms by which the E-AR relaxes VSM cells in various tissues 
have been under investigation for several years, and the AC-cAMP-PKA 
pathway has been frequently implicated. It is thought that phosphorylation 
and inactivation of MLCK by PKA underlies the relaxation induced by E-AR 
agonists (Payne et al., 1987).  PKA, known to target ion channels, may 
also increase Ca2+ efflux by stimulating the Ca2+-ATPase pump and the 
Na+/Ca2+ exchanger, resulting in reduced [Ca2+]i (Raymond et al., 1996). A 
further possible target for PKA in E-AR-mediated vasodilatation is the 
transmembrane protein phospholamban, which modulates the activity of 
the SERCA pump. By phosphorylating phospholamban, PKA prevents its 
interaction with the SERCA pump, thereby increasing Ca2+ extrusion from 
the cytosolic compartment to the SR (Colyer, 1998).   
 
1.3.3. The role of the endothelium in E-AR-mediated 
vasodilatation 
 
That endothelial cells express E-ARs is now widely accepted (Guimaraes et 
al., 2001). Nonetheless, studies probing their roles in E-AR agonist-induced 
VSM relaxation have produced contrasting results. For example, depending 
on the pre-contractile agent used, endothelium denudation either had no 
effect or enhanced isoprenaline-induced relaxations of canine coronary 
artery, suggesting endothelial E-ARs may not be involved in the relaxation 
response (Macdonald et al., 1987). Yet an earlier study of the same vessel 
demonstrated that the effect of isoprenaline was inhibited by endothelium 
removal (Rubanyi et al., 1985). Furthermore, E-AR-mediated vasodilatation 
33 
 
of rat aorta was shown by different groups to be completely endothelium-
dependent (Gray et al., 1992), completely endothelium-independent (Eckly 
et al., 1994) or dependent on both endothelial and non-endothelial factors 
(Ferro et al., 2004). However, in a more recent study of the same vessel, it 
was proposed, firstly, that the intact endothelium mediated relaxation and 
may have even inhibited the effect of smooth muscle cAMP, and secondly, 
that endothelium removal prevented the inhibitory effect, allowing the 
smooth muscle layer to mediate vasodilatation (Kang et al., 2007).  
 
1.3.3.1. Nitric oxide (NO) 
 
The gaseous free radical nitric oxide (NO), also called endothelium-derived 
relaxing factor (EDRF), is synthesised in endothelial cells via a reaction 
requiring L-arginine and catalysed by endothelial NO synthase (eNOS). 
Central to its paracrine effect on VSM, NO is able to diffuse to adjacent 
smooth muscle cells where it activates soluble guanylyl cyclase (sGC), 
which in turn catalyses the conversion of GTP to the second messenger 
cyclic GMP. Subsequently, PKG is activated by cyclic GMP and regulates a 
number of proteins via serine/threonine phosphorylation (Figure 1.6). E2-
AR stimulation has been shown to increase eNOS activity in human 
umbilical vein endothelial cells (HUVEC) in a cAMP-dependent manner 
(Ferro et al., 1999). In the same study, associated relaxations were 
characterised as endothelium dependent. Furthermore, other studies have 
shown that N-nitro-L-arginine methyl ester (L-NAME) and 1H-
(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ), inhibitors of eNOS and 
sGC, respectively, inhibit or abolish the vascular effects of E-AR agonists 
both in vitro and in vivo (Akimoto et al., 2002; Ritter et al., 2006).  
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Figure 1.6. A schematic representation of the biosynthesis and signalling 
of nitric oxide (NO) in blood vessels. NO is synthesised in the endothelium 
by a reaction catalysed by endothelial NO synthase (eNOS). NO diffuses to 
adjacent vascular smooth muscle (VSM) cells where it activates soluble 
guanylyl cyclase (sGC), which causes the accumulation of cyclic-¶¶-
guanosine monophosphate (cGMP). Finally, cGMP activates cyclic-GMP-
dependent protein kinase (PKG), which causes relaxation by 
phosphorylating various effector molecules (Bryan et al., 2009). 
 
1.3.3.2. Arachidonic acid (AA) metabolites 
 
AA metabolites play key roles in the regulation of diverse processes in both 
physiological and pathological states. Their vasoactive properties are 
evident from the finding that AA itself, when applied to blood vessels, 
produces relaxation (Rosolowsky et al., 1993). 
 
1.3.3.2.1. Cyclooxygenase (COX)-derived metabolites of AA 
 
Prostacyclin (PGI2) has long been recognised as the chief AA metabolite in 
blood vessels, where it acts to mediate vasodilatation (Dusting et al., 
1979). However, there is scant evidence suggesting a link between PGI2 
and E-AR-mediated vasodilatation. In fact, it was shown that whereas D-AR 
agonists were able to stimulate PGI2 synthesis in rat aorta, isoprenaline 
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and salbutamol had no effect (Jeremy et al., 1985). Furthermore, in a later 
study the COX inhibitor indomethacin did not alter isoprenaline-induced 
relaxations in the same vessel (Satake et al., 1997). It has been proposed 
that E-AR-mediated vasodilatation in rat coronary circulation may be 
regulated by a COX-dependent endothelium-derived contracting factor 
(EDCF), which regulates the vasodilatation response by opposing the 
relaxing actions of endothelium-derived hyperpolarising factor (EDHF) and 
NO (Vazquez-Perez et al., 2001). However, studies have failed to 
consistently demonstrate an effect of indomethacin on E-AR-agonist-
induced relaxations, suggesting COX metabolites may not be important 
regulators of this process in many vascular beds.  
 
1.3.3.2.2. Cytochrome P450-derived metabolites of AA 
 
The products of AA metabolism by cytochrome P450 system are 
epoxyeicosatrienoic acids (EETs), monohydroxyeicosatetraenoic acids 
(HETEs) and dihydroxyeicosatrienoic acids (DHETs). Of these, EETs are 
most relevant in blood vessels and have been shown to mediate 
vasodilatation in a paracrine manner by activating large-conductance, 
Ca2+-activated K+ (BKCa) channels on adjacent VSM cells (Huang et al., 
2005). The importance of the vasodilator and anti-inflammatory properties 
of EETs in blood vessels is highlighted by accumulating evidence that their 
dysregulation is linked with an elevated risk of cardiovascular disease 
(Zordoky et al., 2010). The cytochrome P450 inhibitor metyrapone 
(Hildebrandt, 1972), has been used to probe the role of cytochrome P450 
metabolites in blood vessels. Isoprenaline-induced relaxation of rat aorta 
has been shown to be sensitive to metyrapone, suggesting a role for the 
cytochrome P450 system in E-AR-mediated vasodilatation (Honda et al., 
1998; Satake et al., 1997).   
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1.3.3.3. Endothelium-derived hyperpolarising factor (EDHF) 
 
The term EDHF was coined to describe an endothelium-derived entity, 
distinct from NO and PGI2, capable of causing relaxation by hyperpolarising 
smooth muscle through K+ channel activation. However, the current 
consensus is that the opening of EC KCa channels initiates the spread of 
hyperpolarisation to the VSM through a number of mechanisms (Busse et 
al., 2002). Connexin proteins form gap junctions, intercellular channels 
which allow electrical communication between adjacent cells of the 
vasculature. Experiments in which electrical communication between ECs 
and VSM cells was disrupted suggest that gap junctions may be important 
in EDHF responses (Chaytor et al., 1998). Other possible mediators of the 
EDHF response include the activation of smooth muscle KCa by EETs 
(Quilley et al., 2000) and the activation of VSM inward-rectifier K+ (KIR) 
channels and the Na+/K+-ATPase pump by K+ released from ECs (Edwards 
et al., 1998).  
 
1.3.4. The role of K+ channels in E-AR-mediated vasodilatation 
 
Although K+ channels are known to participate in the remodelling of the 
vasculature, for instance by controlling smooth muscle cell proliferation 
and migration, greater interest lies in their ability to influence vascular 
tone and thus regulate blood flow.  
 
A marked K+ concentration gradient is maintained across the cell by the 
Na+/K+-ATPase pump, which actively extrudes K+ in exchange for Na+. By 
mediating the efflux of K+ ions along this gradient, K+ channels 
hyperpolarise the cell membrane and prevent Ca2+ influx via L-type Ca2+ 
channels, causing smooth muscle relaxation.  This property of K+ channels 
37 
 
has led to their targeting in the treatment of angina, for which the 
selective ATP-sensitive K+ (KATP) channel opener nicorandil is indicated 
(Joint Formularly Committee, 2011). Various K+ channels have been linked 
to E-AR-mediated vasodilatation, including KATP channels, voltage-gated K+ 
(KV) channels and the Ca
2+-activated K+ (KCa) channels. Furthermore, K
+ 
channel activation by E-ARs has variously been reported to either require 
cAMP (Chang, 1997) or to proceed via cAMP-independent pathways 
(Husken et al., 1997; Randall et al., 1995). 
 
1.3.4.1. KATP channels 
 
Since their first identification in 1983 (Noma, 1983), KATP channels, named 
after their characteristic inhibition by intracellular ATP, have been the 
subject of considerable interest and study. Although KATP channels are 
important regulators of numerous cellular processes, reflecting their 
ubiquitous expression, they are perhaps best known for their role in insulin 
secretion in the pancreatic E-cell. The blocking of KATP channels with 
sulphonylurea drugs such as glibenclamide is routinely indicated in the 
treatment of Type II diabetes (Joint Formularly Committee, 2011). 
 
The KATP channel is composed of eight subunits, four of which form the 
channel pore and are inwardly rectifying K+ channel (KIR) subunits. Each 
KIR subunit associates with a single sulphonylurea receptor (SUR), which 
are required for channel regulation. Two KIR (KIR6.1 and KIR6.2) genes and 
three SUR genes (SUR1, SUR2A and SUR2B) have thus far been identified, 
giving rise to several receptor-subunit combinations. In the pancreatic E-
cell, KATP channel composition is KIR6.2/SUR1 (Sakura et al., 1995), whilst 
in VSM KIR6.2/SUR2B predominates (Isomoto et al., 1996). In addition to 
their expression on the cell surface, KATP channels are also located on 
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mitochondrial (Inoue et al., 1991) and nuclear (Quesada et al., 2002) 
membranes.  
 
KATP channels have been shown to influence vascular tone under resting 
conditions and in response to endogenous and synthetic vasodilators. For 
instance, application of the KATP channel blocker glibenclamide to dog and 
rabbit coronary circulation significantly reduced resting blood flow (Samaha 
et al., 1992). However, glibenclamide did not cause contraction of porcine 
isolated coronary artery rings (O'Rourke, 1996), suggesting species 
differences in the ability of KATP channels to influence resting tone. 
Endogenous activators of KATP channels rely on phosphorylation of channels 
by protein kinases, such as PKA and PKG, to cause vasodilatation; 
conversely, endogenous vasoconstrictors, such as ET-1, may depolarise 
VSM by closing KATP channels, again via phosphorylation-dependent 
mechanisms (Brayden, 2002). Synthetic KATP channel openers cause 
vasodilatation and are of particular interest in cardiovascular disease, 
hence the use of nicorandil in the treatment of angina pectoris (Joint 
Formularly Committee, 2011). Finally, KATP channels are activated in 
pathophysiological states such as hypoxia and ischaemia/reperfusion, 
possibly as a result of altered ATP, ADP or adenosine regulation (Brayden, 
2002). 
 
It has been frequently reported in the literature that KATP channels 
contribute to E-AR-mediated vasodilatation in a range of vascular beds 
both in vivo and in vitro (Chang, 1997; Dumas et al., 1999; Ming et al., 
1997; Randall et al., 1995; Sheridan et al., 1997). However, other studies 
have failed to demonstrate an involvement under physiological conditions 
(Husken et al., 1997; Satake et al., 1996; White et al., 2001). It is 
possible that the mechanism of KATP activation following E-AR stimulation 
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may vary from vascular bed to vascular bed, as cAMP-dependent (Chang, 
1997) and ±independent (Randall et al., 1995) routes have both been 
observed.  
 
1.3.4.2. Voltage-gated K+ (KV) channels 
 
KV channels are members of the voltage-gated superfamily of ion channels, 
the members of which are characterised by their voltage sensitivity and 
include channels for Na+ and Ca2+. Structurally, the KV channel is 
composed of four D subunits, all of which contain a voltage sensor and 
form the central pore (Yellen, 2002). Thus far, as many as 40 KV channel D 
subunits have been identified (Gutman et al., 2011). The D subunits 
associate with four accessory E subunits, which alter channel expression 
and properties (Pongs et al., 1999).  
 
KV channels are believed to influence resting vascular tone, as KV channel 
blockers have been shown to cause phasic contractions of canine and 
porcine isolated coronary artery rings (Nakazawa et al., 1988; O'Rourke, 
1996). Investigations of KV activity during E-AR-mediated vasodilatation 
are uncommon. One study showed that isoprenaline enhanced KV currents 
in rabbit portal vein smooth muscle cells via PKA-dependent 
phosphorylation of the channel (Aiello et al., 1995). Furthermore, in rat 
aortic rings, isoprenaline was proposed to activate KV channels via the 
activation of E1-ARs and subsequent stimulation of a cAMP-dependent 
pathway (Satake et al., 1996). Conflicting evidence presented in a later 
study of the same vessel demonstrated that E3- but not E1- or E2-AR-
mediated vasodilatation was inhibited by 4-aminopyridine (4-AP), a KV 
channel blocker (Matsushita et al., 2006). 
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1.3.4.3. Ca2+-activated potassium (KCa) channels 
 
KCa channels form a large family of K
+ channels which are activated by 
elevations in [Ca2+]i. Three subtypes exist, differing in both their voltage 
sensitivity and single-channel conductance: large-conductance KCa (BKCa), 
intermediate-conductance KCa (IKCa) and small-conductance KCa (SKCa).  
 
1.3.4.3.1. BKCa channels 
 
BKCa channels, also called Maxi-K, have large single-channel conductance 
(100 pS - 250 pS). Like the other KCa channels, they display Ca
2+-
sensitivity but differ in that they are capable of sensing voltage ± 
specifically, their activity increases with depolarisation. Thus, in VSM, 
where they are densely expressed, BKCa channels may act to oppose, or 
modulate, the effects of L-type Ca2+ channels (Nelson et al., 1995a).  
Structurally, BKCa channels are composed of four pore-forming D subunits 
which associate with four modulatory E subunits (Vergara et al., 1998). 
Investigations of BKCa function have relied on the scorpion venom-derived 
toxins iberiotoxin and charybdotoxin; the former produces specific 
blockade of BKCa channels, whilst the latter is a mixed BKCa/IKCa channel 
blocker (Doughty et al., 1999; Galvez et al., 1990; Hanner et al., 1998). 
Furthermore, NS1619, a benzimidazolone compound, selectively opens 
BKCa channels and has been routinely used alongside the toxins (Khan et 
al., 1998).  
 
As described earlier, endothelial stimulation may result in the activation of 
BKCa channels via a number of mechanisms. For example, cytochrome 
P450-derived EETs may hyperpolarise VSM via BKCa activation (Huang et 
al., 2005). NO has also been shown to induce relaxations through the 
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activation of BKCa channels (Bychkov et al., 1998), and this may occur via 
PKG-dependent phosphorylation of the channel (Taniguchi et al., 1993). 
Although BKCa channels are capable of opposing the effects of raised 
[Ca2+]i during depolarisation, some vasoconstrictors are able to prevent 
this feedback action by regulating BKCa activity. For instance, the TXA2 
mimetic U46619 and the endogenous peptides ET-1 and angiotensin II 
have been shown to inhibit BKCa activity in porcine coronary artery smooth 
muscle cells (Minami et al., 1995; Scornik et al., 1992).  
 
Collectively, the relevant studies indicate that BKCa channels are implicated 
in E-AR-mediated vasodilatation. It was proposed by Scornik et al. (1993) 
that E-AR-mediated stimulation of BKCa channels in coronary smooth 
muscle cells may occur through either PKA-dependent and -independent 
phosphorylation. A later experiment using coronary smooth muscle cells 
attributed isoprenaline-induced BKCa channel activation to a cAMP-
dependent cross-activation of PKG (White et al., 2000). Furthermore, 
isoprenaline-induced vasodilatation of intact rat mesenteric artery occurred 
via a PKA-independent stimulation of BKCa, and that inhibition of this 
pathway unmasked a E1-AR-induced, PKA-dependent relaxation mechanism 
(White et al., 2001).  
 
1.3.4.3.2. IKCa and SKCa channels 
 
First described in 1958 (Gardos, 1958), the IKCa channel is characterised by 
³LQWHUPHGLDWH´ VLQJOH-channel conductance (20 pS ± 80 pS), a marked 
Ca2+-dependence and sensitivity to charybdotoxin (Latorre et al., 1989). In 
addition, the antifungal clotrimazole and similar compounds, most notably 
TRAM-34 (Wulff et al., 2000), produce block of this channel and have been 
employed in studies of its function. With single channel conductance 
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ranging from 2 pS ± 20 pS, the SKCa channel is also Ca2+-sensitive and is 
blocked by apamin or UCL 1684 (Dunn, 1999; van der Staay et al., 1999). 
Both SKCa and IKCa channel structures are also based on pore-forming, four 
D subunit motifs. Ca2+ sensitivity is thought to be conferred by binding of 
the Ca2+-binding protein calmodulin to the carboxy terminus of each D 
subunit (Fanger et al., 1999; Schumacher et al., 2001).  
 
In blood vessels, IKCa channels are thought to be predominantly expressed 
on the endothelium, with VSM expression infrequently reported and related 
to non-contractile, proliferative phenotypes (Neylon et al., 1999; Tharp et 
al., 2009). However, IKCa channels have been detected on contractile 
smooth muscle cells (McNeish et al., 2006). In any case, the ability of this 
channel to mediate relaxations following stimulation of the endothelium 
with various vasodilators is undisputed. Furthermore, it is now generally 
accepted that K+ efflux via endothelial IKCa and SKCa channels initiates the 
events associated with the EDHF phenomenon (Busse et al., 2002).  
 
E3-ARs were shown to be expressed on ECs of human coronary resistance 
arteries and to mediate relaxations to the E3-AR agonist BRL 37344 (Dessy 
et al., 2004). eNOS inhibition reduced the degree of relaxation, leaving a 
residual NO-insensitive component that was subsequently blocked by the 
combination of apamin and charybdtoxin, a well-known susceptibility of 
EDHF-mediated responses (Busse et al., 2002). These findings suggest 
that the E3-AR-mediated vasodilatation, in this vessel at least, may involve 
EDHF. Beyond the findings of this study, the relevance of EDHF to E-AR-
mediated vasodilatation is unclear.  
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1.4. ERK AND E-ADRENOCEPTORS IN DISEASE 
 
According to the WHO, cardiovascular disease was the leading cause of 
death worldwide in 2008, accounting for an estimated 30% of total deaths, 
equivalent to 17.3 million people (World Health Organisation, 2011a). This 
figure is predicted to rise to 23.6 million people by 2030, with the majority 
of deaths likely to occur in low- and middle-income countries (World Health 
Organisation, 2011a).  
 
Cardiovascular disease refers to disorders of the heart and vasculature, 
and includes ischaemic heart disease, congenital heart disease, 
cerebrovascular disease and hypertension. Risk factors include obesity, 
diabetes, smoking, excessive alcohol consumption, high-fat diets, 
sedentary lifestyles, stress and age. In addition, transgenic animal models 
and human genome-wide association studies have provided insights into 
the influence of genes on cardiovascular risk (Delles et al., 2008; WTCCC, 
2007). The prevention and treatment of cardiovascular disease often 
involves lifestyle changes. However, drug treatments are integral to 
lowering the cardiovascular disease burden. Several drug classes 
collectively acting on a wide range of molecular targets are employed in 
treatment. Among them are the statins (Section 1.4.3), whose 
effectiveness, tolerability and apparent versatility have led to their 
widespread use in both treatment and prophylaxis.  
 
1.4.1. ERK and E-ARs in cardiovascular disease 
 
ERK has emerged as an important regulator of VSM function. Its 
involvement in the proliferation and migration of VSM cells has long been 
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appreciated (Graf et al., 1997). More recently, non-genomic functions have 
been reported, including the mediation of contractile responses (Roberts, 
2004). A previous study reported that the angiotensin II receptor 
antagonist losartan and the Ca2+ channel blocker nifedipine produced 
parallel reductions of aortic ERK activation and blood pressure in a rat 
model of hypertension (Hamaguchi et al., 1999).  
 
The development of atherosclerosis involves, amongst other things, the 
recruitment and infiltration of monocytes into the arterial subendothelium 
(Gu et al., 1998). Known to be involved in this process is the CC 
chemokine monocyte chemotactic protein-1 (MCP-1), which has also been 
shown to trigger endothelial cell migration (Weber et al., 1999). More 
recently, MCP-1 was reported to stimulate matrix metalloproteinase (MMP) 
release from endothelial cells, also a feature of atherogenesis, via the 
activation of ERK (Werle et al., 2002). In another study linking ERK to the 
progression of atherosclerosis, ERK expression and activity were greater in 
aortae of cholesterol-fed rabbits than in control aortae by factors of 2-3-
fold and 3-5-fold, respectively (Hu et al., 2000). This was accompanied by 
increased migration and proliferation of VSM cells of the atherosclerotic 
aorta. Increased ERK activation in cardiovascular disease has also been 
observed in non-vascular tissues. For instance, the increased activation of 
ERK observed in the myocardia of CHF patients was proposed to contribute 
to the pathology (Dong et al., 2006). Furthermore, elevated myocardial 
ERK activation was associated with susceptibility to viral myocarditis 
following infection with Group B coxsackievirus in mice (Opavsky et al., 
2002).  
 
E-AR function is impaired in various cardiovascular diseases. In a canine 
model of heart failure, for example, abnormalities in myocardial E-ARs 
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were accompanied by altered E-AR-mediated vasodilatation of coronary 
artery (Larosa et al., 1996). In a human study, E2-AR-mediated 
vasodilatation was shown to be impaired in coronary artery disease and 
was accompanied by reduced endothelium-dependent relaxations (Barbato 
et al., 2005). Furthermore, studies using rat models of hypertension have 
consistently reported deficits of E-AR-mediated vasodilatation; for a 
review, see Feldman et al. (1998). Studies providing evidence of impaired 
E-AR-mediated vasodilatation in Type II diabetes and obesity are 
presented in Section 1.4.2.4.   
 
1.4.2. Type II diabetes and obesity 
 
As significant causes of morbidity and mortality, particularly in the 
developed world, Type II diabetes and obesity are among the leading 
public health issues of the 21st century. Due to considerable overlap 
between the clinical features of Type II diabetes and obesity, leading 
international health agencies have recently moved to group the two 
conditions under the same umbrella, known as the metabolic syndrome 
(Alberti et al., 1998; Alberti et al., 2006; Grundy et al., 2006; NCEP, 
2001). Although prevention and lifestyle changes are emphasised, 
pharmacological treatments are key in reducing the burden of metabolic 
syndrome and intensive research efforts continue to fuel progress in the 
development of successful drug therapies.  
 
1.4.2.1. Type II diabetes 
 
Formerly known as adult-onset diabetes or non-insulin-dependent diabetes 
mellitus (NIDDM), Type II diabetes is characterised by insulin resistance, 
chronic hyperglycaemia and dyslipidaemia. It is estimated that Type II 
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diabetes accounts for approximately 90±95% of the total diabetes burden. 
Signs and symptoms of diabetes include polyuria, polydipsia, persistent or 
recurrent infections, tiredness and lethargy and tingling/pain/numbness in 
the hands/feet/legs.  
 
In the UK, antidiabetic drugs are indicated in Type II diabetes if non-
pharmacological measures, such as increased physical activity and reduced 
caloric intake, do not provide adequate glycaemic control (Joint Formularly 
Committee, 2011). Currently used antidiabetics include the sulphonylurea 
drugs, including glibenclamide and gliclazide, the biguanide metformin and 
recently approved agents such as the long-acting glucagon-like peptide 
liraglutide (Joint Formularly Committee, 2011).  
 
In addition to acute complications such as hypoglycaemia and diabetic 
ketoacidosis, uncontrolled diabetes is associated with a raft of long-term 
microvascular and macrovascular complications. Microvascular 
complications include diabetic retinopathy, nephropathy and neuropathy, 
affecting the eyes, kidneys and peripheral nerves, respectively. 
Macrovascular complications include stroke, coronary artery disease and 
peripheral arterial disease. Thus Type II diabetes is a significant risk factor 
for cardiovascular disease.  
 
1.4.2.2. Obesity 
 
In 2008, it was estimated that over 200 million men and 300 million 
women were obese (World Health Organisation, 2011c). Obesity is 
classified as a body mass index (BMI) is of greater than or equal to 30. 
Approximately 44% of the diabetes burden is attributable to overweight 
and obesity (World Health Organisation, 2011c).  
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The associations between obesity and other related disease states, or co-
morbidities, have long been appreciated, with Type II diabetes, 
dyslipidaemia, hypertension and cancer being particularly worthy of note 
(Basen-Engquist et al., 2011; Travers et al., 2011). As in Type II diabetes, 
the strategies for managing obesity involve dietary and lifestyle changes. 
This aims to offset the prevailing trends of increasingly sedentary lifestyles 
and greater consumption of high calorie foods.  
 
In the UK, pharmacological treatment of obesity is only indicated in 
clinically obese individuals (i.e., BMI t 30) in whom at least 3 months of 
managed care failed to produce adequate weight reduction (Joint 
Formularly Committee, 2011). Currently, only orlistat, a lipase inhibitor 
which reduces the absorption of fat, is indicated in the pharmacological 
management of obesity in the UK (Joint Formularly Committee, 2011).  
 
1.4.2.3. Animal models of Type II diabetes and obesity 
 
Analogous to the Spontaneously hypertensive rat (SHR) model of 
hypertension (Okamoto et al., 1964), the Zucker rat and Zucker diabetic 
fatty (ZDF) rats have long been used to model obesity and diabetes, 
respectively.  The characteristic obese phenotype of the Zucker rat is 
derived from an autosomal recessive mutation of the leptin receptor 
(Phillips et al., 1996). As a result, Zucker rats display classic signs and 
symptoms associated with metabolic syndrome: they are 
hyperinsulinaemic, hyperlipidaemic, hyperglycaemic and borderline 
hypertensive (Banday et al., 2004). 
 
The ZDF rat emerged during attempts to inbreed Zucker fatty rats of 
diabetic lineage (Peterson et al., 1990). ZDF rats are characterised by 
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altered metabolic characteristics, including hyperglycaemia, obesity, 
hyperinsulinaemia and hyperlipidaemia, in addition to altered vascular 
reactivity among other cardiovascular changes (Chirieac et al., 2004; 
Oltman et al., 2008; Zhou et al., 1999). Other genetic animal models 
include the Goto-Kakizaki (GK) rat and Akita mouse, both of which are 
non-obese models of Type II diabetes (Srinivasan et al., 2007).   
 
1.4.2.4. ERK and E-AR-mediated vasodilatation in Type II diabetes 
and obesity 
 
Whilst several studies have investigated the effects of Type II diabetes and 
obesity on E-AR-mediated vasodilatation, less is known about the 
interaction between ERK and these disease states. That ERK activation 
may be increased in hyperglycaemic states is suggested by the observation 
that high glucose conditions cause marked increases in ERK activation in 
vitro (Bandyopadhyay et al., 2000; Natarajan et al., 1999). A study using 
the GK rat model demonstrated that ET-1-induced contractions of 
mesenteric artery were increased in comparison to Wistar control rats 
(Matsumoto et al., 2009). The enhancement of the contractile response 
was accompanied by increased ERK activation and abolished by MEK 
inhibitors.  
 
It has been suggested that attenuated ERK signalling may also contribute 
to pathological changes in these disease states. Compensation for chronic 
myocardial ischaemia in coronary artery disease occurs via the 
development of coronary collateral vessels, which increase myocardial 
delivery and confer a survival benefit (Williams et al., 1976). However, 
collateral vessel development is compromised in diabetes and obesity 
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(Abaci et al., 1999; Yilmaz et al., 2003). It has been proposed that a 
contributory factor may be the reduced ability of insulin to phosphorylate 
ERK and synthesize vascular endothelial growth factor (VEGF) in VSM cells 
(Doronzo et al., 2004).   
 
In a human study of the effects of Type II diabetes on vascular reactivity 
in males, dorsal hand vein diameter was measured following the infusion of 
various vasoactive agents (Harada et al., 1999). Isoprenaline-induced 
venodilatation was significantly impaired in diabetic patients compared to 
controls. The finding that responses to noradrenaline and nitroglycerin did 
not differ between the two groups suggests that the diabetic state altered 
vascular properties unique to E-AR-mediated vasodilatation. Despite the 
small sample size (n=8 in each group) and the fact that all subjects were 
male, the findings were not confounded by differences in age, blood 
pressure or lipid status.  
 
E-AR-mediated vasodilatation is also impaired in animal models of diabetes 
and obesity. Firstly, isoprenaline-induced increases in mesenteric blood 
flow were reduced in Zucker rats compared to control rats (D'Angelo et al., 
2006). Second, maximal isoprenaline-induced relaxations of arterioles from 
the hindlimb vascular bed were significantly reduced in pre-diabetic, short-
term diabetic and long-term diabetic ZDF rats as compared to their 
respective age-matched controls (Lesniewski et al., 2008). Thirdly, in the 
Wistar Ottawa Karlsburg W (WOKW) rat model of metabolic syndrome and 
the ZDF rat model of type II diabetes, Grisk et al. (2007) demonstrated 
impaired E-AR-mediated vasodilatation of coronary arteries at 16 months 
and 3 months of age, respectively.  
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Similar impairments of other vasodilator-stimulated pathways are observed 
in these disease states. For instance, ACh-induced, endothelium-dependent 
relaxations of penile artery and forearm circulation were impaired in 
Zucker rats and humans, respectively (Gazis et al., 1999; Sanchez et al., 
2010). Likewise, reduced K+ channel function has been reported in blood 
vessels of human diabetics (Miura et al., 2003) and in mesenteric artery of 
the ZDF rat (Burnham et al., 2006). Furthermore, dysregulation of 
endogenous contractile factors in both Zucker rats (Ouchi et al., 1996) and 
ZDF rats (Lesniewski et al., 2008) has been shown to accompany impaired 
vasodilatations. 
 
In summary, although it is known that alterations in the expression and 
activation of ERK occur in cardiovascular disease, the relevance of this to 
the functional impairments of E-AR-mediated vasodilatation has not been 
studied.  
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1.4.3. Statins in cardiovascular disease 
 
Statins are lipid regulators and exert this effect by competitively inhibiting 
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, a rate-
limiting enzyme in cholesterol biosynthesis. Thus, statins are employed 
primarily to reduce low-density lipoprotein (LDL) cholesterol. Moreover, 
statins have been reported to have additional, pleiotropic effects, 
independent of their main lipid-lowering activity and likely related to anti-
inflammatory actions. As a result statins reduce the risk of cardiovascular 
disease and are first-line treatments in the primary and secondary 
prevention of cardiovascular disease and in the treatment of 
hypercholesterolaemia and hypertriglyceridaemia (Joint Formularly 
Committee, 2011). Statins have also been proposed as potential 
therapeutic options in disease states as varied as colorectal cancer (Bardou 
et al., 2010) DQG$O]KHLPHU¶VGLVHDVH(McGuinness et al., 2010)    
 
In the UK, five statins are licensed for use, namely atorvastatin, 
fluvastatin, pravastatin sodium, rosuvastatin and simvastatin (Joint 
Formularly Committee, 2011). Their chemical structures are shown in 
Figure 1.7. Although statins are generally well tolerated, their use in 
hepatic impairment is cautioned as they are metabolised by the liver, 
which, incidentally, is their principal site of action. Furthermore, statins 
may produce muscle pains and in severe cases rhabdomyolysis, though 
these side-effects are rare.  
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Figure 1.7. Chemical structures of common statins. Clockwise from top-
left: atorvastatin, fluvastatin, pravastatin sodium, simvastatin and 
rosuvastatin. Structures, adapated from Weitz-Schmidt (2002), were 
drawn using ChemDraw software (CambridgeSoft, Cambridge, MA). 
 
1.4.3.1. The mevalonic acid pathway 
 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, targeted 
by statins, is involved in the rate-limiting step in cholesterol biosynthesis 
(Figure 1.8). Firstly, acetyl-CoA is converted to HMG-CoA. HMG CoA 
reductase, as its name implies, reduces HMG-CoA to mevalonate, which in 
turn is converted to cholesterol via a number of isoprenoid intermediates.  
 
The isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP) play key roles in the activation of Ras and Rho 
GTPases. Specifically, FPP and GGPP are involved in the farnesylation and 
geranylgeranylation Ras and Rho, respectively. These post-translational 
modifications allow the small G-proteins to associate with the plasma 
membrane, where they are activated. Therefore, inhibition of the upstream 
reductase disrupts Ras and Rho activation. The consequences of this effect 
are varied and depend on cell type. As discussed in Section 1.2.2.2, RhoK 
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is involved in VSM contraction, meaning that inhibition of Rho, through the 
inhibition of HMG-CoA reductase, may inhibit contractions. Indeed, 
simvastatin and fluvastatin have been shown to inhibit contractile 
responses to various agents in a GGPP-dependent manner (Shiga et al., 
2005).  
 
 
Figure 1.8. A schematic representation of the mevalonate pathway. 
Statins inhibit HMG-CoA reductase and therefore prevent the formation of 
mevalonate. 
 
1.4.3.2. The effect of statins on ERK activation 
 
As described in Section 1.2.2.5.3, Ras can trigger the ERK signalling 
cascade by activating Raf. Therefore, inhibition of HMG-CoA reductase by 
statins may prevent ERK signalling via the inhibition of upstream Ras. In 
fact, it was shown that simvastatin inhibited ERK actvation in isolated 
vascular smooth muscle cells (Tristano et al., 2007). The consequences of 
inhibition of ERK activity would be associated with reduced cell 
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differentiation, cell growth and vasoconstriction, as ERK is involved in 
these processes. As vascular remodelling and excessive contractility are 
generally considered injurious to cardiovascular health, these theorized 
effects of statins would be welcomed, particularly in cardiovascular disease 
states characterised by increased ERK activation. Therefore, inhibition of 
ERK activation using statins represents a promising therapeutic strategy in 
the treatment of cardiovascular disease.  
 
1.4.3.3. The effects of statins in vitro 
 
Due to the ubiquitous expression of the mevalonate pathway enzymes in 
eukaryotes, HMG-CoA inhibition by statins has the potential to influence 
numerous processes in a range of tissues. However, the ability of statins to 
penetrate the plasma membrane, a property defined by their intrinsic 
lipophilicity, may represent a barrier to the actions of weakly lipophilic, 
strongly hydrophobic statins. Variations between the lipophilicities of 
individual statins are appreciated, with simvastatin and pravastatin, for 
example, differing in relative lipophilicity by a factor of > 1000:1 
(Serajuddin et al., 1991). Furthermore, the ionic charge of a statin is likely 
to influence its lipophilicity, this being relevant because various statins can 
be acquired in salt form (typically Na+). This property has been used to 
explain discrepancies in the effects of statins in a number of tissues. For 
instance, simvastatin and lovastatin, also liphophilic, were shown to alter 
rat basilar arterial tone, whereas pravastatin was without effect (Bergdahl 
et al., 2003). However, the roles of specific membrane transporter 
molecules should not be ignored, as they represent a means by which 
weakly lipophilic statins may enter the cell. This is proposed to underlie the 
ability of such statins to inhibit cholesterol synthesis in hepatocytes 
(Yamazaki et al., 1993). On the other hand, unopposed access to virtually 
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any cell, a freedom shared by lipophilic statins, would inevitably be related 
to a greater chance of undesirable effects.  
 
A further issue relating to the effect of statins is the requirement of HMG-
CoA reductase, also called mevalonate dependence. Assessments of the 
mevalonate dependence of statins are made by supplementing the system 
under investigation with mevalonate. As statins inhibit HMG-CoA reductase 
competitively, mevalonate supplementation would be expected to reverse 
the effects of statins that occur as a result of HMG-CoA reductase 
inhibition. Conversely, mevalonate supplementation would not be expected 
to alter any effects of statins that are independent of HMG-CoA reductase 
inhibition. 
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1.5. SUMMARY 
 
Although E-AR-mediated vasorelaxation has been extensively studied for 
several decades, the exact mechanisms involved are not fully understood 
and may vary from blood vessel to blood vessel.  Indeed, the finding that 
isoprenaline and other E-AR ligands were able to activate ERK (Daaka et 
al., 1997; Baker et al., 2003), suggests ERK may be involved in this 
process. However, it will be noted that these observations were made in 
cultured cells and may not be physiologically relevant. Increased ERK 
activation has been observed in hypertension (Kim et al., 1997) and heart 
failure (Dong et al., 2006), suggesting that the influence of ERK on E-AR-
mediated vasodilatation may be greater in such disease states. 
Furthermore, the fact that statins have been shown to inhibit ERK 
activation in vascular smooth muscle cells (Tristano et al., 2007) suggests 
they may alter any influence of ERK on E-AR-mediated vasodilatation. 
 
The primary aims of this investigation are to determine whether ERK is 
involved in E-AR-mediated vasodilatation and, if so, to describe its role in 
this process. The porcine coronary artery (PCA) will be used as the primary 
preparation in this investigation owing to the favourable price and 
availability of porcine tissue and the anatomical and physiological 
similarities between pigs and humans.  However, animal models of named 
disease states will also be employed where possible. Finally, the 
therapeutic potential of statins within the context of the findings will be 
explored. The outline of investigation is shown in Figure 1.9.  
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Figure 1.9. Plan of investigation. The effect of ERK on E-AR-mediated 
vasodilatation in the primary preparation (PCA) and in animal models of 
human disease will be investigated. 
 
 
x Identify components and mechanisms of E-AR-
mediated vasodilatation in porcine coronary 
artery (PCA): 
o Subtype specificity [Chapter 2] 
o AC/cAMP/PKA [Chapter 2] 
o K+ channels [Chapter 3] 
o Endothelium [Chapter 2 and Appendix] 
E-AR-mediated vasodilatation 
x Determine the role of ERK in E-AR-mediated 
vasodilatation in PCA 
o identify interactions between ERK and 
components/mechanisms of E-AR-
mediated vasodilatation [Chapters 2 and 3] 
ERK and E-AR-mediated vasodilatation 
x Determine relevance to clinical setting by 
exploring: 
o the role of ERK in E-AR-mediated 
vasodilatation in animal models of human 
disease [Chapter 4] 
o potential therapeutic 
approaches/strategies targeting ERK in E-
AR-mediated vasodilatation [Chapter 5] 
Clinical significance 
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CHAPTER 2: THE ROLE OF ERK IN  
E-ADRENOCEPTOR-MEDIATED VASODILATATION 
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2.1. INTRODUCTION 
 
E-Adrenoceptors (E-ARs) have been extensively studied owing to their 
widespread expression in mammalian tissues, and the fruits of this 
research have led to successful treatments for a number of disease states, 
including those affecting the cardiovascular system. Although E-AR 
agonists have not been used in the treatment of cardiovascular disease, 
their potential use is suggested by their ability to induce vasodilatation 
when applied to blood vessels. Various mechanisms have been proposed to 
underlie this effect, including the increased production of the second 
messenger cAMP (cAMP) (Murray, 1990) and the opening of K+ channels 
(White et al., 2001).  
 
E-AR signalling has also been linked to extracellular signal-regulated kinase 
(ERK) activity. For instance, the E-AR agonist isoprenaline increased ERK 
activation in Chinese Hamster Ovary (CHO) cells stably expressing human 
E2-ARs (Baker et al., 2003). ERK has previously been studied in the context 
of blood vessels, where its activation has been associated with contractile 
responses (Roberts, 2001). In this chapter, experiments will aim to 
reconcile the seemingly divergent findings that E-AR agonists elicit smooth 
muscle relaxation and also activate ERK, which itself mediates contraction. 
The interaction between ERK and various components of E-AR signalling 
will be investigated.  
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2.2. MATERIALS AND METHODS 
 
2.2.1. Isometric Tension Recordings 
 
2.2.1.1. Tissue preparation 
 
Hearts were obtained from freshly-slaughtered pigs courtesy of a local 
abattoir. The hearts were transferred from the abattoir at ice-cold 
temperature in Krebs-Henseleit (KH) solution, which was pre-gassed with 
O2-CO2 (95:5) and contained, in mM, the following: NaCl, 128; KCl, 4.8; 
MgSO4, 1.1; NaHCO3, 25; KH2PO4, 1.2; d-glucose, 12; CaCl2, 1.25. The 
anterior, descending coronary artery was dissected from each heart, 
stripped of its adipose and connective tissue and finally stored overnight at 
4qC in pre-gassed KH solution containing 2% (w/v) Ficoll.  
 
The following day 2 mm rings segments (1 mm diameter) were dissected 
from the distal portion of each coronary artery under a light microscope, 
and were fitted to a Mulvany, four-channel wire myograph which itself was 
attached to a MacLab data acquisition system (ADInstruments Ltd, 
Charlsgrove, UK). Each ring segment was bathed in 5 ml KH solution 
gassed with O2/CO2 mixture (95:5) at 37qC. After a 20 minute equilibration 
period, a resting tension of 2.5 g (determined in pilot studies to yield 
reproducible contractions to 60 mM KCl) was applied to each ring segment.  
 
2.2.1.2. Experimental procedure 
 
KCl was applied to each well to achieve a final concentration of 60 mM in 
order to confirm tissue viability and to determine maximal tissue 
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contractile capacities. The arteries were then thoroughly rinsed with KH 
solution and allowed to re-equilibrate for 15 to 20 mins. The process was 
repeated twice. 
 
2.2.1.2.1. The effect of MEK inhibition on E-AR-mediated relaxation  
 
In order to determine the role of ERK in E-AR-mediated vasodilatation, 
arteries were incubated for 45 mins with KH solution containing the MEK 
inhibitor PD98059 (10 PM or 50 PM) (Alessi et al., 1995). PD98059, 
insoluble in water, was reconstituted in DMSO whilst control arteries were 
incubated for the same length of time in KH solution containing DMSO only 
(0.26% (v/v) DMSO for 50 PM PD98059 and 0.05% (v/v) DMSO for 10 PM 
PD98059). At the end of the incubation period, arteries were immediately 
exposed to the thromboxane mimetic U46619 (10 nM ± 20 nM) in order to 
evoke a contractile tone equivalent to 65±80% of the maximal KCl 
response and against which subsequent relaxation responses would be 
standardised. Once a stable tone was achieved, cumulative concentrations 
of the non-selective E-AR agonist isoprenaline (1 nM ± 10 PM) were applied 
to relax the tissues.    
 
The general experimental protocol described above was repeated for 
experiments in which arteries were incubated with the structurally 
dissimilar MEK inhibitors U0126 (Davies et al., 2000) or its inactive 
congener U0124 (10 PM) (Favata et al., 1998), rather than PD98059.  
 
Finally, to examine the importance of the contraction phase of the 
experiment on the effect of PD98059, arteries pre-incubated with PD98059 
were exposed to endothelin-1 (1 nM ± 10 nM), rather than U46619, prior 
to relaxation with cumulative concentrations of salbutamol. 
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2.2.1.2.2. The effect of MEK inhibition on E1- and E2-AR-mediated 
relaxation  
 
In experiments investigating the roles of specific E-AR subtypes, E1- and 
E2-AR-selective agonists and antagonists were employed. Following 
incubation with PD98059 and contraction using U46619, arteries were 
relaxed with cumulative concentrations of the E2-AR agonist salbutamol (10 
nM ± 30 PM) or the E1-AR agonist xamoterol (1 nM ± 30 PM). The MEK 
inhibitor PD184352 (5 PM) (Allen et al., 2003) was also assessed against 
relaxations to salbutamol.  
 
Arteries were exposed to the E1-AR antagonist CGP20712A (Gustafsson et 
al., 2000) before being pre-contracted and then relaxed with xamoterol. In 
addition, arteries were incubated with the combination of PD98059 and 
CGP20712A prior to assessing salbutamol relaxations.  
 
2.2.1.2.3. The effect of MEK inhibition on cAMP-mediated relaxation 
 
The adenylyl cyclase (AC) activator forskolin (1 nM ± 3 PM) (de Souza et 
al., 1983) was used to relax pre-contracted arteries incubated with 
PD98059 in order to assess the role of the cAMP-PKA signalling pathway. 
In later experiments, arteries were incubated with the AC inhibitor 
SQ22536 (100 PM) (Hourani et al., 2001) prior to relaxation with forskolin. 
Furthermore, separate experiments assessed the combined effect of 
SQ22536 with 2',5'-dideoxyadenosine (DDA, 50 PM) (Sabouni et al., 1991) 
and adenosine-3',5'-cyclic monophosphorothioate (Rp-cAMPS, 100 PM) 
(Hirshman et al., 2005), inhibitors of AC and PKA, respectively.  
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2.2.1.2.4. The role of the endothelium in E-AR-mediated relaxation 
 
In order to determine the role of endothelium-derived NO, isoprenaline 
relaxation curves were performed following 45 mins incubation with the NO 
synthase inhibitor L-NAME (300 PM).  
 
2.2.1.2.5. The effect of MEK inhibition on TP receptor-mediated 
contraction  
 
The effect of MEK inhibition on TP receptor-mediated contraction was 
determined by performing cumulative contraction curves to U46619 in the 
absence and presence of PD98059 (60 mins incubation period).  
 
2.2.2. Measurement of ERK activation 
 
As previously described in our laboratory (Roberts, 2001), the 
phosphorylation state of ERK at Thr-202 and Tyr-204 was measured using 
Western immunoblotting. 
 
2.2.2.1. Tissue preparation 
 
Porcine coronary artery ring segments were set up in 5 ml organ baths 
attached to a computer via a MacLab data acquisition system. The baths 
contained KH solution and were maintained at 37qC. After three 
consecutive KCl (60 mM) challenges, arteries received one of the following 
treatments: U46619 (10 ± 20 nM), in order to achieve 60±85% of the 
maximal KCl contraction; a submaximal concentration of isoprenaline (1 
PM); or U46619 until a steady contractile tone was achieved, followed by 
isoprenaline. Control arteries received no treatment.  
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Efforts were made to be consistent with the timing of drug addition and the 
removal of arteries from their baths prior to freezing. Thus, arteries 
exposed to U46619 alone were removed from their baths at the point at 
which a steady contractile plateau was reached; control arteries were 
removed at the same time. Isoprenaline was added to the two remaining 
arteries once the second artery receiving U46619 reached its plateau. Once 
the relaxation to isoprenaline had reached its maximum, both arteries were 
removed from their baths and frozen by rapidly placing the arteries on dry 
ice immediately. Finally, the arteries were stored overnight at -80qC.  
 
After defrosting, arteries were chopped into smaller pieces and 
homogenised for approximately 30 seconds (FisherBrand 0.1ml glass-glass 
homogeniser) in ice-cold buffer containing a mixture of components which 
collectively acted to (1) release constituent proteins within the tissue 
sample, allowing them to migrate individually through electrophoresis gels, 
and (2) reduce the rate of protein degradation by inhibiting protease and 
phosphatase enzymes. Specifically, the agents used were: 80 mM sodium 
E-glycerophosphate, 20 mM imidazole [pH 7.6], 1 mM dithiothreitol (DTT), 
1 mM sodium fluoride (NaF), 500 µM 4-(2-aminoethyl)benzenesulphonyl 
fluoride (AEBSF), 1 µM trans-epoxysuccinyl-L-leucylamide-(4-guanidino) 
butane (E-64), 10 µg ml-1 aprotonin, 1 µM leupeptin and 500 µM EDTA 
(Roberts, 2001).  
 
2.2.2.2. Bradford Protein Assay 
 
A fraction of each homogenate was used to estimate protein concentration 
using the Bradford protein assay. Firstly, a standard concentration curve of 
bovine serum albumin (BSA) was prepared using the following 
concentrations: 2 mg ml-1, 1 mg ml-1, 0.5 mg ml-1, 0.25 mg ml-1 and 0.125 
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mg ml-1. The diluent used contained homogenisation buffer at 
concentrations listed above. 10 Pl of each sample was loaded in pairs onto 
a 96-well plate, along with each concentration of BSA and a pair of blanks 
(diluent only). Each well was topped up with 40 Pl BioRad protein assay 
dye reagent concentrate and 150 Pl distilled water. Absorbance readings, 
measured at 595 nm, were generated using a microplate reader and used 
to estimate the concentration of protein in each sample. These estimates in 
turn were used to determine the volume of each homogenate sample to be 
used in the next stage of the experiment.  
 
2.2.2.3. Western immunoblotting 
 
The remainder of the homogenised samples were diluted (1:1) in Laemmli 
sample buffer (4% (w/v) SDS, 20% (w/v) glycerol, 10% (v/v) 2-
mercaptoethanol, 0.004% (v/v) bromophenol blue and 0.125 M Tris HCl at 
pH 6.8) and heated at 95qC for 5 min. Equal amounts of each sample (5 Pg 
protein) were carefully loaded into wells of pre-cast 10% (w/v) SDS-PAGE 
gels3URWHLQORDGLQJZDVQRWFRUUHFWHGIRUXVLQJD³KRXVHNHHSLQJ´SURWHLQ
such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Loaded gels 
were slotted into an electrode tank containing electrophoresis buffer (25 
mM Tris, 192 mM glycine and 0.1% (w/v) SDS in distilled H2O at pH 8.3). 
A potential difference of 150 V was placed across the gel for 65 mins, 
causing protein separation. Protein was transferred from gel to 
nitrocellulose membrane (GE Healthcare Life Sciences, Amersham, UK) 
using a mini Transblot (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) 
immersed in transfer buffer (25 mM Tris, 192 mM glycine and 20% 
methanol in distilled H20 at pH 8.3). A voltage of 100 V was applied for 60 
mins.  
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To prevent non-specific attachment of antibodies to the nitrocellulose 
membrane, the membrane was µEORFNHG¶E\ incubating for 60 min in 5% 
(w/v) milk solution (Marvel skimmed milk powder dissolved in Tris-
buffered saline [25 mM Tris, 125 mM NaCl to pH 7.6 in distilled H20] 
containing 0.1% Tween-20). Membranes were incubated overnight at 4qC 
in 5% (w/v) PLON VROXWLRQ FRQWDLQLQJ D  LQ  GLOXWLRQ RI ³SULPDU\´
antibodies specific to (i) the dual-phosphorylated forms of ERK1/2 and (ii) 
total ERK1/2 (New England Biolabs, Hitchin, UK).   
 
The following morning, membrane blots were incubated at room 
temperature for 60 mins in 5% (w/v) milk solution containing 
fluorescently-tagged ³VHFRQGDU\´ antibodies (1 in 10,000 dilution) raised in 
goat against mouse (LI-COR IRDye 680 nm [phosphorylated ERK]) or 
rabbit (LI-COR IRDye 800 nm [total ERK]) proteins (LI-COR Biotechnology 
Ltd., Cambridge, UK). The blots were then scanned at 700 nm and 800 nm 
wavelengths using an Odyssey Infrared Imaging System (LI-COR 
Biotechnology Ltd., Cambridge, UK). Odyssey software (LI-COR 
Biotechnology Ltd., Cambridge, UK) was used to analyse the optical 
densities and molecular weights of the visualised bands.   
  
2.2.3. Statistical and data analyses 
 
Data were analysed using GraphPad Prism 5.0 (Graphpad Software Inc., La 
Jolla, CA, USA). Relaxation response measurements are expressed as 
means r SEM. Statistical comparisons between groups were made using 
the two-WDLOHG XQSDLUHG 6WXGHQW¶V W-test except where stated. As there 
were insufficient repeat experiments to determine distribution, the data 
were assumed to be normally distributed and parametric tests were 
employed. A P value < 0.05 was considered statistically significant. In all 
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H[SHULPHQWV ³Q´ QXPEHUV UHSUHVHQW WKH QXPEHU RI DQLPDOV from which 
tissues were obtained.  
The following equation, based on Gaddum analysis (Gaddum, 1957; 
Lazareno et al., 1993), was used to estimate the binding affinity of 
competitive antagonists, KD: 
KD   =  [antagonist]  
          (dose ratio - 1) 
 
[Antagonist] represents a fixed concentration of antagonist and the dose 
ratio is the ratio of EC50 values of functional responses measured in the 
presence and absence of the antagonist. 
 
2.2.4. Materials 
 
2-Amino-3-PHWKR[\ÀDYRQH 3' ZDV REWDLQHG IURP &DOELRFKHP
Beeston, Nottingham. Forskolin, salbutamol (sulphate salt) and (Z)-7-
[(1S,3S,4S)-3-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxabicyclo[2.2.1]heptan-2-
yl]hept-5-enoic acid (U46619) were obtained from Axxora (Bingham, 
Nottinghamshire, UK).  
 
Xamoterol, salbutamol (neutral and hemisulphate salt), (2Z,3Z)-2,3-
bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile (U0126), 
(Z,2Z)-4-amino-2-[amino(methylsulfanyl)methylidene]-3-isocyano-4-
methylsulfanylbut-3-enenitrile (U0124), 2-(2-chloro-4-iodoanilino)-N-
(cyclopropylmethoxy)-3,4-difluorobenzamide (PD184352), 2-hydroxy-5-[2-
[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-
yl]phenoxy]propyl]amino]ethoxy]benzamide (CGP20712A), 9-(oxolan-2-
yl)purin-6-amine (SQ22536), (R)-adenosine cyclic-3,5-
hydrogenphosphorothioate triethylammonium (Rp-cAMPS, 6-(6-
aminopurin-9-yl)-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-
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furo[3,2-d][1,3,2]dioxaphosphinin-7-ol) and 4-[5-(4-Fluorophenyl)-2-[4-
(methylsulfonyl)phenyl]-1H-imidazol-4-yl]pyridine (SB 203580) were 
obtained from Tocris Bioscience (Bristol, UK). N'-Nitro-L-arginine-methyl 
ester hydrochloride (L-NAME, methyl (2S)-2-amino-5-
>>DPLQRQLWUDPLGRPHWK\OLGHQH@DPLQR@SHQWDQRDWH ¶¶-
dideoxyadenosine (DDA, (2R,3S,5R)-5-(6-aminopurin-9-yl)-2-
methyloxolan-3-ol)), endothelin 1, isoprenaline and the remaining 
chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK). 
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2.3. RESULTS 
 
2.3.1. The effect of MEK inhibition on E-AR-mediated relaxation 
 
Application of E-AR agonists produced a concentration-dependent 
relaxation of pre-contracted coronary artery segments. A representative 
trace is shown in Figure 2.1. Relaxations to isoprenaline (1 nM ± 3 PM) 
were enhanced by pre-incubation with the MEK inhibitor PD98059 (10 µM), 
with pEC50 values increasing from 7.9 ± 0.1 in controls (0.05% (v/v) 
DMSO) to 8.1 ± 0.1 (P<0.05; Figure 2.2).  
 
 
Figure 2.1. A representative trace of U46619- and isoprenaline-evoked 
responses in PCA. U46619 (10±20 nM) was used to contract PCA before 
relaxations were induced using cumulative concentrations of isoprenaline. 
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Figure 2.2. The effect of MEK inhibition on isoprenaline relaxations in PCA 
(n=7). PD98059 (10 µM) increased isoprenaline pEC50 values from 7.9 ± 
0.1 in controls (0.05% (v/v) DMSO) to 8.1 ± 0.1 (P<0.05). 
 
50 µM PD98059 also caused an enhancement of isoprenaline responses, 
increasing pEC50 values from 7.5 ± 0.1 in controls (0.26% (v/v) DMSO) to 
8.1 ± 0.1 (P<0.05; Figure 2.3). Neither concentration of PD98059 
significantly affected the maximal response to isoprenaline.  
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Figure 2.3. The effect of MEK inhibition on isoprenaline relaxations in PCA 
(n=6). Incubation with PD98059 (50 PM) resulted in a leftward shift of the 
isoprenaline response curve, with pEC50 values increasing from 7.5 ± 0.1 in 
controls (0.26% (v/v) DMSO) to 8.1 ± 0.1 (P<0.05). 
 
The structurally dissimilar MEK inhibitor U0126 (10 PM) produced similar 
effects: pEC50 values were increased from 8.0 ± 0.1 in controls (0.05% 
(v/v) DMSO) to 8.4 ± 0.2 (P<0.05; Figure 2.4). However, as shown in 
Figure 2.5, U0124 (10 PM), a pharmacologically inactive variant of U0126, 
failed to alter isoprenaline relaxations (pEC50 value of 7.9 r 0.1 in both 
control and U0124-exposed vessels; P>0.05).  
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Figure 2.4. The effect of the MEK inhibitor U0126 on isoprenaline 
relaxations in PCA (n=15). In comparison to control experiments (0.05% 
(v/v) DMSO), U0126 (10 PM) enhanced isoprenaline relaxations, increasing 
pEC50 values from 8.0 ± 0.1 in controls (0.05% (v/v) DMSO) to 8.4 ± 0.2 
(P<0.05). 
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Figure 2.5. Isoprenaline concentration-response curves in the absence 
(0.05% (v/v) DMSO) and presence of U0124, the inactive congener of the 
MEK inhibitor U0126 (n=4 or 5). In contrast to U0126, U0124 did not 
enhance isoprenaline relaxations (pEC50 value of 7.9 r 0.1 in both 
experiments; P>0.05). 
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2.3.2. The effect of MEK inhibition on E1- and E2-AR-mediated 
relaxation  
 
As shown in Figure 2.6, relaxations induced by the E2-AR agonist 
salbutamol (10 nM ± 30 PM) were also enhanced by MEK inhibition. 
PD98059 (50 PM) significantly increased relaxation responses to 
salbutamol at 1 PM (12 r 4% in controls to 35 r 11%; P<0.05), 3 PM (28 r 
7 % to 59 r 13%; P<0.05), 10 PM (44 r 9% to 83 r 13%; P<0.05) and 30 
PM (54 r 10% to 92 r 13%; P<0.05).  
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Figure 2.6. The effect of MEK inhibition on relaxations to salbutamol in 
PCA rings pre-contracted with U46619 (n=9). Salbutamol produced a 
concentration-dependent relaxation of PCA rings pre-contracted with 
U46619. Compared to corresponding relaxations in control experiments 
(0.26% (v/v) DMSO), relaxations to 1 PM, 3 PM, 10 PM and 30 PM 
salbutamol in PD98059-exposed ring segments were significantly greater 
(P<0.05). 
 
The MEK inhibitor PD184352 (5 PM) also produced an enhancement of 
salbutamol responses, increasing the log concentration required to produce 
50% of the response to 30 PM salbutamol from -7.1 r 0.2 in controls to -
7.7 r 0.3 (P<0.05; Figure 2.7). A similar enhancement was observed when 
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artery segments pre-exposed to PD98059 were pre-contracted with 
endothelin-1, rather than U46619, and subsequently relaxed with 
salbutamol (relaxation response to 30 PM salbutamol 40 r 7% in controls 
compared to 66 r 7% in PD98059-incubated arteries; P<0.05; Figure 2.8).  
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Figure 2.7. The effect of the MEK inhibitor PD184352 (5 PM) on 
salbutamol-induced relaxations in PCA (n=4 or 5). PCA rings were pre-
contacted using U46619. PD184352 increased the log concentration 
required to produce 50% of the response to 30 PM salbutamol from -7.1 r 
0.2 in controls (0.1% (v/v) DMSO) to -7.7 r 0.3 (P<0.05). 
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Figure 2.8. The effect of MEK inhibition on salbutamol relaxations in PCA 
rings pre-contracted with endothelin-1 (n=16 or 17). The relaxation 
response to 30 PM salbutamol was greater in PCA rings incubated with 50 
PM PD98059 (66 r 7%) than in controls (0.26% (v/v) DMSO; 40 r 7% 
relaxation; P<0.05).  
 
PD98059 (50 PM) did not change the relaxation characteristics of the E1-AR 
agonist xamoterol (1 nM ± 30 PM; RMAX in controls = 56 r 15% relaxation 
compared to 58 r 5% in PD98059-incubated vessels, P>0.05; pEC50 in 
controls = 6.2 r 0.2 compared to 6.2 r 0.1 in PD98059-incubated vessels, 
P>0.05; Figure 2.9).  
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Figure 2.9. The effect of the MEK inhibitor PD98059 on E1-AR-mediated 
vasodilatation induced by xamoterol (n=7). PD98059 (50 PM) did not alter 
relaxations to the E1-AR agonist xamoterol (control RMAX = 56 r 15% 
relaxation versus 58 r 5% in PD98059-treated vessels, P>0.05; control 
pEC50 = 6.2 r 0.2 compared to 6.2 r 0.1 in PD98059-treated vessels, 
P>0.05). Control experiments were performed in 0.26% (v/v) DMSO. 
 
The E1±AR antagonist CGP20712A (10 nM) significantly inhibited 
relaxations to xamoterol, reducing the control pEC50 value from 7.2 r 0.3 to 
5.6 r 0.3 (P<0.01; Figure 2.10; KB = 0.26 nM). CGP20712A did not 
prevent the enhancement of salbutamol-induced relaxations by PD98059 
(response to 10 PM salbutamol of 74 r 6% in controls, versus 97 r 4% in 
the presence of PD98059 and CGP20712A; P<0.01; Figure 2.11).  
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Figure 2.10. The effect of E1-AR blockade on relaxations to xamoterol in 
PCA (n=4 or 5). The E1-AR antagonist CGP20712A (10 PM) shifted the 
xamoterol relaxation curve to the right, corresponding to a reduction in 
pEC50 from 7.2 r 0.3 in control rings (0.26% (v/v) DMSO) to 5.6 r 0.3 in 
CGP20712A-treated rings (P<0.01; KB = 0.26 nM). 
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Figure 2.11. The effect of MEK inhibition on salbutamol-induced 
relaxations in PCA rings treated with the E1-AR antagonist CGP20712A 
(n=8 or 11). Pre-incubation with CGP20712A (10 PM) did not prevent 
enhancement of salbutamol relaxations by PD98059. Relaxations to 10 PM 
salbutamol were significantly greater in PD98059+CP20712A-treated rings 
(pEC50 value 7.2 r 0.3) than in controls (0.26% (v/v) DMSO; pEC50 value 
5.6 r 0.3; P<0.01). 
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2.3.3. The effect of MEK inhibition on cAMP-mediated relaxation 
 
Pre-contracted porcine coronary artery segments were relaxed by the 
adenylyl cyclase activator forskolin (1 nM ± 3 PM) (de Souza et al., 1983) 
in a concentration-dependent manner. Pre-incubation with PD98059 had 
no effect on the relaxation characteristics (Figure 2.12).  
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Figure 2.12. The effect of PD98059 on relaxations to the AC activator 
forskolin in PCA (n=6). Pre-incubation with PD98059 (50 PM) did not alter 
relaxations to forskolin in comparison to control experiments, which were 
performed in 0.26% (v/v) DMSO. Forskolin produced RMAX values of 126 r 
6% and 115 r 4% in control and PD98059 experiments, respectively 
(P>0.05); corresponding pEC50 values were 7.3 r 0.1 and 7.4 r 0.1, 
respectively (P<0.05). 
 
 
SQ 22536, an adenylyl cyclase inhibitor (Hourani et al., 2001), had no 
effect on forskolin relaxations, either alone (100 PM; Figure 2.13) or in 
combination with other inhibitors of cAMP signalling, namely the adenylyl 
cyclase inhibitor DDA (50 PM) and PKA inhibitor Rp-cAMPS (100 PM; Figure 
2.14). As these agents were unable to inhibit forskolin relaxations, they 
were not assessed for effects against E-AR agonist-induced relaxations.  
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Figure 2.13. Forskolin-induced relaxations in PCA rings pre-incubated with 
an inhibitor of adenylyl cyclase (n=2). The relaxation characteristics of 
forskolin in PCA were very similar in the absence and presence of SQ22536 
(100 PM). 
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Figure 2.14. The effect of inhibition of the AC/cAMP/PKA pathway on 
forskolin-induced relaxations (n=2). The combination of the AC inhibitors 
SQ22536 (100 PM) and DDA (50 PM) and the PKA inhibitor Rp-cAMPS (100 
PM) failed to alter relaxations to forskolin. 
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2.3.4. The role of the endothelium in E-AR-mediated relaxation 
 
In experiments assessing the effect of NO synthase inhibition on E-AR-
mediated relaxations, the potency of isoprenaline was reduced by L-NAME 
(300 PM), with pEC50 values falling from 7.7 r 0.1 in controls to 7.5 r 0.1 
in treated artery segments (P<0.05, two-WDLOHGXQSDLUHG6WXGHQW¶VW-test; 
Figure 2.15). In contrast, RMAX values were increased by L-NAME, rising 
from 112 r 3% in controls to 122 r 4% (P<0.05).  
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Figure 2.15. The effect of eNOS inhibition on relaxation curves to 
isoprenaline in PCA (n=7). L-NAME (300 PM) reduced the potency of 
isoprenaline relaxations (7.5 r 0.1 versus 7.7 r 0.1 in controls; P<0.05) 
but increased RMAX (122 r 4% versus 112 r 3% in controls; P<0.05). 
 
 
 
2.3.5. The effect of MEK inhibition on TP receptor-mediated 
contraction 
 
U46619 evoked a concentration-dependent contraction of PCA rings (Figure 
2.16). Pre-incubation with PD98059 caused a rightward shift of the 
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concentration response curve, with the mean pEC50 value falling from 7.6 r 
0.1 in control arteries to 7.2 r 0.1 in PD98059-treated arteries (P<0.05).  
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Figure 2.16. The effect of MEK inhibition on TP receptor-mediated 
contractions in PCA (n=5). Contractions to U46619 were inhibited by 50 PM 
PD98059 (mean pEC50 value fell from 7.6 r 0.1 in controls (0.26% (v/v) 
DMOS) to 7.2 r 0.1; P<0.05). 
 
 
2.3.6. The effect of TP receptor and E-AR activation on ERK 
activation 
 
The effects of various treatments on levels of phosphorylated ERK (pERK), 
total ERK (tERK) and the ratio of pERK to tERK in PCA, including a 
representative blot, are shown in Figure 2.17. Values in Figures 2.17B 
(ERK2) and 2.17C (ERK1) are normalised to basal levels (control arteries 
received no treatment).  
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Figure 2.17. The effect of TP receptor and E-AR activation on ERK 
activation in PCA. (A) Representative immunoblot of ERK activation. Prior 
to freezing and homogenisation, PCA segments were pre-treated as 
follows: (a) no treatment (control), (b) U46619, (c) U46619 + isoprenaline 
and (d) isoprenaline. (B) and (C) The effect of U46619, isoprenaline and 
both agents in combination on levels of pERK, tERK and pERK expressed as 
a fraction of tERK (ERK2 (B) and ERK1 (C)). All data, shown as means r 
SEM (n=3), are normalised to the corresponding control value (arteries not 
exposed to any compound).  
 
 
The intensity of pERK2 in arteries treated with U46619, isoprenaline and 
both agents in combination were raised compared to controls but did not 
A 
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differ significantly from each other (P>0.05, one-way ANOVA followed by 
'XQQHWW¶VPXOWLSOHFRPSDULVRQVWHVWTotal ERK2 levels were unchanged in 
all treatment groups. In arteries treated with the combination of U46619 
and isoprenaline, the ratio of pERK2 to tERK2 increased by a factor of 1.48 
r 0.10 (P<0.05, one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V PXOWLSOH
comparisons test).  
 
U46619 and the combination of U46619 and isoprenaline increased levels 
of pERK1 by factors of 1.51 r 0.09 and 1.54 r 0.10, respectively (P<0.05, 
one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V PXOWLSOH FRPSDULVRQV WHVW
Isoprenaline slightly increased pERK1 levels but the change was 
statistically non-significant. As observed in the tERK2 dataset, none of the 
treatments altered tERK1 levels. The ratio of pERK1 to tERK1 was 
increased from control in each treatment group. U46619 alone, U46619 + 
isoprenaline and isoprenaline alone produced a 1.36 r 0.08 ±fold (P<0.01, 
one-ZD\$129$IROORZHGE\'XQQHWW¶VPXOWLSOHFRPSDULVRQVWHVWr 
0.02 ±fold increase (P<0.005, one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V
multiple comparisons test) and 1.28 r 0.08 ±fold (P<0.05, one-way ANOVA 
IROORZHG E\ 'XQQHWW¶V PXOWLSOH FRPSDULVRQV WHVW LQFUHDVH LQ WKH UDWLR
(one-ZD\$129$IROORZHGE\'XQQHWW¶VPXOWLSOHFRPSDULVRQVWHVW 
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2.4. DISCUSSION 
 
Porcine coronary artery (PCA) rings were pre-contracted with the 
thromboxane mimetic U46619, and the cumulative application of 
isoprenaline (1 nM ± 3 PM) completely reversed the contractile tone. E-ARs 
are known to mediate relaxation responses in blood vessels and indeed the 
vasorelaxant effect of isoprenaline observed in the current investigation 
has frequently been reported in the literature (Begonha, 1995; Graves et 
al., 1993; Ushio-Fukai et al., 1993).  
 
Variations in isoprenaline-induced relaxations were observed between sets 
of experiments. For instance, isoprenaline relaxed control PCA rings with 
greater potency in the experiment shown in Figure 2.2 (pEC50 = 7.9 r 0.1) 
than in the experiment shown in Figure 2.3 (pEC50 = 7.5 r 0.1). Similar 
observations were made with salbutamol-induced relaxations. These 
variations may be explained by the heterogeneity of the animals from 
which tissues were obtained (pigs used were of either sex and, unlike the 
rat models described in Chapter 4 of this report, were reared in largely 
uncontrolled environments). A possible approach to controlling for inter-
animal variability involves SHUIRUPLQJ ERWK ³DUPV´ RI WKH H[SHULPHQW RQ
the same tissue segment. Initially, the experiment would be performed in 
the absence of investigational drug(s), i.e. control conditions. After 
thorough washout, the procedure would be repeated in the presence of 
investigational drug(s). 
 
PCA rings that were pre-incubated with the selective MEK inhibitor 
PD98059 (10 PM) (Alessi et al., 1995) were more responsive to the 
vasorelaxant effects of isoprenaline, as indicated by a significant leftward 
shift in the concentration-response curve. Pre-incubation with a higher 
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concentration of PD98059, namely 50 PM, produced a more noticeable 
leftward-shift of the concentration-response curve to isoprenaline, 
suggesting a concentration-dependent effect of the MEK inhibitor. 
 
The MEK inhibitors U0126 (10 PM) (Davies et al., 2000) and PD184352 (5 
PM) (Allen et al., 2003) caused a similar enhancement of the E-AR-
mediated relaxation responses. Although the three MEK inhibitors produced 
the same effect in these experiments, their chemical structures are 
unrelated (Figure 1.5). This lends credence to the proposal that their 
common effect is related to MEK inhibition, rather than a result of 
interactions with non-specific targets. In further support of this is the 
observation that U0124 (10 PM) (Favata et al., 1998), the inactive 
analogue of U0126, did not alter relaxation responses to isoprenaline. 
Taken together, these data suggest that ERK acts to limit the degree of 
vasodilatation elicited by E-AR stimulation and that this inhibitory influence 
is removed in the presence of MEK inhibitors.  
 
Using radioligand binding studies, Schwartz et al. (1983) detected the 
expression of E1- and E2-ARs in PCA and calculated that the receptor 
subtypes existed in a ratio of approximately 65:35. A similar ratio (70:30) 
was later described in the proximal region of the same vessel (Brehm et 
al., 1999). Activation of each of E-AR subtype with selective agonists in 
bovine coronary artery resulted in artery dilatation, which itself was 
abolished by corresponding subtype-selective receptor antagonists (Vatner 
et al., 1986). Xamoterol (Nuttall et al., 1982) and salbutamol (Cullum et 
al., 1969) have previously been shown to be selective agonists at the E1- 
and E2-AR, respectively. 
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In the current investigation, activation of E-ARs using these agents caused 
vasodilatation of pre-contracted PCA, suggesting that both E1- and E2-AR 
may regulate PCA blood flow. The selectivity of xamoterol was assessed 
using CGP20712A (10 nM), a E1-AR-selective antagonist (Gustafsson et al., 
2000). Relaxations to xamoterol were competitively inhibited by 
CGP20712A, lending support to earlier characterisations of its status as a 
E1-AR agonist. Furthermore, the antagonist affinity of CGP20712A for the 
E1AR, estimated to be 0.26 nM, is consistent with figures reported 
elsewhere in the literature (Baker, 2005) and suggests the effects of 
xamoterol were mediated via the E1-AR.  
 
As discussed earlier, MEK inhibition resulted in an enhanced relaxation of 
PCA treated with isoprenaline. However, since isoprenaline activates E-ARs 
in a non-selective manner, it is not possible to use this agonist to 
determine whether the MEK inhibitors mediate their effects via specific 
receptor subtypes. Relaxations of PCA elicited by salbutamol, but not 
xamoterol, were enhanced by PD98059, suggesting that the effect of MEK 
inhibitors on E-AR-mediated relaxations is specific to the E2-AR subtype. In 
support of this is the observation that enhancement of salbutamol-induced 
responses by PD98059 persisted in the presence of the E1-AR antagonist 
CGP20712A (10 nM).  
 
The classical signalling pathway associated with E-ARs involves the 
stimulation of AC, followed by increases in intracellular cAMP levels and the 
subsequent activation of protein kinase A (PKA). In smooth muscle, PKA is 
thought to mediate relaxation by phosphorylating, and thus inactivating, 
myosin light chain kinase (MLCK) and RhoA (Conti et al., 1980; Murthy et 
al., 2003). In tissues expressing E-ARs, direct activation of the 
AC/cAMP/PKA axis has been shown to produce effects mimicking receptor 
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activation. For instance, isoprenaline, forskolin and dibutyryl cAMP 
concentration-dependently relaxed phenylephrine-pre-contracted rat 
aortae (El-Hajj et al., 2006). 
 
In the current investigation, application of cumulative concentrations of 
forskolin to U46619-pre-contracted PCA resulted in a concentration-
dependent relaxation response, matching the observations made with E-AR 
agonists. A combination of AC and PKA inhibitors failed to alter relaxations 
to forskolin, suggesting that higher concentrations of the inhibitors may 
have been required to produce an inhibitory effect. Alternatively, the 
inhibitors may not have been able to enter tissues in order to produce an 
effect. The AC inhibitor 9-cyclopentyladenine, which has been shown to 
inhibit cAMP-mediated relaxations in guinea pig taenia coli (King et al., 
2008), may have proven a more successful means of disrupting the 
AC/cAMP/PKA pathway. Likewise, measurements of cAMP accumulation in 
parallel with functional studies would have given a clearer indication of the 
activity (or inactivity) of the inhibitors. Unlike relaxations to salbutamol 
and isoprenaline, forskolin-induced relaxations were unaffected by MEK 
inhibition. This finding rules out an interaction between ERK and the 
AC/cAMP/PKA pathway and suggests that ERK may regulate E-AR-mediated 
relaxations via effects on other signalling systems.  
 
MEK inhibition was associated with an enhancement of E-AR-mediated 
vasodilatation but also produced effects on the pre-contraction evoked by 
U46619. Indeed, PD98059 inhibited U46619-induced contractions of PCA. 
This raises the possibility that relaxations were enhanced simply as a result 
of an impairment of the preceding contraction phase of the experiment. 
However, this explanation is unlikely for four reasons.  
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Firstly, when conducting the experiment, care was taken to pre-contract 
arteries to the same extent; vessels treated with MEK inhibitors received 
greater concentrations of U46619 in order to achieve this. Secondly, MEK 
inhibition failed to alter the relaxation characteristics of forskolin and 
xamoterol despite inhibiting U46619-induced pre-contractions in the same 
experiments; therefore, if the enhancement was due to inhibition of the 
pre-contraction, all subsequent relaxation responses would have been 
enhanced. Thirdly, in porcine palmar lateral vein, PD98059 enhanced E-AR-
mediated relaxations despite having no effect on U46619-evoked 
contractions (unpublished data). Finally, salbutamol-induced relaxations of 
PCA following pre-contraction using endothelin-1 (ET-1) were enhanced by 
MEK inhibition in a manner similar to those observed following pre-
contraction using U46619. In comparison to U46619-induced pre-
contractions, ET-1 responses appeared more resistant to MEK inhibition. 
Furthermore, data previously collected in this laboratory in PCA showed 
that contractile responses evoked by cumulative concentrations of ET-1 
were not affected by PD98059 (50 PM).  
 
 
As discussed earlier, PKA is widely regarded as a key mediator of 
relaxations induced by E-AR agonists. Evidence for the involvement of K+ 
channels also exists in abundance and will be discussed in Chapter 3 along 
with the relevant data collected in this study. NO is thought to be yet 
another key regulator of E-AR-mediated vasodilatation. However, studies in 
this area have often produced conflicting findings (Eckly et al., 1994; Ferro 
et al., 2004; Gray et al., 1992). In the current experiment, NO signalling 
was disrupted by inhibition of NOS using L-NAME. Treatment with L-NAME 
inhibited the potency of isoprenaline-induced relaxations but not the 
maximal response. An explanation for this is that the E-AR may recruit NO 
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in the presence of relatively low concentrations of E-AR agonists, whilst 
relying on other mediators at higher concentrations. However, the 
magnitude of the inhibition (pEC50 value reduced from 7.7 to 7.5) suggests 
that NO is unlikely to be a major mediator of E-AR-mediated relaxation. 
The finding that the maximal response to isoprenaline was significantly 
enhanced by L-NAME treatment is counter-intuitive, but similar findings 
have previously been presented. Liang et al., (2010) showed that NO 
inhibited natriuretic peptide-induced relaxations of PCA by desensitising K+ 
channels. It is possible that inhibition of NO signalling in PCA augments E-
AR-mediated relaxation via enhanced K+ channel function; however, 
further experimentation would be required to test this hypothesis. In 
addition, future experiments would aim to assess the effect of endothelium 
removal on E-AR-mediated vasodilatation (the results of preliminary 
experiments are shown in Figures A3 and A4, Appendix). 
 
In conclusion, inhibition of ERK activation is associated with an 
enhancement of E-AR-mediated vasodilatation of PCA, suggesting ERK may 
somehow regulate this process. That MEK inhibitors produced some effect 
is consistent with findings from immunoblotting experiments that suggest 
ERK may not only be activated under basal conditions but its activation 
may also be stimulated by TP receptor and E-AR activation. The observed 
enhancement of relaxations is specific to the E2-AR subtype and is unlikely 
to be related to non-specific effects on contractile responses or to 
desensitisation, which was not detectable in this tissue (Figures A1 and A2, 
Appendix). Rather, the enhancement may be the result of interactions 
between ERK and cAMP-independent relaxation mechanisms. Activation of 
K+ channels represents one such mechanism and will be the subject of the 
following chapter.  
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CHAPTER 3: THE ROLE OF POTASSIUM CHANNELS IN 
ENHANCED E-ADRENOCEPTOR-MEDIATED 
VASODILATATION 
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3.1. INTRODUCTION 
 
K+ channels are ubiquitously expressed and contribute to the regulation of 
numerous cellular processes. In vascular smooth muscle, activation of K+ 
channels permits the efflux of K+ ions, resulting in cell hyperpolarisation 
and relaxation. Thus, by altering blood vessel diameter, K+ channels are 
able to regulate blood flow, and agents promoting opening of K+ channels 
are used in the prevention and treatment of angina  pectoris (Joint 
Formularly Committee, 2011).  
 
$FWLYDWLRQ RI YDVFXODU ǃ-adrenoceptors (E-ARs) results in vasodilatation. 
Several intracellular factors, including cAMP-dependent protein kinase 
(PKA) (Murray, 1990) and nitric oxide (NO) (Graves et al., 1993), have 
been implicated in this process, though their relative roles are disputed. K+ 
channels are also thought to play a role E-AR-mediated vasodilatation 
(White et al., 2001). In this chapter, the contributions of distinct K+ 
channel subtypes to E-AR-mediated vasodilatation will be investigated. 
Furthermore, as data presented in Chapter 2 linked ERK activation to 
reduced E±AR-mediated vasodilatation, experiments in this chapter will aim 
to determine whether this association may involve K+ channels.  
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3.2. MATERIALS AND METHODS 
 
3.2.1. Isometric Tension Recordings 
 
3.2.1.1. Tissue preparation 
 
Porcine coronary artery (PCA) rings were prepared and set up in a Mulvany 
wire myograph as described in Section 2.2.1.1.  
 
3.2.1.2. Experimental procedure 
 
PCA rings were challenged with KCl (60 mM) to confirm tissue viability and 
to determine their maximal contractile capacities. The arteries were then 
thoroughly rinsed with Krebs-Henseleit (KH) solution and allowed to re-
equilibrate for 15 to 20 mins. The process was repeated twice.  
 
3.2.1.2.1. The role of K+ channels in enhanced E-AR-mediated 
vasodilatation 
 
PCA rings were incubated for 45 mins in KH solution containing PD98059 
(50 PM) before performing the pre-contraction phase of the experiment 
using KCl (25 mM ± 40 mM) rather than U46619. Subsequent relaxation 
curves were performed using isoprenaline (1 nM ± 3 PM). Similar 
experiments assessed the role of K+ channels by exposing arteries to a 
combination of PD98059 and tetraethylammonium (TEA, 10 mM), a non-
selective K+ channel blocker (Iwaki et al., 1988), before pre-contracting 
and relaxing using U46619 and isoprenaline, respectively. 
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3.2.1.2.2. The effect of KATP channel blockade on enhanced E-AR-
mediated vasodilatation 
 
PCA ring segments were incubated for 45 mins in Krebs-Henseleit (KH) 
solution containing glibenclamide (10 PM), a blocker of ATP-sensitive 
potassium (KATP) channels (Zhang et al., 1995). U46619 (10 nM ± 20 nM) 
was used to pre-contract the arteries, which were subsequently relaxed by 
applying cumulative concentrations of isoprenaline. Higher concentrations 
of U46619 (20 nM ± 40 nM) were required to pre-contract glibenclamide-
incubated arteries. Control arteries were incubated in 0.1% (v/v) DMSO.  
 
In a related experiment, arteries were incubated for 45 mins in KH solution 
containing either PD98059 alone (50 PM), PD98059 with glibenclamide (1 
PM) or PD98059 with glibenclamide (10 PM). Again, isoprenaline was used 
to relax the arteries following U46619-evoked contraction. Respective 
vehicle controls were as follows: 0.36% (v/v) DMSO (control), 0.1% (v/v) 
DMSO and 0.09% (v/v) DMSO.  
 
The effect of glibenclamide on relaxation responses to the E2-AR agonist 
salbutamol was also assessed. In this experiment, arteries were pre-
contracted with U46619 after a 45 min exposure to either PD98059 (50 
PM), glibenclamide (10 PM) or both agents in combination. The respective 
vehicle controls were as follows: 0.36% (v/v) DMSO (control), 0.1% (v/v) 
DMSO and 0.26% (v/v) DMSO. 
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3.2.1.2.3. The effect of BKCa channel blockade on enhanced E-AR-
mediated vasodilatation 
 
Similar experiments were carried out using the large-conductance, calcium 
activated K+ (BKCa) channel blocker iberiotoxin (Au et al., 2004). Arteries 
were treated for 45 mins with iberiotoxin (100 nM), PD98059 (50 PM) or a 
combination of the two agents before they were contracted with U46619 
and subsequently relaxed with either isoprenaline or salbutamol. In a 
related experiment, U46619-pre-contracted arteries were relaxed using 
100 nM ± 10 PM NS1619, a BKCa channel activator (Khan et al., 1998), in 
the absence and presence of PD98059 (50 PM). 
 
 
3.2.1.2.4. The effect of IKCa channel blockade on enhanced E-AR-
mediated vasodilatation 
 
The effect of TRAM-34, a blocker of intermediate-conductance calcium-
activated K+ (IKCa) channels (Gluais et al., 2005), on salbutamol-induced 
relaxations was investigated. Arteries were exposed for 45 mins to a 
combination of TRAM-34 (10 PM) and PD98059 (50 PM) as well as to each 
compound alone. Vehicle effects were controlled for as follows: 0.36% 
(v/v) DMSO (control), 0.1% (v/v) DMSO in PD98059-incubated arteries 
and 0.26% (v/v) in TRAM-34-incubated arteries. 
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3.2.2. Electrophysiology experiments 
 
3.2.2.1. Tissue preparation 
 
Porcine coronary artery (PCA) rings were prepared and stored overnight at 
4qC in KH solution as described in Section 2.2.1.1.   
 
3.2.2.2. Development of a method of smooth muscle cell isolation 
from PCA for patch clamp recording 
 
Initial attempts to isolate PCA cells were based on a procedure previously 
developed in the laboratory to isolate rat superior mesenteric artery (SMA) 
cells. Briefly, PCA were finely dissected into flat strips of roughly 5 mm2 
and incubated at 37qC in KH solution containing dithiothreitol (DTT; 1mg 
ml-1) and papain (1.5mg ml -1) for 30 mins. The artery segments were then 
incubated in KH solution containing collagenase type H (1.5 mg ml-1) for 
15 mins. Afterwards, the segments were extracted from solution following 
gentle centrifugation and washed with KH solution and triturated by gently 
agitating the solution using a shortened plastic pipette tip. Unfortunately, 
this protocol yielded isolated PCA smooth muscle cells infrequently, and 
any cells produced appeared damaged when observed under a light 
microscope.  
 
A number of changes to the procedure were therefore implemented. 
Firstly, the duration of incubation in collagenase was varied, and it was 
determined that an incubation period of at least 20 mins was required to 
produce cells. However, isolated cells still appeared damaged. Suspicions 
that overnight storage of the arteries might have reduced their viability led 
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to the third modification of the above procedure. Although functional 
experiments of PCAs stored overnight had not suggested reduced tissue 
viability, it was possible that cell-based investigations were more sensitive 
to such means of storage. Thus PCA rings were prepared and digested on 
the same day they were transported to the laboratory rather than on the 
morning after. This meant that the cell isolation procedure was completed 
within 5 hours of animal sacrifice rather than after roughly 20 hours as was 
previously the case. However, the modification did not appear to improve 
cell quality. The decision was finally taken to abandon the isolation 
procedure, which appeared more suitable for isolating rat SMA cells than 
PCA cells.  
 
The enzymatic dissociation of PCA smooth muscle has previously been 
described (Au et al., 2004). Following the disappointing attempts described 
above to isolate PCA smooth muscle cells, methods used in this earlier 
study were adapted. Initially, arteries were stored overnight at 4qC in KH 
solution. A low [Ca2+] solution was prepared in distilled water and 
contained, in mM, the following: NaCl, 110; KCl, 5; NaH2PO4, 0.5; KH2PO4, 
0.5; NaHCO3, 10; HEPES (H
+), 10; pyruvic acid, 5; glucose, 11; CaCl2, 
0.16; MgCl2, 2; EDTA, 0.5; and L-ascorbic acid, 0.3. After gassing with 
O2:CO2 (95:5), pH was corrected to 7.0 using NaOH.  
 
PCAs were dissected into flat, 2 mm2 strips and incubated at 37qC in the 
above solution containing DTT (6.0 mg ml-1), papain (2.0 mg ml-1) 
collagense type II (7.5mg ml-1) and bovine serum albumin (fatty-acid free; 
2.0 mg ml-1) for 45 ± 60 mins. Subsequent yields were much greater than 
in earlier attempts and smooth muscle cells, apparently healthier, 
appeared characteristically long and spindle-shaped. However, the outlines 
of most cells appeared rough under a light microscope, suggesting a 
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degree of membrane damage.  This was accompanied by an inability of a 
large proportion of cells to stick to the petri dish upon plating, even when 
using glass-bottomed petri dishes. Attempts to generate high-resistance 
seals using glass capillary electrodes (see later) were predominantly 
unsuccessful.  
 
It was therefore likely that tissues were being overly digested. Several 
variables were modified in attempts to determine optimal digestion 
conditions. The concentration of collagenase was reduced to 5.0 mg ml-1 
and digested arteries were washed three times in enzyme-free low [Ca2+] 
solution. Also, centrifugation prior to rinsing was omitted as this may have 
contributed to tissue damage; instead, forceps were used to gently 
transfer digested PCA segments from enzyme solution to enzyme-free 
solution. As attempted before, the digestion process was performed on the 
same day tissues were received in the laboratory. Alas, these changes 
failed to produce sticky, patchable cells. Despite further adjustments which 
appeared to yield healthier cells, including reductions in enzyme incubation 
durations (20 ± 30 mins), the fraction of cells amenable to sealing 
remained low in subsequent yields.  
 
3.2.2.3. Patch clamp recording 
 
Patch micropipettes were made from borosilicate glass capillaries (GC150T-
15; Clark Electromedical Instruments, Pangbourne, Reading, UK). Sylgard 
was carefully cured onto the upper shaft area immediately below the 
pipette tip in order to reduce electrical noise during recording. The pipettes 
were briefly fire-polished to produce a tip resistance of 2 ± 5 M:. High [K+] 
solution (see Section 3.2.2.4) was then back-filled into the pipettes using a 
microsyringe, with care taken to remove bubbles from the tip.  
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Following cell isolation, PCA smooth muscle cells were plated on glass-
bottomed petri dishes and allowed to settle for up to 10 mins. Prior to 
recording, plated cells were superfused with high [K+] solution to, first, 
wash out debris and, second, determine whether cells had stuck to the 
glass base. Only long, spindle-shaped cells that had stuck were chosen for 
recordings. Gigaohm seals were achieved by bringing the patch pipette into 
contact with the cell of interest and then gently applying negative pressure 
to the pipette using an attached syringe. Recordings were made in this 
(cell-attached) or inside-out configuration using an Axopatch patch clamp 
amplifier (Molecular Devices Inc., Sunnyvale, CA, USA). Single-channel 
currents were filtered at 2 kHz prior to digitisation at 10 kHz using Clampfit 
10.3 (Molecular Devices Inc., Sunnyvale, CA, USA).  
 
As discussed earlier, it proved difficult to isolate healthy, compliant smooth 
muscle cells. Only a few cells stuck to the glass bottom, and of those, 
fewer still were not dislodged upon contact with the pipette. Furthermore, 
attempts to generate G: seals using suction were frequently unsuccessful, 
presumably due to a loss of cell membrane integrity during enzymatic 
digestion. Finally, on occasions when such seals were formed, the tendency 
was for the seals to prematurely break, particularly during superfusion, 
resulting in incomplete experiments.  
 
Solutions containing salbutamol (1 PM or 10 PM) or quinine (300 PM) were 
superfused onto plated cells 1 min prior to data recording. In some 
experiments, cells were plated in high [K+] solution containing PD98059 
(50 PM) for 25 ± 35 min prior to current recordings. Current-voltage 
relationships were assessed by recording currents for 15 seconds at 
voltage intervals ranging from either -60 mV to +60 mV or -100 mV to 
+100 mV. All experiments were performed at 22±23qC.  
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3.2.2.4. Solutions 
 
In order to clamp membrane potential to 0 mV, all recordings were made 
in symmetrical, high [K+] conditions, with both pipette and extracellular 
solutions containing, in mM, the following: KCl, 145; NaCl, 5; MgCl2, 1.15; 
CaCl2, 5.5; HEPES (H
+), 10; glucose, 5.5; EGTA, 5; with pH adjusted to 7.2 
using KOH (Srivastava et al., 2006). The concentration of free Ca2+ in this 
solution at pH 7.2 was 1 PM.  
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3.2.3. Statistical analyses 
 
Data recorded in wire myography experiments were analysed using 
GraphPad Prism 5.0 (Graphpad Software Inc., La Jolla, CA, USA). 
Relaxation response measurements are expressed as means r SEM. 
Statistical comparisons between groups were made using the two-tailed, 
unpaired 6WXGHQW¶V W-test except where stated. As there were insufficient 
repeat experiments to determine distribution, the data were assumed to be 
normally distributed and parametric tests were employed. A P value < 0.05 
was considered statistically significant. ,Q DOO H[SHULPHQWV ³Q´ QXPEHUV
represent the number of animals from which tissues were obtained. 
 
Patch-clamp data were analysed using Clampfit 10.3 (Molecular Devices 
Inc., Sunnyvale, CA, USA) and GraphPad Prism 5.0. Single channel current 
amplitudes were calculated by fitting all-points histograms to a Gaussian 
function. Open probabilities (NPO) were calculated by expressing the area 
under the curve for the open components of the histogram as a fraction of 
the total area under the curve. Conductance values were estimated using 
the gradients of straight-line components of current-voltage plots fitted 
with either linear regression or third-order polynomials.  
 
3.2.4. Materials 
 
Tetraethylammonium acetate, (R)-[(2S,4S,5R)-5-ethenyl-1-
azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol (quinine), 
5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-
methoxybenzamide (glibenclamide), iberiotoxin, 1,3-dihydro-1-[2-
hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-
one (NS1619), 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole (TRAM-34), 
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4-aminopyridine, Papain from papaya latex and collagenase (Types II and 
H) from Clostridium histolyticum    were acquired from Sigma (Poole, 
Dorset, UK). The remaining chemicals were obtained as stated in Section 
2.2.4. 
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3.3. RESULTS 
 
3.3.1. The role of K+ channels in enhanced E-AR-mediated 
vasodilatation 
 
Figure 3.1 shows that PD98059 does not alter relaxations to isoprenaline in 
PCA segments pre-contracted with KCl (pEC50 and RMAX values: 7.6 r 0.1 
and 115 r 5%, respectively, in controls versus 7.8 r 0.1 and 109 r 4%, 
respectively, in 50 PM PD98059-treated arteries; P>0.05).  
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Figure 3.1. The effect of MEK inhibition on E-AR-mediated vasodilatation 
in PCA rings pre-contracted with KCl (n=5). PD98059 (50 PM) failed to 
alter the relaxation characteristics of isoprenaline. There were no 
differences between rings treated with PD98059 (50 PM) and 
corresponding controls (0.26% (v/v) DMSO) with respect to pEC50 (7.6 r 
0.1 versus 7.8 r 0.1; P>0.05) or RMAX (115 r 5% versus 109 r 4%; 
P>0.05). 
 
In arteries pre-contracted with U46619 following pre-incubation with the 
combination of PD98059 and the K+ channel blocker TEA (10 mM), 
isoprenaline-induced relaxations were not significantly different from 
control arteries (pEC50 and RMAX values: 7.1 r 0.2 and 123 r 8%, 
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respectively, in controls versus 7.5 r 0.2 and 113 r 4%, respectively, in 
PD98059-treated arteries; P>0.05; Figure 3.2). 
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Figure 3.2. The effect of MEK inhibition on E-AR-mediated relaxations in 
PCA rings treated with the non-selective K+ channel blocker TEA. U46619 
was used to pre-contract rings prior to inducing relaxations with 
isoprenaline. The combination of 10 mM TEA and 50 PM PD98059 did not 
alter relaxations to isoprenaline, with pEC50 and RMAX values (7.1 r 0.2 and 
123 r 8%, respectively) unchanged compared to corresponding controls 
(7.5 r 0.2 and 113 r 4%, respectively; P>0.05 in both cases). Control 
experiments were performed in KH solution containing 0.26% (v/v) DMSO. 
 
3.3.2. The role of KATP channels in enhanced E-AR-mediated 
vasodilatation 
 
The KATP channel blocker glibenclamide (10 PM) had no effect on the 
relaxation characteristics of isoprenaline in porcine coronary artery 
segments pre-contracted with U46619 (Figure 3.3). Consistent with earlier 
findings, pre-incubation of PD98059 enhanced isoprenaline-induced 
relaxations versus control (Figure 3.4). Pre-incubation with the 
combination of PD98059 and glibenclamide caused a comparable 
enhancement of the relaxation response (pEC50 values: control = 7.6 r 0.1, 
PD98059 = 8.0 r 0.1, PD98059 + 1 PM glibenclamide = 8.1 r 0.1, 
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PD98059 + 10 PM glibenclamide = 8.2 r 0.1; P<0.05 for PD98059 (r 
glibenclamide) experiments versus control experiment, one-way ANOVA 
IROORZHGE\7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW).  
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Figure 3.3. The effect of KATP channel blockade on E-AR-mediated 
relaxations in PCA rings (n=3 or 4). Under control conditions (0.1% (v/v) 
DMSO), isoprenaline produced pEC50 and RMAX values (7.9 r 0.1 and 114 r 
4%, respectively) that did not significantly differ from corresponding values 
in glibenclamide (10 PM) experiments (7.9 r 0.1 and 112 r 8%, 
respectively; P>0.05 in both cases).  
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Figure 3.4. The effect of MEK inhibition on E-AR-mediated relaxations in 
PCA (n=5±10). Recordings were made in KH solution containing the 
following: 0.36% (v/v) DMSO (control), PD98059 (50 PM) + 0.1% (v/v) 
DMSO, PD98059 (50 PM) + glibenclamide (1 PM) + 0.09% (v/v) DMSO, or 
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PD98059 (50 PM) + glibenclamide (10 PM). PD98059 enhanced 
isoprenaline relaxations in each experiment (pEC50 values versus control 
pEC50 value of 7.6 r 0.1: PD98059 = 8.0 r 0.1, PD98059 + 1 PM 
glibenclamide = 8.1 r 0.1, PD98059 + 10 PM glibenclamide = 8.2 r 0.1; 
P<0.05 versus control in each experiment). 
 
As shown in Figure 3.5, similar phenomena were observed when 
relaxations were evoked using salbutamol, with glibenclamide failing to 
reverse the PD98059-induced enhancement (pEC50 values: control = 5.6 r 
0.2, PD98059 = 6.3 r 0.2, 10 PM glibenclamide = 5.7 r 0.2, PD98059 + 10 
PM glibenclamide = 6.4 r 0.1; P<0.05, one-way ANOVA followed by 
7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW).  
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Figure 3.5. The effect of the MEK inhibitor PD98059 with and without the 
KATP channel blocker glibenclamide on E2-AR-mediated relaxations in PCA 
(n=4 or 5). Recordings were made in KH solution containing the following: 
0.36% (v/v) DMSO (control), PD98059 (50 PM) + 0.1% (v/v) DMSO, 
glibenclamide (10 PM) + 0.26% (v/v) DMSO, or PD98059 (50 PM) + 
glibenclamide (10 PM). Relaxations to salbutamol were enhanced by 
PD98059 alone and in combination with glibenclamide (pEC50 values versus 
control pEC50 value (5.6 r 0.2): PD98059 = 6.3 r 0.2, PD98059 + 10 PM 
glibenclamide = 6.4 r 0.1; P<0.05 versus control in each experiment). 
Glibenclamide alone failed to alter relaxations (pEC50 value 5.7 r 0.2; 
P>0.05 versus control pEC50). 
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3.3.3. The role of BKca channels in enhanced E-AR-mediated 
vasodilatation 
 
Iberiotoxin (100 nM), like glibenclamide, had no effect on relaxations to 
either isoprenaline or salbutamol (Figures 3.6 and 3.7, respectively). 
However, PD98059, alone or in combination with iberiotoxin, also failed to 
enhance isoprenaline or salbutamol responses in these experiments, 
though statistically non-significant leftward shifts of the relaxation curves 
were observed (isoprenaline pEC50 values: control = 7.7 r 0.1, PD98059 = 
8.0 r 0.2, iberiotoxin = 7.7 r 0.1, PD98059 + iberiotoxin = 7.9 r 0.1, 
P>0.05, one-ZD\ $129$ IROORZHG E\ 7XNH\¶V PXOWLSOH FRPSDULVRQV WHVW; 
salbutamol pEC50 values: control = 7.1 r 0.2, PD98059 = 7.5 r 0.2, 
iberiotoxin = 7.0 r 0.1, PD98059 + iberiotoxin = 7.3 r 0.2, P>0.05, one-
ZD\$129$IROORZHGE\7XNH\¶V multiple comparisons test).  
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Figure 3.6. The effect of MEK inhibition and BKCa channel blockade on E-
AR-mediated relaxations (n=4). Recordings were made in KH solution 
containing the following: 0.26% (v/v) DMSO (control), PD98059 (50 PM), 
iberiotoxin (100 nM) + 0.26% (v/v) DMSO, or PD98059 (50 PM) + 
iberiotoxin (100 nM). None of the treatment experiments were associated 
with altered relaxation characteristics of isoprenaline in comparison with 
control experiments. 
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Figure 3.7. The effect of MEK inhibition and BKCa channel blockade on E2-
AR-mediated relaxations in PCA (n=6±9). Recordings were made in KH 
solution containing the following: 0.26% (v/v) DMSO (control), PD98059 
(50 PM), iberiotoxin (100 nM) + 0.26% (v/v) DMSO, or PD98059 (50 PM) 
+ iberiotoxin (100 nM). Salbutamol relaxations were unaffected by 
PD98059, iberiotoxin or a combination of both agents. 
 
 
In a related experiment, NS1619-induced relaxations were assessed 
against PD98059 (Figure 3.8). Unfortunately, the data analysis software 
was unable to estimate RMAX and pEC50 values from this dataset. Therefore, 
the following were calculated and used as substitutes for RMAX and pEC50 
values, respectively: (1) the relaxation response produced by the highest 
concentration of NS1619 (i.e., 10 PM) and (2) the negative log 
concentration of NS1619 producing 50% of this response. Incubation with 
PD98059 did not change these values (control = 106 r 13% and 5.5 r 
0.04, PD98059 = 110 r 8% and 5.6 r 0.03; P>0.05). 
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Figure 3.8. The effect of MEK inhibition on relaxations to the BKCa channel 
opener NS1619 in PCA (n=7). NS1619 evoked a concentration-dependent 
relaxation of U46619-pre-contracted PCA rings that was unaffected by 
PD98059 (50 PM). Control experiments were performed in 0.26% (v/v) 
DMSO. The relaxation responses produced by 10 PM NS1619 under control 
conditions and in the presence of 50 PM PD98059 were not significantly 
different (106 r 13% and 110 r 8%, respectively; P>0.05). Equally, the 
potency (as assessed by the negative log of the concentration of NS1619 
producing 50% of the highest measured response) did not differ between 
controls and PD98059-incubated rings (5.5 r 0.04 versus 5.6 r 0.03, 
respectively; P>0.05).   
 
3.3.4. The role of IKCa channels in enhanced E-AR-mediated 
vasodilatation 
 
Figure 3.9 shows the effects of PD98059 and the IKCa channel blocker 
TRAM-34 (10 PM) on relaxation responses to salbutamol. TRAM-34 alone 
did not significantly alter the relaxation, though there was a slight trend 
towards inhibition at the lower concentrations of salbutamol. PD98059 
produced a significant leftwards shift of the response curve. However, this 
shift was abolished when arteries were pre-incubated with the combination 
of PD98059 and TRAM-34 (pEC50 values: control = 6.1 r 0.1, PD98059 = 
6.6 r 0.1, TRAM-34 = 5.9 r 0.1, PD98059 + TRAM-34 = 6.2 r 0.1; P<0.05, 
one-ZD\$129$IROORZHGE\7XNH\¶VPXOWLSOHFRPSDULVRQVWHVW).  
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Figure 3.9. The effect of MEK inhibition and IKCa channel blockade on 
salbutamol-induced relaxations in PCA rings (n=5 or 6). Recordings were 
made in KH solution containing the following: 0.36% (v/v) DMSO (control), 
PD98059 (50 PM) + 0.1% (v/v) DMSO, TRAM-34 (10 PM) + 0.26% (v/v) 
DMSO, or PD98059 (50 PM) + TRAM-34 (10 PM). Salbutamol relaxations 
(control pEC50 value = 6.1 r 0.1) were enhanced by PD98059 (pEC50 value 
= 6.6 r 0.1; P<0.05) but not by the combination of PD98059 and TRAM-34 
(pEC50 value = 6.2 r 0.1; P>0.05) or by TRAM-34 alone (pEC50 value = 5.9 
r 0.1; P<0.05). 
 
 
 
3.3.5. Electrophysiological studies of K+ channels in porcine 
coronary artery 
 
Using cell-attached and inside-out patch-clamp experiments, single-
channel currents from at least two distinct channel types were observed. 
Figure 3.10A shows representative 10 s traces of one channel from a single 
cell-attached patch of an isolated PCA smooth muscle cell. In this 
experiment, the pipette and extracellular solutions contained the same 
[K+], i.e. 145 mM. Channel activity was only observed at positive 
membrane potentials in the cell-attached configuration. Thus, all traces 
represent recordings performed at +60 mV.  
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Figure 3.10. The effects of salbutamol and quinine on channel currents in 
a single cell-attached patch. (A) Five representative ~10 s traces of 
channel activity. Recordings were made at +60 mV following voltage steps 
from a holding potential of 0 mV under the following conditions: (a) 
control, (b) salbutamol (1 PM), (c) salbutamol (1 PM) + quinine (300 PM), 
(d) salbutamol (10 PM) and (e) quinine (300 PM). (B) All-points 
histograms of current amplitude in a single cell-attached patch 
corresponding to trace recordings shown in (A). Recordings were made at 
+60 mV following voltage steps from a holding potential of 0 mV under the 
following conditions: (a) control, (b) salbutamol (1 PM), (c) salbutamol (1 
PM) + quinine (300 PM), (d) salbutamol (10 PM) and (e) quinine (300 PM).  
 
A 
B 
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Figure 3.10B shows all-points current amplitude histograms derived from 
corresponding 60 sec recordings of the same cell-attached patch shown in 
Figure 3.10A. In each case, the larger peak represents the closed state of 
the channel whilst a smaller peak, if present, indicates a conducting level. 
NPO values derived from amplitude histograms were as follows: 0.08 under 
control conditions, 0.03 in the presence of salbutamol (1 PM), 0.06 in both 
salbutamol (1 PM) and quinine (300 PM) and 0.19 in salbutamol (10 PM).  
Analyses of current-voltage relationships estimated corresponding unitary 
conductances of 37 pS, 55 pS, 87 pS and 65 pS, respectively. In the 
presence of quinine (300 PM) alone, conductance and NPO values were 
negligible. Quinine has previously been shown to block voltage-dependent 
(KV) and ATP-sensitive (KATP) K
+ channels (Fatherazi et al., 1991); 
however, attempts to further characterise this channel using the inside-out 
configuration were unsuccessful as the seal was lost.  
 
 
Representative trace recordings and corresponding all-points current 
amplitude histograms of a second patched channel are shown in Figures 
3.11A and 3.11B. Cells were exposed to 50 PM PD98059 for 25 ± 35 min 
prior to data collection. Recordings were made under symmetrical high 
[K+] conditions in the cell attached (a) and inside-out configurations (b and 
c). Channel activity was not detected at negative membrane potentials in 
the cell-attached configuration.  
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Figure 3.11. Channel currents in a single patch-clamp experiment in 
which cells were pre-incubated in PD98059 (50 PM) for 35 mins. (A) 
Representative ~10 s traces of ion channel activity. Recordings were made 
at +60 mV following voltage steps from a holding potential of 0 mV under 
the following conditions: (a) PD98059 (50 PM), (b) PD98059 (50 PM) + 
salbutamol (10 PM) and (c) salbutamol (10 PM) + quinine (300 PM). (B) 
All-points histograms of current amplitude in a single cell-attached patch 
corresponding to trace recordings shown in (A). Recordings were made at 
+60 mV following voltage steps from a holding potential of 0 mV under the 
following conditions: (a) PD98059 (50 PM), (b) PD98059 (50 PM) + 
salbutamol (10 PM) and (c) salbutamol (10 PM) + quinine (300 PM). 
 
In the presence of PD98059 alone, NPO and conductance were 0.03 and 
137 pS, respectively, at +60 mV. Superfusion of high [K+] solution 
containing PD98059 (50 PM) and salbutamol (10 PM) resulted in the 
excision of the patch to the inside-out configuration. Channel activity was 
detected at negative membrane potentials in this configuration. The 
conductance derived from the associated current-voltage relationship 
A 
B 
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(Figure 3.12) was 210 pS. Channel activity also increased, with NPO rising 
to 0.70 at +60 mV. The voltage sensitivity of the channel is described by 
the PO-voltage relationship shown in Figure 3.13.  
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Figure 3.12. Current-voltage relationships in a single cell-attached patch 
of a large conductance channel. Recordings were made at 20 mV 
increments for 15 secs in the presence of either salbutamol (10 PM) or the 
combination of salbutamol (10 PM) and quinine (300 PM). 
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Figure 3.13. PO-voltage relationships in a single cell-attached patch 
corresponding of a large conductance channel. Recordings were made at 
20 mV increments for 15 secs in the presence of either salbutamol (10 PM) 
or the combination of salbutamol (10 PM) and quinine (300 PM). 
 
Application of salbutamol (10 PM) and quinine (300 PM) prevented channel 
activation across a range of voltages (0 mV to +60 mV) and reduced 
current amplitude between -20 mV and -60 mV (Figure 3.12), producing a 
conductance of 30 pS. In addition to reducing current amplitude, quinine 
caused a rapid flickering of the current trace, representing increased 
114 
 
frequency of channel closures. Changes in voltage-sensitivity caused by 
quinine are shown in Figure 3.13. Channel opening was prevented at 
positive voltages but persisted at negative voltages, a discrepancy likely 
related to the experimental protocol. Specifically, after the application of 
quinine, currents were recorded at each voltage for 15 secs, with 
recordings made sequentially every 20 mV from -60 mV to +60 mV. The 
channel had therefore been exposed to quinine for a longer period of time 
during data recording at positive voltages.  
 
Based on the large single-channel conductance, voltage-sensitivity and 
blockade by quinine (Bokvist et al., 1990; Mancilla et al., 1990; Nelson et 
al., 1995b), these recordings represent the large-conductance calcium-
activated K+ (BKCa) channel.  
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3.4. DISCUSSION 
 
As important regulators of vascular tone, K+ channels in blood vessels have 
long been subjected to intensive research, the fruits of which have 
contributed to the treatment of ischaemic heart disease. In virtually all 
cells K+ is the predominant intracellular cation, existing at much higher 
concentrations in the cytoplasm than outside the cell. This chemical 
gradient is maintained by the Na+/K+-ATPase pump and provides the 
driving force for the outward movement of K+ through open channels. K+ 
efflux is accompanied by a reduction in cell membrane potential, termed 
hyperpolarisation, and, as a result, reduces the influx of Ca2+ through L-
type Ca2+ channels. The effects of reduced intracellular Ca2+ levels are 
dependent on cell type, with relaxation occurring in vascular smooth 
muscle cells.  
 
K+ channels are expressed on both endothelial cells and smooth muscle 
cells, and both receptor populations are known to participate in regulating 
vascular tone. For example, activation of small- and intermediate-
conductance Ca2+-activated K+ channels (SKCa and IKCa, respectively) on 
endothelial cells results in smooth muscle relaxation; it is believed that this 
phenomenon may be mediated by an as yet unidentified endothelium-
derived hyperpolarising factor (EDHF) (Coleman et al., 2004). Equally, 
activation of smooth muscle K+ channels, such as the large-conductance 
Ca2+-activated K+ channel (BKCa), leads to vasorelaxation (Balwierczak et 
al., 1995).  
 
Vascular K+ channels are regulated by numerous factors, including G-
protein-coupled receptors (GPCRs). For example, ATP-sensitive K+ 
channels (KATP) have been proposed as mediators of E-AR agonist-induced 
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relaxations (Chang, 1997; Ming et al., 1997; Randall et al., 1995; Sheridan 
et al., 1997). In Chapter 2 of the present study, it was shown that 
inhibition of extracellular signal-regulated kinase (ERK) activation in 
porcine coronary artery (PCA) enhances subsequent E2-AR-mediated 
vasodilatation. Furthermore, ERK activation has been associated with 
reduced dilator responses to K+ channel openers in pig pial artery (Ross et 
al., 2003). In the current chapter, experiments aimed to determine 
whether K+ channels are implicated in the enhancement phenomenon.   
 
In initial experiments, attempts were made to prevent K+ channel 
activation during E-AR-mediated vasodilatation. This was done in the first 
instance by performing pre-contractions with KCl rather than the 
thromboxane mimetic U46619. By pre-contracting with KCl, extracellular 
[K+] is increased to an extent that abolishes the concentration gradient 
responsible for driving the efflux of K+ ions through open K+ channels. 
Subsequent relaxations to isoprenaline were not enhanced by incubation 
with PD98059, in contrast to relaxations made following U46619-induced 
pre-contraction. This finding suggests that K+ channels are involved in the 
enhancement of E-AR-mediated caused by MEK inhibition.  
 
In support of this is the finding that isoprenaline-induced relaxations of 
arteries incubated with the non-selective K+ channel blocker TEA were not 
enhanced by PD98059. However, there appeared to be a slight, albeit 
statistically insignificant, leftward shift of the response curve, indicating a 
degree of enhancement by PD98059. Incomplete K+ channel blockade by 
TEA may explain this discrepancy. An alternative interpretation is that 
PD98059 enhances relaxations via a K+ channel-independent signalling 
pathway, and that K+ channel blockade, which itself acts to inhibit 
relaxations, indirectly masks the enhancement. The net result is no overall 
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change in the relaxation response. This explanation could be confirmed or 
ruled out by further experiments designed to assess the effect of TEA alone 
on isoprenaline-induced relaxations.  
 
The data above suggest that inhibition of ERK activation enhances E-AR-
mediated relaxations through an increase in K+ channel activation. 
Therefore further experiments were carried out to determine which K+ 
channels are involved. Previous studies have suggested that E-AR 
relaxations are mediated through activation of KATP channels (Randall et 
al., 1995). Therefore it was determined whether blocking KATP channels 
with glibenclamide prevented the enhancement by PD98059.  
 
Since its development as a potent hypoglycaemic agent (Loubatieres et al., 
1968), the sulphonylurea glibenclamide has been successfully used in the 
treatment of Type II diabetes owing to its ability to block KATP channels in 
insulin-secreting cells (Schmid-Antomarchi et al., 1987). Glibenclamide has 
also been frequently employed in cardiovascular research as a blocker of 
KATP channels in blood vessels. As mentioned earlier, several authors have 
reported an involvement of KATP channels in E-AR-mediated vasodilatation 
(Chang, 1997; Ming et al., 1997; Randall et al., 1995; Sheridan et al., 
1997).  
 
In the current study, glibenclamide was found to have no effect on 
relaxations induced by either isoprenaline or salbutamol. This is in contrast 
to the previously quoted studies, which collectively demonstrated an 
inhibitory effect of glibenclamide on both E1- and E2-AR-mediated 
vasorelaxation. The concentrations of glibenclamide used in these studies 
ranged from 1 PM to 10 PM, suggesting that the lack of effect of 
glibenclamide in the current experiment was not related to its 
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concentration (10 PM). This finding has been observed in other tissues, 
such as rat isolated thoracic aorta (Husken et al., 1997) and mesenteric 
artery (White et al., 2001), suggesting it is not specific to PCA. The 
possibility that the negative result in this study was related to the absence 
of glibenclamide-sensitive channels in PCA is ruled out by (1) the detection 
of functional KATP channels in cultured PCA smooth muscle cells (Wakatsuki 
et al., 1992) and (2) the observation that vasorelaxation of PCA was 
induced by the KATP channel openers pinacidil (Figure 5.7) and 
levcromakalim (McPherson et al., 1997). Nonetheless, further 
experimentation in PCA to assess relaxation responses to pinacidil in the 
presence of glibenclamide is warranted. It is possible that blockade of KATP 
channels in PCA is compensated for by enhanced signalling via other 
pathways. As discussed earlier, MEK inhibition in the presence of raised 
extracellular K+ or the non-selective blocker TEA did not result in 
enhancement of E-AR-mediated vasodilatation. When selectively blocking 
KATP channels using glibenclamide, MEK inhibition produced enhancements 
of isoprenaline- and salbutamol-induced vasodilatation, which suggests 
that KATP channels are not involved in the enhancement mechanism.  
 
Patch-clamp experiments of PCA smooth muscle cells in the presence of 
PD98059 (50 PM) revealed a voltage-dependent, quinine-sensitive channel 
with large conductance (137 pS). The BKCa channel is characterised by its 
voltage sensitivity, large unit conductance (> 100 pS), and is blocked by 
200 - 300 PM quinine (Bokvist et al., 1990; Mancilla et al., 1990; Nelson et 
al., 1995b). The open probability of this channel in unstimulated conditions 
was low (NPO = 0.03 at +60 mV), suggesting that the channel may not be 
important in setting resting arterial tone. Due to difficulties in isolating 
smooth muscle cells, experiments controlling for the effects of PD98059 or 
vehicle (DMSO) were not performed, so it is also possible that the low 
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channel activity was due to effects of these compounds. However, this 
explanation is unlikely as low basal activity of the BKCa channel has 
previously been observed in these cells (Deenadayalu et al., 2001; Hu et 
al., 1997).  
 
Application of salbutamol increased channel activity (NPO 0.70 at +60 mV), 
suggesting an interaction between the E2-AR and BKCa channels. However, 
excision of the patch occurred during superfusion of salbutamol. As a 
result, the intracellular face of the channel was exposed to 1 PM Ca2+, 
which was present in the bathing solution and may have contributed to the 
increased channel activity. On the other hand, prior to excision, the intact 
cell was bathed in depolarising concentrations of K+ which normally cause 
Ca2+ influx via L-type Ca2+ channels. In fact, cytosolic Ca2+ concentrations 
of up to 1 PM have been measured in arterial smooth muscle under such 
conditions (Abe et al., 1990; Hirano et al., 1991). It is therefore likely that 
the increased BKCa activity occurred at least in part as a result of E2-AR 
stimulation. Furthermore, the activation of BKCa channels by isoprenaline in 
PCA smooth muscle cells has previously been reported, with the authors 
proposing cross-activation of PKG by cAMP as the underlying mechanism 
(White et al., 2000).  
 
Related isometric tension experiments used iberiotoxin which, at 100 nM, 
the concentration used in this study, has been shown to reduce BKCa 
channel activity and associated relaxations in PCA (Leung et al., 2007; 
Yang et al., 2008).  Like glibenclamide, iberiotoxin failed to alter 
relaxations to either isoprenaline or salbutamol. PD98059 appeared to shift 
agonist curves to leftwards, though this effect was statistically non-
significant. Co-incubation with PD98059 and iberiotoxin also appeared to 
enhance agonist curves though, again, these effects were not statistically 
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significant. These data suggest that PD98059 does not enhance E-AR-
mediated relaxations by altering BKCa channel activity and are consistent 
with the subsequent finding that vasorelaxations induced by the BKCa 
channel opener NS1619 were insensitive to PD98059. Further supporting 
evidence is provided by the facts that isoprenaline-induced activation of 
BKCa channels in PCA smooth muscle cells occurred via a cAMP-dependent 
pathway (White et al., 2000); however, as indicated in Chapter 2, the 
enhancement of E-AR-mediated relaxations by PD98059 appears to occur 
through a cAMP-independent pathway.  
 
IKCa channels are characterised by their Ca
2+ dependence, voltage-
independence and sensitivity to the scorpion venom charybdotoxin and the 
triarylmethane clotrimazole. A related triarylmethane derivative, namely 
TRAM-34, was recently developed (Wulff et al., 2000) and has since been 
used (1 PM ± 10 PM) to study IKCa function in blood vessels (Crane et al., 
2003; Eichler et al., 2003; McSherry et al., 2005). In the current study, 
TRAM-34 was used in conjunction with PD98059 to determine whether the 
enhancement of E2-AR agonist-mediated vasodilatation involves IKCa 
channels. By itself, TRAM-34 (10 PM) failed to alter relaxation responses to 
salbutamol, though there appeared to be a slight, statistically non-
significant inhibitory effect at lower concentrations. In the same 
experiments, PD98059 alone, but not in combination with TRAM-34, 
enhanced relaxations. The fact that TRAM-34 blocked the enhancement of 
the salbutamol-induced relaxation by PD98059 indicates that the IKCa 
channel may be involved in the enhancement of E2-AR-mediated 
vasodilatation. In other words, E2-AR-mediated vasodilatation may be 
inhibited by an interaction between ERK and the IKCa channel, with 
inhibition of ERK activation resulting in the disinhibition of IKCa channel 
activity and, therefore, the E2-AR-mediated response. This finding also 
121 
 
suggests that reduced IKCa channel-mediated dilator activity may 
contribute to the pathology of cardiovascular disease states characterised 
by increased ERK activation (see Chapter 4).  
 
The EDHF phenomenon has been the subject of considerable interest and 
study (Busse et al., 2002). It is thought that elevations of cytosolic [Ca2+] 
in endothelial cells results in the activation of IKCa and SKCa channels 
causing hyperpolarisation which is subsequently conducted to smooth 
muscle cells. IKCa channel expression in blood vessels has frequently been 
observed in endothelial cells and less commonly in smooth muscle cells 
(McNeish et al., 2006). In the current experiment, attempts to probe for 
the existence of IKCa currents using electrophysiology in PCA smooth 
muscle cells were unsuccessful due to difficulties in isolating healthy, 
patchable cells. Immunohistochemistry techniques using IKCa±specific 
antibodies may be warranted to confirm or rule out the expression of the 
channel in PCA smooth muscle cells. However, the up-regulation of 
vascular smooth muscle IKCa channel expression has been observed in 
human coronary artery disease and both mouse and pig models of 
atherosclerosis, suggesting that, in smooth muscle, IKCa channels may be 
relevant in proliferative but not contractile phenotypes (Tharp et al., 2006; 
Toyama et al., 2008). On the other hand, the upregulation of endothelial 
IKCa channels observed in a rat models of hypertension (Giachini et al., 
2009) and obesity (Chadha et al., 2010) served to restore impaired 
endothelium-dependent vasodilation. To further investigate these 
discrepancies, application of the IKCa channel opener 1-EBIO (Adeagbo, 
1999) to endothelium-denuded PCAs would be warranted, as the 
observation of vasodilatation under these conditions would indicate the 
presence of functional IKCa channels on smooth muscle.  
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A possible role for the SKCa channel which, along with IKCa channels, has 
been implicated in EDHF-mediated responses was not investigated in this 
study. However, the suggestion from previous investigations that smooth 
muscle IKCa channels may be unimportant within the contractile phenotype 
opens the possibilities that, firstly, the interaction between ERK and the 
IKCa may exist at the level of the endothelium and, secondly, that the 
interaction may also involve SKCa channels and EDHF.  
 
It is not known whether voltage-dependent K+ (KV) channels are involved 
in the enhancement of E-AR-mediated vasodilatation. Attempts to block 
their activity using 4-aminopyridine (Doggrell et al., 1999) produced strong 
phasic contractions, making the measurement of relaxation responses very 
difficult, and suggesting that these channels may play an important role in 
regulating resting arterial tone, which is consistent with the literature 
(Yuan, 1995). Two quinine-sensitive channels were observed in patch-
clamp experiments, both of which were activated by salbutamol, but it was 
possible to fully characterise only one of these, namely the BKCa channel. 
Unfortunately, attempts to investigate the enhancement phenomenon 
using patch-clamp experiments were unsuccessful.  
 
In conclusion, the E-AR has frequently been reported to dilate blood 
vessels via pathways involving K+ channels. The lack of effect of K+ 
channel blockers on E±AR-agonist-induced vasodilatation may have been 
related to the compensatory recruitment of alternative signalling pathways. 
Inactivation of K+ channels provided evidence that the enhancement of E2-
AR-mediated vasodilatation by MEK inhibitors involves K+ channels. The 
use of selective K+ channel blockers ruled out roles for the KATP and BKCa 
channels in this phenomenon and revealed that at least one K+ channel 
subtype, namely the IKCa channel, may be involved.  
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The interaction between ERK and the IKCa channel may involve direct 
phosphorylation of the channel by ERK or an ERK-dependent kinase, 
resulting in reduced channel activity. Further experiments probing the 
nature of this interaction are warranted, particularly in light of the facts 
that (i) ERK has been reported to regulate K+ channel activity (Li et al., 
2006; Ross et al., 2003) and (ii) the IKCa channel is known to be regulated 
by phosphorylation (Gerlach et al., 2000). 
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CHAPTER 4: THE ROLE OF ERK IN E-ADRENOCEPTOR-
MEDIATED VASODILATATION IN ANIMAL MODELS OF  
TYPE II DIABETES AND OBESITY 
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4.1. INTRODUCTION 
 
Also known as non-insulin-dependent diabetes mellitus, Type II diabetes is 
a complex metabolic condition characterised by insulin resistance and 
hyperglycaemia. It is estimated that 346 million people worldwide suffer 
from this condition, with many cases undiagnosed (World Health 
Organisation, 2011b). Type II diabetes is associated with considerable 
lifestyle disruption and serious long-term consequences, including 
macrovascular complications such as coronary artery disease and stroke. 
Defined b\WKH:+2DV³DEQRUPDORUH[FHVVLYHIDWDFFXPXODWLRQWKDWPD\
LPSDLU KHDOWK´ REHVLW\ KDV PRUH WKDQ GRXEOHG VLQFH  ZLWK DQ
estimated 500 million obese adults worldwide in 2008 (World Health 
Organisation, 2011c). Obesity is associated with elevated insulin resistance 
and hyperglycaemia, and represents a significant risk factor for Type II 
diabetes.  
 
As both Type II diabetes and obesity are responsible for significant 
morbidity and mortality, considerable efforts have been undertaken to 
develop effective treatment options. In biomedical research, animal models 
of these conditions have been developed and provide valuable insights into 
the pathological changes that occur in these disease states. The obese 
phenotype of the Zucker obese rat is derived from an autosomal recessive 
mutation of the leptin receptor (Chua et al., 1996; Phillips et al., 1996). 
Efforts to inbreed selected Zucker obese rats of diabetic lineage produced 
the Zucker diabetic fatty (ZDF) rat (Peterson et al., 1990).  
 
Neither the Zucker rat nor the ZDF rat is a perfect model of human 
disease. First, leptin abnormalities, which underlie the pathological changes 
in these animals, rarely occur in humans and account for a small fraction of 
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the disease burden in obesity and Type II diabetes (Farooqi et al., 2007). 
In addition, differences in pathophysiology exist between human and 
rodent, an example being the observation that islet amyloid deposition is a 
key pathological feature of Type II diabetes in humans but not in ZDF rats 
(Matveyenko et al., 2006). Despite these differences, the Zucker rat and 
ZDF rat exhibit characteristics that also occur in humans with obesity and 
Type II diabetes, respectively, and justify their use as models of these 
disease states. The Zucker rat is hyperphagic and develops obesity by 3±5 
weeks of age (Zucker et al., 1972); hypertriglyceridaemia and 
hyperinsulinaemia (but not gross hyperglycaemia) also occur in early life  
(Ionescu et al., 1985). Similarly, the ZDF rat develops hyperinsulinaemia, 
obesity and hyperglycaemia by 6±8 weeks of age and exhibits micro- and 
macrovascular pathologies that also complicate human disease (Belin de 
Chantemele et al., 2009; Danis et al., 1993; Hempe et al., 2012). The 
timeframe of disease progression in these animals (weeks, compared to 
several years in humans) facilitates the study of the underlying 
pathophysiology and the development of treatment interventions.  
 
As shown in Chapter 2, E-AR-mediated vasodilatation is modulated by ERK. 
A recent study using the ZDF rat model of Type 2 diabetes reported 
reduced E-AR function in coronary artery of this animal (Grisk et al., 2007). 
The current Chapter will explore a possible role for ERK in E-AR-mediated 
vasodilatation in animal models of Type II diabetes and obesity. 
Additionally, ex vivo experiments exposing animal vessels to high glucose 
concentrations in order to mimic the hyperglycaemic state will be 
performed.  
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4.2. MATERIALS AND METHODS 
 
4.2.1. Isometric Tension Recordings 
 
4.2.1.1. Tissue preparation 
 
Thoracic aortae and superior mesenteric arteries (SMA) were dissected 
from freshly-sacrificed, 12-week old male Zucker diabetic fatty rats (ZDF), 
Zucker obese rats and Wistar rats (Charles River Laboratories 
International, Inc.). Wistar rats were used as controls where Zucker lean 
rats were not available. Weight and glucose levels of the rats were not 
available. The vessels were stored in KH solution and prepared as 
described in Section 2.2.1.1. After mounting the rat SMA and aorta to a 
Mulvany wire myograph, a resting tension of 0.5 g and 1.0 g, respectively, 
was applied. In experiments using porcine coronary arteries (PCA), the 
protocol described in Section 2.2.1.1 was used. 
 
4.2.1.2. Experimental procedure 
 
Mounted arteries were challenged with KCl (60 mM) in order to confirm 
tissue viability and to determine their maximal contractile capacities. The 
arteries were then thoroughly rinsed with KH solution and allowed to re-
equilibrate for 15 to 20 min. The process was repeated twice. 
 
4.2.1.2.1. The effect of MEK inhibition on E-AR-mediated relaxation  
 
To assess the role of ERK activation in E-AR-mediated relaxation, arteries 
were incubated with either PD98059 (50 PM) or 0.26% (v/v) DMSO. This 
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was followed by contraction with the thromboxane mimetic U46619 (10 ± 
20 nM) to 60±70% of the maximum response to KCl. Finally, cumulative 
concentrations of isoprenaline (1 nM ± 3 PM) were used to relax the pre-
contracted arteries.  
 
4.2.1.2.2. The effect of high glucose concentration on E-AR-mediated 
relaxation 
 
In a separate series of experiments, the effect of overnight incubation of 
PCA in high glucose conditions was investigated. The aim was to determine 
whether the effects of diabetes on E-AR-mediated relaxation could be 
mimicked in vitro. In the following experiments, arteries were prepared in 
KH solution modified to contain 5.5 mM glucose.  
 
Arteries were stored in pre-gassed KH solution containing 25 mM glucose 
at 4qC for roughly 16 hours. Control arteries were stored in KH solution 
containing 5.5 mM glucose. To account for the osmotic effects of high 
glucose concentrations, a second control group was stored overnight in 
mannitol (19.5 mM). Immediately after the incubation period, arteries 
were set up on a Mulvany wire myograph in order to carry out isometric 
tension recordings. Following KCl challenges and pre-contraction with 
U46619, cumulative concentrations of salbutamol (10 nM ± 30 PM) were 
applied to generate concentration-response curves. The KH solution used 
during the course of the experiment was continuously gassed and 
contained 5.5 mM glucose.  
 
In a similar set of experiments, arteries were stored overnight as described 
above. However, during isometric tension recordings arteries were exposed 
only to the same solutions in which they were incubated. A related 
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experiment was performed in which the arteries were incubated for 16 
hours in their respective solutions at 37qC. To prevent microbial growth, 
solutions were supplemented with penicillin-streptomycin (500 units/0.5 
mg ml-1) and all manipulations prior to isometric tension recordings were 
carried out under aseptic conditions. Again, during isometric tension 
recordings, arteries were exposed only to the same solutions in which they 
were incubated. 
 
4.2.2. Measurement of ERK activation 
 
As previously described in our laboratory (Roberts, 2001), the 
phosphorylation state of ERK at Thr-202 and Tyr-204 was measured using 
immunoblotting. 
 
4.2.2.1. Tissue preparation 
 
SMA dissected from ZDF rats and their Zucker lean controls were set up on 
a Mulvany wire myograph as described earlier. Following KCl challenges 
and re-equilibration periods, arteries were either contracted with U46619 
to 60±70% of the maximal KCl response or left to incubate in KH solution 
(controls). As soon as the contractile response to U46619 had reached a 
plateau, the arteries were dismounted from the myograph and immediately 
frozen on dry ice. They were stored at -80qC. After defrosting, arteries 
were prepared for immunoblotting experiments as described in Section 
2.2.2.1.   
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4.2.2.2. Immunoblotting 
 
The arteries were assessed for changes in the dual phosphorylation of ERK 
using immunoblotting as described in Section 2.2.2.3.  
 
4.2.3. Statistical analyses 
 
Data were analysed using GraphPad Prism 5.0 (Graphpad Software Inc., La 
Jolla, CA, USA). Relaxation response measurements are expressed as 
means r SEM. Statistical comparisons between groups were made using 
the two-WDLOHG XQSDLUHG 6WXGHQW¶V W-test except where stated. As there 
were insufficient repeat experiments to determine distribution, the data 
were assumed to be normally distributed and parametric tests were 
employed. A P value < 0.05 was considered statistically significant. In all 
H[SHULPHQWV ³Q´ QXPEHUV UHSUHVHQW WKH QXPEHU RI DQLPDOV IURP ZKLFK
tissues were obtained. 
  
4.2.4. Materials 
 
Penicillin-streptomycin (10,000 units/10 mg ml-1) was ordered from Sigma 
(Poole, Dorset, UK). The remaining chemicals were acquired as stated in 
Section 2.2.4.  
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4.3. RESULTS 
 
4.3.1. The effect of MEK inhibition on E-AR-mediated 
vasodilatation in Zucker diabetic fatty rats 
 
In ZDF rat aortae, isoprenaline reversed the U46619-evoked pre-
contraction to a maximal relaxation of 50 r 7% (Figure 4.1). This was 
significantly lower than the corresponding value in aortae from Wistar 
control rats (93 r 5%; P<0.05; Figure 4.2).  
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Figure 4.1. The effect of MEK inhibition on relaxations to the E-AR agonist 
isoprenaline in ZDF rat aorta (n=6 or 7). Isoprenaline relaxations in control 
rings (treated with 0.26% (v/v) DMSO) were similar to those in PD98059-
treated rings: there were no differences in either pEC50 (7.5 r  0.3 versus 
7.4 r 0.2; P>0.05) or RMAX values (45 r 5% versus 50 r 7%; P>0.05). 
 
132 
 
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100 Control
PD98059 (50 PM)
[Isoprenaline] (log M)
R
e
la
x
a
ti
o
n
(%
 U
4
6
6
1
9
-e
v
o
k
e
d
 c
o
n
tr
a
c
ti
o
n
)
 
Figure 4.2. The effect of the MEK inhibitor PD98059 on E-AR-mediated 
relaxations in Wistar rat aorta (n=5 or 6). PD98059 (50 PM) did not alter 
relaxation responses to isoprenaline with respect to either pEC50 (7.5 r 0.1 
versus 7.6 r 0.1 in controls; P>0.05) or RMAX (93 r 5% from 97 r 5% in 
controls; P>0.05). Control experiments were performed in (0.26% (v/v) 
DMSO).  
 
As shown in Figure 4.1, PD98059 appeared to inhibit isoprenaline-induced 
relaxations of pre-contracted ZDF aortae, though this effect was not 
statistically significant (RMAX: 45 r 5% from 50 r 7% in controls, P>0.05; 
pEC50: 7.4 r 0.2 from 7.5 r 0.3 in controls; P>0.05). Likewise, Figure 4.2 
shows that PD98059 did not alter isoprenaline responses in Wistar rat 
aorta, though there appeared to be a trend towards inhibition at lower 
concentrations of isoprenaline (RMAX: 93 r 5% from 97 r 5% in controls; 
P>0.05, two-WDLOHGXQSDLUHG6WXGHQW¶VW-test; pEC50: 7.5 r 0.1 from 7.6 r 
0.1 in controls; P>0.05).  
 
Figures 4.3 and 4.4 show the effect of PD98059 on isoprenaline-induced 
relaxations of SMA from ZDF rats and Wistar rats, respectively. Whilst 
isoprenaline was able to reverse the U46619-evoked pre-contraction in 
Wistar SMA almost completely, the responses in ZDF rats were markedly 
133 
 
blunted. In fact, the latter artery failed to respond to high concentrations 
of isoprenaline (1 PM and 3 PM).  
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Figure 4.3. The effect of MEK inhibition on E-AR-mediated relaxations in 
ZDF rat SMA (n=7). Isoprenaline reversed the U46619-induced contraction 
by only 25 r 8% under control conditions (0.26% (v/v) DMSO), and 
PD98059 (50 PM) enhanced the isoprenaline response (50 r 7% reversal of 
U46619-evoked contraction; P<0.05). 
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Figure 4.4. The effect of MEK inhibition on E-AR-mediated relaxations in 
Wistar rat SMA (n=4). Isoprenaline response curves performed in the 
presence of 50 PM PD98059 were not significantly different to those 
performed under control conditions (0.26% (v/v) DMSO). 
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As it was not possible to determine RMAX values in the ZDF rat SMA dataset 
using the computer software, maximal responses are instead quoted as the 
response to the highest concentration of isoprenaline (3 PM). At 3 PM 
isoprenaline, ZDF rat SMA relaxed to 25 r 8% compared to 85 r 14% in 
SMA from Wistar rats (P<0.01). PD98059 increased the response in ZDF 
rat SMA (50 r 7%; P<0.05) but not Wistar rat SMA (88 r 6%; P>0.05).  
 
4.3.2. The effect of MEK inhibition on E-AR-mediated 
vasodilatation in Zucker obese rats 
 
Figure 4.5 shows that isoprenaline induced concentration-dependent 
relaxations of Zucker obese rat aortae. Isoprenaline reversed the U46619-
evoked contractile tone by only 34 r 8%, compared to 95 r 4% in Wistar 
rat aortae (Figure 4.2; P<0.001; values represent responses to 3 PM 
isoprenaline).  
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Figure 4.5. The effect of MEK inhibition on E-AR-mediated relaxations in 
Zucker obese rat aorta (n=7 or 8). Under control conditions (0.26% (v/v) 
DMSO), the U46619-evoked contraction was reversed by only 34 r 8% 
following the application of 3 PM isoprenaline. The corresponding response 
in rings exposed to PD98059 (50 PM) was 30 r 6% (P>0.05). 
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PD98059 did not alter the response to isoprenaline in Zucker obese rat 
aorta (30 r 6% relaxation to 3 PM isoprenaline; P>0.05, two-tailed, 
XQSDLUHG 6WXGHQW¶V W-test; Figure 4.5). In addition, the concentration of 
isoprenaline required to produce 50% of the response to 3 PM isoprenaline 
also did not differ between controls and PD98059 (7.6 r 0.2 versus 7.7 r 
0.2, respectively; P>0.05). In contrast to its effect on Wistar rat SMA (RMAX 
= 85 r 14%; Figure 4.4), isoprenaline produced only modest relaxations in 
Zucker obese rat SMA (RMAX = 28 r 4%; P<0.01; Figure 4.6). PD98059 
increased the maximal relaxation response to isoprenaline in Zucker obese 
rat SMA from 28 r 4% in controls to 43 r 9% (P<0.05). However, there 
was no change in the potency (pEC50 values of 7.5 r 0.3 in controls and 
7.3 r 0.4 with PD98059; P>0.05).  
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Figure 4.6. The effect of MEK inhibitor PD98059 (50 PM) on E-AR-
mediated relaxations in Zucker obese rat SMA (n=6 or 7). The maximal 
relaxation to isoprenaline was greater in PD98059-treated SMA rings than 
in controls (0.26% (v/v) DMSO): 43 r 9% versus 28 r 4%; P<0.05. 
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4.3.3. Summary of E-AR vasodilatation in ZDF rats and Zucker 
obese rats 
 
A summary of the differences in E±AR-mediated relaxations that exist 
between the various rat strains is shown in Table 4.1, along with effects of 
MEK inhibition.  
 
Strain 
Aorta SMA 
Relaxations 
compared to 
control rats 
Effect of MEK 
inhibition on 
relaxations 
Relaxations 
compared to 
control rats 
Effect of MEK 
inhibition on 
relaxations 
Wistar NA l NA l 
ZDF p l p n 
Obese p l p n 
Table 4.1. Summary of changes in E-AR-mediated relaxation in rat models 
of Type II diabetes and obesity. Impairments (p), enhancements (n) and 
no changes (l) are indicated.  
 
4.3.4. The effect of TP receptor activation on ERK activation in 
ZDF rats 
 
A representative blot of western immunoblotting experiments assessing 
the effect of TP receptor activation on ERK activation in SMA of ZDF and 
Zucker lean rats is shown in Figure 4.7. The associated densitometric 
analysis is summarised in Table 4.2. In both preparations, the levels of 
total ERK1 (tERK1) and tERK2 were unchanged by U46619 (P>0.05, two-
way ANOVA followed by Bonferroni post-hoc test). In Zucker lean rats, 
U46619 had no effect on phosphorylated ERK1 (pERK1) or pERK2. 
However, in ZDF rats U46619 increased the levels of pERK1 and pERK2 by 
factors of 1.56 and 1.84, respectively (P<0.01, two-way ANOVA followed 
by Bonferroni post-hoc test). 
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Figure 4.7. Representative blot of western immunoblotting experiments 
assessing the effect of TP receptor activation on ERK activation in SMA 
taken from Zucker lean rats (a-d) and ZDF rats (e-h). Prior to freezing and 
homogenisation, SMA rings were incubated in tissue baths for 45 mins in 
the absence (a, c, e and g) or presence (b, d, f and h) of U46619. 
 
 
Taken together, the data indicate that treatment with U46619 stimulates 
ERK activation in ZDF rat SMA, whilst having no effect on ERK activation in 
SMA of Zucker lean controls.  
 
 Zucker Lean (n=4) Zucker Diabetic (n=5) 
 Basal U46619 Basal U46619 
pERK1 4.63 (0.8) 4.25 (0.7) 4.72 (0.7) 7.34 (1.2)** 
tERK1 5.45 (0.3) 4.98 (0.2) 5.35 (0.3) 6.19 (0.3) 
pERK2 1.68 (0.4) 2.09 (0.8) 2.16 (0.6) 3.98 (0.7)** 
tERK2 2.75 (0.4) 2.83 (0.2) 3.24 (0.3) 3.55 (0.3) 
Table 4.2. The effect of U46619 on the levels of pERK1/2 and tERK1/2 in 
SMA of ZDF rats and Zucker lean rats. Values are mean (SD) optical 
densities (arbitrary units) derived from analysis using Odyssey software 
(LI-COR Biotechnology Ltd., Cambridge, UK). U46619 caused a significant 
increase (versus basal) in pERK1 and pERK2 activation in ZDF rats but not 
in Zucker lean rats. ** represents P<0.01 (two-way ANOVA followed by 
Bonferroni post-hoc test). 
 
4.3.5. The effect of high glucose concentration on E-AR-
mediated vasodilatation 
 
To determine whether the impaired E-AR-mediated vasodilator responses 
observed in Zucker obese rats and ZDF rats could be replicated in vitro, 
PCA segments were exposed to high glucose conditions in order to mimic 
the hyperglycaemic state. Salbutamol-induced relaxations of porcine 
coronary artery segments pre-contracted with U46619 were unaffected by 
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pre-treatment with high concentrations of glucose at 4qC (Figure 4.8). 
Control vessels relaxed to a maximum of 83 r 8% with a pEC50 value of 6.0 
r 0.1; 25 mM glucose-incubated vessels relaxed to 94 r 5% with a pEC50 
value of 5.8 r 0.1; and vessels incubated with 19.5 mM mannitol (osmotic 
control) relaxed to 95 r 13% with a pEC50 value of 5.8 r 0.2.  
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Figure 4.8. The effect of high glucose concentrations on E-AR-mediated 
relaxations in PCA rings incubated overnight at 4qC (n=2). PCA rings had 
previously been incubated at 4qC in KH solution containing either 5.5 mM 
glucose (open circles), 25 mM glucose (open squares) or 5.5 mM 
glucose/19.5 mM mannitol (osmotic control; closed circles), and 
experiments were carried out in KH solution containing 5.5 mM glucose. 
Neither high glucose (25 mM) nor mannitol appeared to alter the relaxation 
response to salbutamol.  
 
Figure 4.9 shows the effect of incubating coronary arteries with 25 mM 
glucose for 16 hours prior to experimenting, as well as during the 
experiment itself. There was no significant difference between the 
relaxation characteristics of isoprenaline in each dataset (RMAX and pEC50 
values: control = 80 r 7% and 5.8 r 0.1, 25 mM glucose = 95% and 5.7, 
19.5 mM mannitol = 81 r 5% and 5.6 r 0.1). 
 
 
139 
 
Figure 4.9. The effect of high glucose concentrations on E-AR-mediated 
relaxations in PCA rings incubated overnight at 4qC (n=2). Log 
concentration±response curves to salbutamol in PCA. Relaxations, shown 
as means r SEM (n=1 or 2), are expressed as a percentage of the U46619-
evoked contraction. PCA rings had previously been incubated at 4qC in KH 
solution containing either 5.5 mM glucose (open circles), 25 mM glucose 
(open squares) or 5.5 mM glucose/19.5 mM mannitol (osmotic control; 
closed circles), and experiments were carried out in the corresponding 
solutions. The relaxation response to salbutamol was not altered by either 
high glucose (25 mM) or mannitol. 
 
Coronary arteries incubated in KH solution containing 5.5 mM glucose for 
16 hours at 37qC relaxed to 88 r 4%, compared to 87 r 8% and 85% in 
arteries incubated in KH solution containing 25 mM glucose and 19.5 mM 
mannitol, respectively, in response to salbutamol (Figure 4.10). There 
appeared to be a trend towards inhibition of the relaxation response as a 
result of exposure to 25 mM glucose (pEC50 values: 7.0 r 0.1 in controls, 
6.3 r 0.2 in high glucose-incubated arteries, and 6.9 in osmotic controls).  
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Figure 4.10. The effect of high glucose concentration on E-AR-mediated 
relaxations in PCA rings incubated overnight at 37qC (n=1 or 2). PCA rings 
had previously been incubated at 37qC in KH solution containing either 5.5 
mM glucose (open circles), 25 mM glucose (open squares) or 5.5 mM 
glucose/19.5 mM mannitol (osmotic control; closed circles), and 
experiments were carried out in the corresponding solutions. Incubation 
with glucose (25 mM) but not mannitol appeared to inhibit salbutamol 
relaxations.  
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4.4. DISCUSSION 
 
In this Chapter, animal models of diabetes and obesity were used in 
conjunction with isometric tension and immunoblotting techniques to 
assess the role of ERK in regulating blood vessel tone in these disease 
states. Two blood vessels derived from Zucker obese rats and Zucker 
diabetic fatty (ZDF) rats were assessed for E-AR-mediated vasodilatation, 
namely the thoracic aorta and superior mesenteric artery (SMA).  
 
Isoprenaline-induced relaxations of arteries taken from Zucker obese rats 
and ZDF rats were significantly impaired as compared to corresponding 
measurements in arteries from Wistar rats.  These findings are consistent 
with the observation in a previous study that mesenteric blood flow 
responses to isoprenaline were markedly blunted in Zucker obese rats 
(D'Angelo et al., 2006). Similar impairments of vasodilator responses to 
isoprenaline have been observed in skeletal muscle arterioles from ZDF 
rats (Lesniewski et al., 2008). The observation that MEK inhibition failed to 
enhance E-AR-mediated relaxations in healthy Wistar rats is not consistent 
with findings from corresponding experiments in healthy pigs (Section 
2.3.1). Different levels of basal and agonist-stimulated ERK activation 
between the two species may explain this discrepancy.  
 
In this study, it was difficult to determine whether reduced vasodilatation 
in diseased rat arteries was accompanied by exaggerated contractile 
responses as cumulative concentration-contraction curves to 
vasoconstrictors were not performed. Nonetheless, detailed assessments of 
vascular reactivity in these models have been performed elsewhere, with 
reports of augmented contractility in Zucker obese rats (Frisbee, 2004; 
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Ouchi et al., 1996) and ZDF rats (Belin de Chantemele et al., 2009; 
Lesniewski et al., 2008).  
 
A combination of impaired vasodilatation and enhanced contractility would 
be expected to compromise the ability of Zucker obese rats and ZDF rats 
to adequately regulate blood flow and maintain physiological arterial 
pressures. Although changes were detected in the function of both the 
thoracic aorta and SMA of diseased rats, it is more likely that alterations in 
the latter are more relevant. Owing to its proximity to the mesenteric 
vascular bed and smaller lumen diameter (roughly 0.5 mm versus 2 mm in 
aorta), the SMA may be a more important contributor to vascular 
resistance than the thoracic aorta, which mainly serves as a conduit vessel. 
However, investigations of higher-order mesenteric arteries may be 
warranted, as it is thought that arteries with lumen diameters of less than 
0.4 mm are the most relevant to vascular resistance (Intengan et al., 
2000).  
 
As demonstrated in Chapter 2, ERK activation is associated with reduced E-
AR-mediated vasodilatation in porcine coronary arteries (PCA). To test the 
hypothesis that ERK contributes to the observed impairment of E-AR-
mediated vasodilatation in obese and diabetic rats, experiments were 
carried out in the absence and presence of the MEK inhibitor PD98059. In 
SMA of Zucker obese rats and ZDF rats, PD98059 partially restored 
functional responses to isoprenaline, whereas no enhancement was 
observed in thoracic aorta. These findings suggest that ERK activation may 
be increased in SMA but not in aorta. Although biochemical assessments of 
ERK activation in aorta were not performed, immunoblotting experiments 
using SMA showed an increased U46619-induced activation of ERK in ZDF 
rats as compared to Zucker lean rats. An alternative interpretation is that 
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SMA and aorta may exhibit similar ERK activation characteristics, but ERK 
does not regulate E±AR-mediated vasodilatation in aorta. Additionally, 
given that E2- but not E1-AR-mediated vasodilatation was enhanced by 
PD98059 (Section 2.3.2), E2-ARs may be more relevant in isoprenaline-
induced relaxations of SMA, whilst the E1 subtype may predominate in 
aorta. ,Q IXWXUH LPPXQREORWWLQJ H[SHULPHQWV D ³KRXVHNHHSLQJ´ SURWHLQ 
such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) would be 
employed in order to correct for protein loading and thus substantiate 
changes, if any, in pERK and tERK levels.  
 
Although PD98059 partially corrected isoprenaline-induced relaxations of 
SMA from ZDF rats and Zucker obese rats, the degree of enhancement 
appeared greater in the former preparation. Again, this may be related to 
differences in ERK activation and/or the relative expression of E-AR 
subtypes between the two preparations. The partial, rather than complete, 
correction of isoprenaline-induced responses by PD98059 may reflect 
incomplete inhibition of ERK activation at the concentration of PD98059 
used in the experiment (50 PM). A more likely explanation is that 
additional signalling pathways may contribute to the impairment of E-AR-
mediated vasodilatation. A possible candidate is the MAPK p38, the 
activation of which in VSM cells has been linked to high glucose 
concentrations (Igarashi et al., 1999). In fact, data presented in the 
current investigation suggests a role for p38 MAPK in E-AR-mediated 
vasodilatation (Figure A5, Appendix). However, further experimentation 
would be required to confirm the involvement of p38 MAPK in impaired E-
AR-mediated vasodilatation in ZDF rats and Zucker obese rats.  
 
Regulation of vascular tone by the endothelium has been the subject of 
considerable research in recent decades (Mas, 2009). Endothelial function 
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has previously been investigated in rat models of Type II diabetes. 
Initially, Bohlen et al. (1995) demonstrated that endothelial-dependent 
vasodilatation of intestinal arterioles were comparable between ZDF rats 
and Zucker lean rats. In contrast, it was later shown in a different rat 
model, namely the Otsuka Long-Evans Tokushima Fatty (OLETF) rat, that 
endothelium-dependent relaxation of thoracic aorta was reduced relative to 
non-diabetic controls (Sakamoto et al., 1998).  
 
In the present study, it is not known whether the blunted E-AR-mediated 
vasodilatation observed in arteries from ZDF rats (12-week-old) was 
caused by endothelial dysfunction. However, a recent study showed that 
impaired E-AR-mediated relaxation of coronary artery from 12-week-old 
ZDF rats was not accompanied by endothelial dysfunction (Grisk et al., 
2007). This is in agreement with an earlier study which reported that 
endothelial dysfunction emerged after 16 ± 24 weeks in ZDF rats (Oltman 
et al., 2006). Furthermore, E-AR-mediated relaxation of dorsal hand vein 
was shown to be reduced in diabetic patients as compared to controls, 
whilst endothelium-dependent relaxations were similar between the two 
groups (Harada et al., 1999). Together, these data suggest that the 
impairment of E-AR-mediated vasodilatation in Type II diabetes may 
precede endothelial dysfunction.  
 
Investigations in diabetic humans have also demonstrated impairments of 
endothelium-dependent vasodilatation. Gazis et al. (1999) showed that 
acetylcholine (ACh)-induced increases of forearm blood flow was blunted in 
diabetic subjects compared to controls. Blood flow changes to sodium 
nitroprusside (SNP), an endothelium-independent vasodilator, were similar 
between the two groups, suggesting that endothelium dysfunction was 
responsible for the impairment of ACh-mediated vasodilatation. However, 
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these findings were confounded by the fact that systolic blood pressure, 
triglycerides and HDL cholesterol were also significantly different between 
the two groups. Impaired endothelium-dependent vasodilatation has also 
been shown in in vivo studies of human coronary artery (Nitenberg et al., 
1993) and brachial artery (Enderle et al., 1998). The mechanisms by which 
Type II diabetes reduce endothelium-dependent vasodilatation are not fully 
understood. However, it is possible that the release and/or signalling of 
endothelium-derived vasodilator substances, such as nitric oxide (NO) and 
endothelium-derived hyperpolarising factor (EDHF), are in some way 
disrupted.  
 
In Zucker obese rats, impaired endothelium-dependent vasorelaxations 
have been demonstrated in several blood vessels. In aorta of 16-week old 
rats, for example, endothelium-dependent vasorelaxation was blunted and 
accompanied by enhanced vasoconstriction, possibly via changes in Akt- 
and Rho-dependent pathways, respectively (Nishimatsu et al., 2005), 
Furthermore, it was shown in penile arteries of 17 ± 18-week-old  Zucker 
obese rats that impaired ACh-induced relaxation responses were related to 
an inability of prostanoids to mediate vasodilatation (Sanchez et al., 2010). 
Again, it is not known whether the impaired E-AR-mediated vasodilatation 
observed in Zucker obese rats in the current study was associated with 
altered endothelial function. Although previous studies have shown 
reduced endothelial function in this model, the animals used were older 
than those used in the current study (16 ± 18-week-old versus 12-week-
old). Furthermore, Oltman et al. (2006) demonstrated that endothelium 
dysfunction occurs after 28 weeks in Zucker obese rats. Human studies 
have also reported abnormal endothelial function in obese individuals 
compared to lean controls (Oflaz et al., 2003; Weil et al., 2011; Worthley 
et al., 2009).  
146 
 
It has been frequently reported that K+ channel activity is reduced in blood 
vessels of human diabetics (Irat et al., 2006; Miura et al., 2003). As 
discussed in Chapter 3, the inhibitory actions exerted by ERK on E-AR-
mediated vasodilatation may involve an interaction with K+ channels. 
Activation of ERK in U46619-stimulated SMA from ZDF rats was 
significantly higher than in lean rats. This may have produced impaired E-
AR-mediated vasodilatation via a greater disruption of K+ channels. To test 
this hypothesis further, the effects of K+ channel blockers and openers, in 
conjunction with MEK inhibitors, would need to be studied in arteries from 
ZDF rats.  
 
Similar experiments in other laboratories have demonstrated that K+ 
channel function in rat models of diabetes may be altered. For instance, 
ATP-sensitive K+ channels (KATP) and calcium-activated K
+ channels (KCa) in 
arteries from fructose-fed, insulin-resistant rats have been shown to 
function abnormally (Erdos et al., 2002). A later study showed, using 
voltage clamp recordings, that NS1619, a selective large-conductance, 
calcium activated K+ (BKCa) channel opener, produced significantly smaller 
currents in mesenteric artery smooth muscle cells derived from ZDF rats 
compared to those from their lean littermates (Burnham et al., 2006).  
 
The BKCa channel is activated by both membrane depolarisation and 
increases in intracellular Ca2+, and, in addition to mediating responses to 
vasodilator agents, may also play a role in modulating vasoconstriction 
(Nelson et al., 1995a). Thus, an expected consequence of reduced BKCa 
channel function would be enhanced contractile responses due to a loss of 
this regulatory mechanism. It is not possible to endorse this hypothesis 
based on the data presented in the current study; as mentioned earlier, 
cumulative contraction-response curves to vasoconstrictors were not 
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performed. Nonetheless, the clinical significance of these findings is 
highlighted by a previous study in mice, where disruption of BKCa channel 
function via genetic deletion of the E1 subunit resulted in hypertension 
(Pluger et al., 2000). Moreover, based on investigations of a rat model of 
hypertension, Amberg et al. (2003) proposed that loss of BKCa channel 
function, via reduced expression of the E1 subunit, may contribute to the 
development of hypertension.  
 
As discussed earlier, the effects of long-term hyperglycaemia on vascular 
function have been intensely studied, both in humans and animal models 
of Type II diabetes. In attempts to replicate hyperglycaemic conditions, 
porcine coronary artery (PCA) rings were incubated in Krebs-Henseleit 
(KH) solution containing 25 mM glucose at 4qC and 37qC. Glucose 
concentrations as high as 44 mM have previously been used to mimic 
hyperglycaemia (Tesfamariam et al., 1990; Weisbrod et al., 1993). In the 
present investigation, potential osmotic effects due to high glucose 
concentration (25 mM) were controlled for through the use of an 
osmotically equivalent concentration of mannitol (19.5 mM). Cumulative 
concentration-relaxation curves to salbutamol were subsequently 
performed and the results suggest that osmotic effects were not important, 
as mannitol failed to alter salbutamol-induced relaxations in all 
experiments. Overnight incubation with 25 mM glucose at 4qC had no 
effect on the relaxation characteristics of salbutamol, even when the 
arteries were exposed to 25 mM glucose during the course of the 
experiment. Overnight incubation of arteries at 37qC appeared to shift the 
concentration-relaxation curves leftwards when compared to values 
measured following overnight incubation at 4qC (pEC50 values for control 
arteries = 7.0 r 0.1 at 37qC and 5.8 r 0.1 at 4qC). Temperature has been 
shown to influence vasorelaxation (Garcia-Villalon et al., 1995; Saito et al., 
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1998), possibly by altering ion channel activity. However, in the present 
experiment, all relaxation responses were recorded at the same 
temperature, 37qC, suggesting the enhanced relaxation was due to 
overnight incubation at a higher temperature. 
 
Whereas salbutamol-induced relaxations were unaffected by high glucose 
treatment at 4qC, relaxations following incubation with high glucose at 
37qC appeared to be inhibited, as shown by a modest right-shift of the 
relaxation curve. Maximal relaxation responses, however, were unaffected 
by high glucose treatment, in contrast to the dramatic reductions of 
maximal relaxations observed in arteries from diabetic rats. This difference 
suggests that chronic exposure to high glucose produce greater deficits of 
E-AR-mediated vasodilatation than acute exposure. In any case, further 
experimentation relating to the acute effects of high glucose concentrations 
is warranted as the small number of repeats in each experiment may have 
obscured findings. It would also be worth investigating the effect of this 
treatment on ERK activation, and whether inhibition of ERK activation 
restores relaxation capacity.  
  
The finding that U46619-stimulated ERK activation was greater in ZDF rats 
than in lean controls. Increased ERK activation in ZDF rats may occur via a 
number of mechanisms. One possibility is the hyperglycaemic state per se, 
as high glucose treatment has been associated with marked increases in 
ERK phosphorylation in range of tissues (Bandyopadhyay et al., 2000; 
Cohen et al., 2003; Farrokhnia et al., 2005; Natarajan et al., 1999). 
Secondly, by inducing the non-enzymatic glycation of various plasma 
proteins and lipids, chronic hyperglycaemia accelerates the production of 
advanced glycation end-products (AGEs), which are implicated in diabetes 
complications and have been shown to activate ERK (Berrou et al., 2009; 
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Huang et al., 2008). Furthermore, hyperglycaemia-related activation of 
ERK may also occur via intermediate glycated products. For instance, 
glycated albumin, which, incidentally, is recognised as a reliable marker of 
short-term glycaemic control in diabetic patients, has been shown to 
stimulate ERK activity in VSM and other tissues (Cohen et al., 2003; 
Hattori et al., 2001; Treins et al., 2001).  
 
Both the ZDF rat and Zucker obese rat strains are characterised by 
hyperlipidaemia, with overtly raised triglyceride and cholesterol levels 
compared to healthy, lean rats (Hoshida et al., 2000; Liszka et al., 1998). 
In humans, it has long been known that derangements of lipid levels 
present an increased risk of cardiovascular disease (Keys et al., 1984; 
Stamler et al., 1986). Free fatty acids (FFAs), as well as elevated glucose 
levels, were reported to activate PKC and reactive oxygen species (ROS) 
(Inoguchi et al., 2000), both of which are implicated in cardiovascular 
complications of diabetes (Idris et al., 2001; Jay et al., 2006). Moreover, 
low-density lipoprotein (LDL), known to contribute to the development of 
atherosclerosis and endothelial dysfunction, was shown to activate ERK in 
human endothelial cells and rat aortic smooth muscle cells (Pintus et al., 
2003; Velarde et al., 2001).  
 
The fatty acid arachidonic acid (AA) and its numerous eicosanoid 
metabolites are recognised as key regulators of diverse functions. In blood 
vessels, for instance, accumulations of prostacyclin and thromboxane, both 
cyclooxygenase (COX) products of AA metabolism, are respectively 
associated with contraction and relaxation of VSM, reflecting a contractile 
phenotype (Shibamoto et al., 1995; Shimokawa et al., 1988). Previous 
studies have linked AA/eicosanoids with ERK activation in blood vessels. 
For example, a lipoxygenase (LOX) metabolite of AA, namely leukotriene 
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B4 (LTB4), was recently shown to mediate VSM cell migration via activation 
of ERK2 (Moraes et al., 2010). These signalling mechanisms may be more 
relevant in disease states characterised by hyperlipidaemia and/or 
increased ERK activation. Thus it is possible that such disease states may 
exhibit altered regulation of processes such as cell proliferation and 
migration. The resulting changes in blood vessel structure, reflecting a shift 
from a contractile to a proliferative phenotype, would likely produce 
functional deficits similar to those observed in the current study.   
 
In summary, E-AR-mediated vasodilatation was impaired in rat models of 
Type II diabetes and obesity. This impairment was observed both in SMA 
and thoracic aorta of Zucker obese rats and ZDF rats. Inhibition of ERK 
activation partially restored E-AR-mediated relaxations in SMA but not in 
aorta. Furthermore, TP receptor-stimulated ERK activation was elevated in 
SMA of ZDF rats compared to those of Zucker lean rats. In experiments 
designed to mimic the hyperglycaemic state, E-AR-mediated vasodilatation 
appeared to be blunted by high glucose concentrations, though a greater 
number of repeat experiments are required. Taken together, these data 
suggest that impairments of E-AR-mediated vasodilatation caused by Type 
II diabetes and obesity may occur as a result of increased ERK activation. 
Further experimentation would be required to determine the precise 
mechanism(s) involved, including a possible role for ERK in the regulation 
of K+ channels.  
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CHAPTER 5: THE EFFECT OF STATINS ON  
E-ADRENOCEPTOR-MEDIATED VASODILATATION 
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5.1. INTRODUCTION 
 
Statins are widely used in the prevention and treatment of cardiovascular 
disease. Their cholesterol-lowering effects are caused by the inhibition of 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which 
prevents the formation of mevalonate, a key precursor in the biosynthesis 
of cholesterol (Figure 1.8).  
 
HMG-CoA reductase is also involved in the formation of the isoprenoids 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), 
which in turn play key roles in the post-translational modification of GTP-
binding proteins (also known as GTPases) such as Ras and Rho. These 
modifications occur via prenylation, the covalent attachment of an 
isoprenoid group to the GTPase, allowing it associate with the cell 
membrane, where it is activated.  By inhibiting HMG-CoA reductase, statins 
may decrease levels of FPP and GGPP and therefore prevent the activation 
of Ras and Rho. This mechanism might underlie the beneficial effects of 
statins unrelated to cholesterol lowering.  
 
As shown in Chapter 2, inhibition of extracellular signal-regulated kinase 
(ERK) activation results in the enhancement of relaxation responses to E-
adrenoceptor (E-AR) agonists. In the aforementioned experiments, specific 
inhibitor compounds, namely PD98059, PD184352 and U0126, were used 
to prevent activation of ERK. However, it is possible that inhibition of ERK 
activation may be achieved using statins due to their ability to inhibit the 
activation of Ras, which lies upstream of ERK. This raises the possibility of 
extending the clinical use of statins to include inhibition of ERK activation 
in order to enhance E-AR-mediated vasodilatation, and is supported by the 
following observations. Firstly, in a mouse osteosarcoma cell line, statins 
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were shown to disrupt ERK signalling via inhibitory effects on GGPP 
biosynthesis (Tsubaki et al., 2011); secondly, lipopolysaccharide-
stimulated activation of ERK in mononuclear cells was inhibited by 
simvastatin, and this inhibition was reversed by GGPP (Sundararaj et al., 
2008).  
 
The aim of these experiments was to determine the effect of statins on 
relaxations induced by E-AR agonists in order to assess their potential 
utility as enhancers of E-AR-mediated vasodilatation in the clinical setting. 
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5.2. MATERIALS AND METHODS 
 
5.2.1. Tissue preparation 
 
Porcine coronary artery (PCA) rings were prepared and set up in a Mulvany 
wire myograph as described in Section 2.2.1.1.  
 
5.2.2. Experimental procedure 
 
5.2.2.1. The effect of statins on E-AR-mediated relaxation  
 
The effects of various statins on the relaxation characteristics of 
salbutamol were assessed. Artery rings were contracted with U46619 to 
60±85% of their maximal response to KCl (60 mM) after a 45 min 
incubation period with one of the following statins, as shown in Table 5.1: 
simvastatin (5 PM and 10 PM), lovastatin (10 PM), pravastatin (10 PM) and 
simvastatin Na+ (5 PM). Control tissues received vehicle only (0.09% (v/v) 
DMSO for 10 PM simvastatin/lovastatin and 0.05% (v/v) DMSO for 5 PM 
simvastatin/lovastatin; the water-soluble pravastatin and Na+ salt of 
simvastatin did not require vehicle control).  
 
The concentration of U46619 required to pre-contract arteries to 60±85% 
was 10 nM ± 20 nM with the exception of arteries treated with simvastatin 
(5 PM) and lovastatin, which required 20 nM ± 50 nM, and simvastatin (10 
PM) which required in excess of 100 nM. In the latter case, subsequent 
attempts to induce relaxations with salbutamol were unsuccessful. 
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Statin 
Concentration 
used Reference 
Simvastatin 5 PM, 10 PM Nagaoka et al. (2007) 
Lovastatin 10 PM Fatehi-Hassanabad et al. (2006) 
Pravastatin 10 PM Sonmez Uydes-Dogan et al. (2005) 
Simvastatin Na+ 5 PM Seto et al. (2007) 
Table 5.1. Concentrations of statins used in the current experiments. 
Arteries were incubated with a statin for 45 min prior to contraction with 
U46619 and relaxation with salbutamol, forskolin, pinacidil or NS1619. 
 
5.2.2.2. The effect of statins on cAMP-mediated relaxation  
 
In related experiments, arteries incubated for 45 min with simvastatin (5 
PM) and contracted with U46619 were relaxed using cumulative 
concentrations of the adenylyl cyclase (AC) activator forskolin (1 nM ± 3 
PM), the ATP-sensitive K+ (KATP) channel opener pinacidil (1 nM ± 30 
PM(Gojkovic-Bukarica et al., 1999) or the large-conductance, Ca2+-
activated K+ (BKCa) channel opener NS1619 (10 nM ± 30 PM; (Edwards et 
al., 1994).  
 
5.2.2.3. The effect of mevalonate supplementation on statin-
induced inhibition of E-AR-mediated relaxation 
 
In order to determine the involvement of HMG-CoA reductase in the effect 
of statins on salbutamol-induced relaxations, PCA were incubated with 
simvastatin (5 PM), mevalonolactone (250 PM) or both agents in 
combination for 45 min. Control tissues received vehicle only (0.09% (v/v) 
ethanol for 250 PM mevalonolactone). U46619 was subsequently applied to 
pre-contract the vessels before relaxations were evoked using salbutamol. 
 
156 
 
5.2.2.4. The effect of Rho kinase inhibition on E-AR-mediated 
relaxation  
 
In a separate set of experiments, arteries were incubated for 45 mins in 
Krebs-Henseleit (KH) solution containing the Rho kinase inhibitor Y27632 
(5 PM) before being contracted with U46619. In vitro experiments 
investigating the effect of Y27632 typically use a concentration of 10 PM 
(Maekawa et al., 1999). However, in the current experiment Y27632 
caused a powerful impairment of the U46619-evoked pre-contraction at 
that concentration, preventing the establishment of a stable contractile 
tone. The impairment was much less significant at 5 PM, and the 
concentration of U46619 required to pre-contract Y27632-incubated 
arteries was 50 nM ± 100 nM, compared to 10 nM ± 20 nM in control 
arteries. Finally, cumulative concentrations of salbutamol were applied to 
pre-contracted arteries in order to induce relaxation. 
 
5.2.3. Statistical analyses 
 
Data were analysed using GraphPad Prism 5.0 (Graphpad Software Inc., La 
Jolla, CA, USA). Relaxation response measurements are expressed as 
means r SEM. Unless otherwise stated, statistical comparisons between 
groups were made using two-way ANOVA followed by a Bonferroni post-
test. As there were insufficient repeat experiments to determine 
distribution, the data were assumed to be normally distributed and 
parametric tests were employed. A P value < 0.05 was considered 
statistically significant. ,Q DOO H[SHULPHQWV ³Q´ QXPEHUV UHSUHVHQW WKH
number of animals from which tissues were obtained. 
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5.2.4. Materials 
 
(2S)-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-
[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-
naphthalenyl-2-methyl butanoate (lovastatin), ǃ5į56666D5-
1,2,6,7,8,8a-hexahydro-ǃį-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-
oxobutoxy]-1-naphthaleneheptanoic acid monosodium salt (pravastatin 
sodium salt) and (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-
dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-
1-naphthalenyly-2,2-dimethyl butanoate (simvastatin) were acquired from 
Tocris Bioscience (Bristol, UK). Simvastatin sodium salt was acquired from 
Calbiochem (Nottingham, Nottinghamshire, UK). (±)-ǃ-Hydroxy-ǃ-methyl-
į-valerolactone (mevalonolactone), 1,3-Dihydro-1-[2-hydroxy-5-
(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS 
1619) and (±)-N-cyano-N-4-pyridinyl-1ļ-(1,2,2-trimethylpropyl)guanidine 
monohydrate (pinacidil) were acquired from Sigma (Poole, Dorset, UK).  
The remaining chemicals were purchased as stated in Section 2.2.4. 
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5.3. RESULTS 
 
5.3.1. The effect of statins on E-AR-mediated vasodilatation 
 
Salbutamol-induced relaxations of porcine coronary artery ring segments 
pre-contracted with U46619 were significantly inhibited by simvastatin and 
lovastatin (Figures 5.1 and 5.2, respectively). Simvastatin (5 PM) reduced 
the response to 30 PM salbutamol from 90 r 13% in controls to 26 r 12% 
(P<0.001; n=4), whilst also significantly inhibiting salbutamol responses at 
10 PM, 3 PM (P<0.001) and 1 PM (P<0.05).  
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Figure 5.1. The effect of simvastatin on E-AR-mediated relaxations in PCA 
(n=4). 
Simvastatin (5 PM) inhibited relaxations induced by salbutamol. Control 
experiments were pre-treated with 0.05% (v/v) DMSO. * indicates P<0.05 
and *** indicates P<0.001. 
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Figure 5.2. The effect of lovastatin on E-AR-mediated relaxations in PCA 
(n=7±9). Relaxations to salbutamol were blunted in the presence of 
lovastatin (10 PM). Control experiments were performed with 0.05% (v/v) 
DMSO. *** indicates P<0.001. 
 
Salbutamol was unable to relax pre-contracted arteries following 
incubation with simvastatin (10 PM). Lovastatin inhibited relaxation 
responses to salbutamol at 30 PM (94 r 3% in controls to 56 r 12% in 
lovastatin-incubated arteries; P<0.001; n=7±9) and 10 PM (P>0.001). 
Figures 5.3 and 5.4 show that neither pravastatin (P>0.05; n=4) nor 
simvastatin Na+ (P>0.05; n=5 or 6) altered relaxation responses to 
salbutamol.  
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Figure 5.3. The effect of the hydrophilic statin pravastatin on E-AR-
mediated relaxations in PCA (n=4). Salbutamol-induced relaxations were 
unaltered in the presence of pravastatin.  
 
Figure 5.4. The effect of the Na+ salt of simvastatin on E-AR-mediated 
vasodilatation in PCA (n=5 or 6). The hydrophilic simvastatin Na+ (5 PM) 
did not affect relaxation responses to salbutamol. 
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5.3.2. The effect of statins on cAMP-mediated vasodilatation 
 
Simvastatin (5 PM) had no effect on the relaxation characteristics of 
forskolin in porcine coronary arteries pre-contracted with U46619 (n=4 or 
5, Figure 5.5). Maximum response values were 124 r 4% in controls and 
118 r 4% in simvastatin-incubated arteries (P>0.05), whilst pEC50 values 
were 7.4 r 0.1 and 7.3 r 0.1, respectively (P>0.05).  
 
Figure 5.5. The effect of simvastatin on the AC activator forskolin in PCA 
(n=4 or 5). Relaxation responses to forskolin were not altered by 
simvastatin (5 PM). Control experiments were conducted in (0.05% (v/v) 
DMSO).  
 
5.3.3. The effect of statins on K+ channel-mediated vasodilatation 
 
Cumulative concentrations of the BKCa channel opener NS1619 (10 nM ± 30 
PM) relaxed pre-contracted artery segments in a concentration-dependent 
manner (Figure 5.6). Simvastatin (5 PM) inhibited responses to NS1619 at 
1 PM, 3 PM, 10 PM (P<0.001; n=5 or 6) and 30 PM (P<0.05).  
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Figure 5.6. The effect of simvastatin on relaxations to the BKCa channel 
opener NS1619 in PCA (n=5 or 6). Simvastatin (5 PM) inhibited NS1619-
induced relaxations. Control recordings were made in 0.05% (v/v) DMSO. 
* indicates P<0.05 and *** indicates P<0.001. 
 
 
The KATP channel opener pinacidil (1 nM ± 30 PM) also evoked a 
concentration-dependent relaxation of pre-contracted coronary artery ring 
segments (Figure 5.7) and was inhibited by 5 PM simvastatin (responses to 
pinacidil at 1 PM, 3 PM, 10 PM and 30 PM were significantly inhibited; 
P<0.001; n=3 or 4). 
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Figure 5.7. The effect of simvastatin on relaxations to the KATP channel 
opener NS1619 in PCA (n=3 or 4). Pinacidil produced concentration-
dependent relaxations that were inhibited by simvastatin (5 PM). Control 
recordings were made in 0.05% (v/v) DMSO. * indicates P<0.05 and *** 
indicates P<0.001. 
 
5.3.4. The effect of mevalonate supplementation on the inhibitory 
effect of statins 
 
Simvastatin (5 PM) inhibited salbutamol-induced relaxations at 1 PM 
(P<0.05), 3 PM, 10 PM and 30 PM (P<0.001; n=4±6; Figure 5.8). 
Mevalonolactone (250 PM) alone did not alter the relaxation characteristics 
of PCA to salbutamol. In addition, relaxations carried out in the presence of 
both mevalonolactone and simvastatin were inhibited at 3 PM, 10 PM and 
30 PM salbutamol (P<0.001) but did not differ from those carried out in 
the presence of simvastatin alone.  
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Figure 5.8. The effect of simvastatin on E-AR-mediated relaxations in PCA 
rings supplemented with mevalonolactone (n=4±6). Recordings were made 
in the absence or presence of simvastatin (0.05% (v/v) DMSO or 5 PM, 
respectively), mevalonolactone (0.09% (v/v) ethanol or 250 PM, 
respectively) or both agents in combination. Simvastatin inhibited 
relaxations to salbutamol, even in the presence of mevalonolactone, while 
mevalonolactone alone was without effect. * indicates P<0.05 and *** 
indicates P<0.001 for simvastatin versus control; and LLL indicates P<0.001 
for simvastatin + mevalonate versus control. 
 
5.3.5. The effect of Rho kinase inhibition on E-AR-mediated 
vasodilatation 
 
Figure 5.9 shows the effect of the Rho kinase inhibitor Y27632 (5 PM) on 
salbutamol-induced relaxations. Y27632 inhibited relaxations to 10 PM 
salbutamol (from 80 r 6% in controls to 62 r 6%; P<0.05) and 30 PM 
salbutamol (from 85 r 6% in controls to 68 r 7%; P<0.05).  
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Figure 5.9. The effect of the Rho kinase inhibitor Y27632 on E-AR-
mediated relaxations in PCA (n=8±10). Relaxations were inhibited in the 
presence of presence of Y27632 (5 PM). * indicates P<0.05. 
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5.4. DISCUSSION 
 
The isoprenoid FPP is required for the farnesylation of Ras, allowing its 
association to the cell membrane where it is activated. Activated Ras can 
switch on the signalling cascade involving Raf and MEK and ultimately 
activating ERK. By inhibiting HMG-CoA reductase, statins prevent the 
formation of intermediates of the mevalonate pathway, such as FPP. 
Therefore, statins would be expected to inhibit ERK activation. Indeed, 
simvastatin has been reported to inhibit ERK activation in isolated vascular 
smooth muscle cells (Tristano et al., 2007).  
 
As described in Chapter 2, inhibition of ERK activation in PCA using specific 
inhibitors of MEK results in an enhancement of E-AR-mediated 
vasodilatation. Data presented in the current chapter, however, 
demonstrate that statins produced the opposite effect. Incubation with 
simvastatin (5 PM) and lovastatin (10 PM) significantly inhibited relaxation 
responses to the E2-AR agonist salbutamol. Moreover, when a higher 
concentration of simvastatin (10 PM) was used, salbutamol was unable to 
relax pre-contracted arteries.  
 
The inhibition of relaxations was not a universally observed phenomenon 
amongst the statins used. Pravastatin, unlike simvastatin and lovastatin, 
did not alter the relaxation characteristics of salbutamol. Likewise, the 
sodium salt of simvastatin was also without effect. Similar findings have 
been reported in rat basilar artery, in which simvastatin and lovastatin, but 
not pravastatin, have been shown to induce relaxation (Bergdahl et al., 
2003).  
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It is likely that the selectivity of inhibition is related to the lipophilicity of 
the statin. Simvastatin and lovastatin are described as lipophilic (or 
hydrophobic), in contrast to pravastatin and simvastatin Na+, which are 
hydrophilic. In fact, based on octanol-water partition coefficients it was 
estimated that lovastatin and simvastatin may be approximately 75- and 
200-fold, respectively, more lipophilic than pravastatin (Serajuddin et al., 
1991). Furthermore, according to XLogP3 values (Cheng et al., 2007), 
shown in Table 5.2, the differences are even greater, at approximately 
500- and 1250-fold, respectively. These differences, coupled with the fact 
that lipophilicity is an important characteristic in the ability of a molecule to 
penetrate the lipid-rich cell membrane, explain the disparity between the 
observed effects of the statins used in this experiment.  
 
Statin XLogP3 Relative lipophilicity 
Pravastatin 1.6 1 
Lovastatin 4.3 501 
Simvastatin 4.7 1259 
Table 5.2. XLogP3 values of pravastatin, lovastatin and simvastatin. 
Relative lipophilicities are compared to the lowest value (pravastatin). Data 
acquired from U.S. National Library of Medicine, 2011. 
 
Furthermore, based on the lack of effect of pravastatin, it would be 
reasonable to assume that PCA smooth muscle cells do not express 
membrane proteins capable of transporting hydrophilic statins. Such 
transport mechanisms have been detected in hepatocytes and are 
proposed to be responsible for the uptake of hydrophilic statins into this 
cell type, allowing the statins to mediate their cholesterol-lowering effects 
(Yamazaki et al., 1993).  
 
It is not known whether the effects of statins observed in the current 
experiment are caused by the lactone prodrug forms in which they were 
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administered or their corresponding E-hydroxy acids. The latter are formed 
by chemical or enzymatic hydrolysis of the lactones, and have been shown 
to be more potent inhibitors of HMG-CoA reductase (Vickers et al., 1990). 
Candidates for the conversion of statins are the paraoxonase (PON) 
enzymes (Draganov et al., 2005). PONs 1 and 3 have been implicated in 
the hydrolysis of statin lactones in human serum (Billecke et al., 2000; 
Suchocka et al., 2006). PON-2, a predominantly intracellular protein 
expressed in a wide range of cell types including smooth muscle (Ng et al., 
2001), may hydrolyse statin lactones inside cells, though this has not yet 
been investigated.  
 
Experimental assessments of statins typically evaluate reversibility by 
supplementation with intermediates of the mevalonate pathway. For 
example, mevalonate prevented the reduction in pulmonary artery 
pressure caused by simvastatin in a rat model of chronic pulmonary 
hypertension (Girgis et al., 2007). In human macrophages, 
lipopolysaccharide-induced stimulation of phospholipase A2 (PLA2) 
expression was inhibited by simvastatin, an effect blocked by treatment 
with mevalonate or GGPP (Song et al., 2011). In this experiment, 
mevalonolactone, which is hydrolysed to mevalonate in aqueous solution, 
had no effect on relaxation responses to salbutamol. Importantly, 
treatment with the combination of mevalonolactone and simvastatin failed 
to reverse the inhibitory effect of simvastatin on salbutamol-induced 
relaxations, suggesting that this effect of statins is independent of HMG-
CoA inhibition.  
 
An alternative explanation for the lack of effect of mevalonolactone is that 
the treatment conditions ± specifically the concentration of 
mevalonolactone and duration of incubation ± were insufficient to deliver a 
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pharmacologically significant amount of mevalonate to target cells. Arteries 
were exposed for 45 mins to 250 PM mevalonolactone, a concentration 
that has previously been shown to be sufficient to rescue isoprenoid 
function in the presence of statins (Cole et al., 2005). Indeed, 250 PM 
mevalonolactone abolished the cytoprotective effects of lovastatin on rat 
cortical glial cells (Paintlia et al., 2008). These findings suggest that the 
mechanism of action of statins in the current experiment is independent of 
HMG-CoA reductase inhibition.  
 
The AC/F\FOLF¶¶-adenosine monophosphate/protein kinase A (cAMP/PKA) 
signal transduction pathway has been closely associated with E-AR 
signalling. In this experiment, direct activation of AC using forskolin 
mimicked the response to the E-AR agonist salbutamol, namely relaxation. 
However, while simvastatin inhibited relaxations to salbutamol, it failed to 
affect forskolin-induced relaxations. This finding suggests that simvastatin 
does not affect signalling via the AC/cAMP/PKA pathway but may instead 
inhibit a separate pathway employed by the E-AR during relaxation. One 
such mechanism may involve K+ channels, which have been shown to 
mediate E-AR-induced relaxations via a cAMP-independent mechanism 
(White et al., 2001).  
 
In this experiment, relaxations caused by the application of openers of KATP 
and BKCa channels were inhibited by simvastatin. Consistent with this is the 
finding in smooth muscle cells of the PCA that simvastatin inhibited BKCa 
channel currents (Seto et al., 2007). Interestingly, in the same study 
neither pravastatin nor simvastatin Na+ had any observable effect, a 
finding consistent with those discussed earlier in this section. These data 
support the idea that simvastatin inhibits EAR-mediated relaxations 
through inhibition of K+ channel activity.  The mechanism of K+ channel 
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inhibition may involve disruption of signalling between the activated E-AR 
and downstream K+ channels; alternatively, the effect may be a result of 
direct channel blockade by the statin. The latter hypothesis could be tested 
using specific configurations of the patch-clamp technique. A lack of effect 
of statins on K+ channel activity under inside-out or outside-out 
configurations would suggest that statins may inhibit K+ channels by 
targeting elements of the intracellular signalling machinery. Conversely, 
direct blockade of K+ channels by statins would be detectable under these 
configurations.  
 
By impairing the activity of HMG-CoA reductase, statins prevent the 
formation of the isoprenoid GGPP and subsequent activation of the GTP-
binding protein Rho. Previous studies have linked the effects of statins to 
the inhibition of Rho. For instance, the Rho inhibitor C3 exoenzyme 
mimicked the inhibitory effect of simvastatin on LPS-induced elevation of 
PLA2 expression in human macrophages (Song et al., 2011). Similarly, 
simvastatin was shown to impair the self-renewal of mouse embryonic 
stem cells via inhibitory effects on Rho (Lee et al., 2007). In the current 
investigation, the Rho kinase inhibitor Y27632 inhibited relaxation 
responses to salbutamol, reflecting findings made with simvastatin. 
Therefore, it is possible that the inhibitory effect of statins on E-AR-
mediated vasodilatation may involve inhibition of Rho. However, it is worth 
noting that inhibition of Rho by statins would unlikely be related to any 
potential upstream effects on HMG-CoA reductase as mevalonate 
supplementation did not reverse the effect of statins.  
 
A further possible mechanism by which statins inhibit relaxation responses 
to salbutamol may involve indirect effects on the U46619-evoked pre-
contraction. Arteries pre-incubated with lovastatin or simvastatin (5 PM) 
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required approximately 20 nM ± 50 nM of U46619, whilst those incubated 
with simvastatin (10 PM) required > 100 nM of U46619. In contrast, 
vehicle controls were pre-contracted using only 10 nM ± 20 nM. This 
difference suggests that the statins inhibited contractions to U46619 
meaning that higher concentrations of U46619 were required to achieve a 
given level of pre-contractile tone.  
 
A previous investigation showed that lovastatin inhibited L-type Ca2+ 
currents in rat basilar artery smooth muscle cells and impaired associated 
contractile responses to serotonin and K+ (Bergdahl et al., 2003). 
Additionally, this property of statins may be associated with their ability to 
inhibit Rho, which itself is required for the activation of Rho kinase and 
subsequent signalling associated with smooth muscle contraction (Fukata 
et al., 2001). Although the level of tone induced by U46619 was the same 
in the presence and absence of statins, by inhibiting one mechanism of 
contraction, U46619 would need to recruit an alternative mechanism to 
induce contraction. Increased activation of this alternative signalling 
pathway may inhibit the E-AR-mediated relaxation. This would be 
consistent with the Rho kinase inhibitor data. In any case, it is possible 
that greater concentrations of salbutamol were needed to overcome the 
U46619-evoked contraction, representing inhibition of the salbutamol 
responses. However, this fails to explain why forskolin-induced relaxations 
were not inhibited by simvastatin in these experiments. Furthermore, data 
presented in Chapter 2 show that U46619-evoked contraction of PCA was 
inhibited by PD98059 but subsequent relaxation responses to salbutamol 
were not impaired.  
 
In these experiments, arteries were exposed to statins (or vehicle control) 
for 45 mins. Repeating the experiments with longer statin incubation 
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periods (for example, overnight incubation at 37qC under aseptic 
conditions) may yield findings more relevant to the clinical setting. 
Furthermore, the concentrations of statins used in this study (5 PM ± 10 
PM) considerably exceeded those measured in the clinical setting. It has 
been shown, for example, that in healthy adults a single 40 mg oral dose 
of simvastatin produces peak plasma lactone and acid concentrations of 
7.3 ng ml-1 (17 nM) and 2.6 ng ml-1 (6.0 nM), respectively (Lilja et al., 
2004). An equivalent dose of pravastatin appears to produce higher serum 
concentrations (45.3 ng ml-1 or 110 nM) of its active metabolite (Lilja et 
al., 1999), likely due to less extensive first-pass metabolism and plasma 
protein binding than simvastatin (Schachter, 2005).  
 
In conclusion, statins inhibit E-AR-mediated vasodilatation of PCA. This 
effect, specific to lipophilic statins, appears to be cAMP-independent and 
may be related to inhibitory effects on K+ channels. It is also possible that 
the phenomenon occurs indirectly as a consequence of impairment of pre-
contraction due to inhibition of Ca2+ channels and/or Rho-associated 
signalling. The inhibition of relaxation is inconsistent with the findings that 
(1) inhibitors of ERK activation enhance E-AR-mediated relaxations, as 
shown in Chapter 2, and (2) statins inhibit ERK activation (Tristano et al., 
2007). Future biochemical experiments assessing the effects of statins on 
ERK activation in intact PCA are warranted. Although the observed 
inhibition of contractions by statins are consistent with their 
cardioprotective characteristics, the inhibition of relaxation responses is 
unexpected in this context and would be an undesirable effect in patients 
with established cardiovascular disease.  
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CHAPTER 6: GENERAL DISCUSSION 
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Vascular E±adrenoceptors (E-ARs) mediate vasodilatation by recruiting a 
range of effector systems capable of relaxing vascular smooth muscle 
(VSM) cells. The precise mechanisms involved are often complex and vary 
between species and vessels. The main preparation studied in this 
investigation was the left, anterior descending porcine coronary artery 
(PCA). The non-selective E-AR agonist isoprenaline concentration-
dependently relaxed U46619-pre-contracted PCA rings as measured using 
wire myography. The subtype-selective agonists xamoterol and salbutamol 
also produced concentration-dependent relaxation responses, indicating 
the functional expression of E1-AR and E2-ARs, respectively, in this tissue, 
consistent with the literature (Brehm et al., 1999; Schwartz et al., 1983).   
 
Triggered by GDs-dependent activation of adenylyl cyclase (AC), the cyclic 
¶¶-adenosine monophosphate-protein kinase A (cAMP-PKA) signalling 
pathway is the most commonly reported route of E-AR-mediated relaxation 
of VSM. Consistent with this was the observation that the AC activator 
forskolin elicited relaxations of PCA. However, attempts to disrupt this 
pathway using pharmacological inhibitors of AC and protein kinase A (PKA) 
did not reduce E-AR-mediated relaxation. The recruitment of alternative 
signalling pathways is proposed as an explanation for this finding. The 
gaseous free radical NO is derived from the endothelium and exerts a 
paracrine effect on adjacent VSM by engaging the soluble guanylyl cyclase-
F\FOLF¶ ¶-guanosine monophosphate-protein kinase G (sGC-cGMP-PKG) 
pathway. Studies of its potential role in E-AR-mediated vasodilatation have 
produced conflicting findings. In the current investigation, inhibition of 
endothelial nitric oxide synthase (eNOS) was associated with a modest 
reduction of relaxations to low concentrations of isoprenaline, suggesting 
an involvement, albeit minor, of nitric oxide (NO) in this process. 
Interestingly, eNOS inhibition was also accompanied by an enhancement of 
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relaxations at higher concentrations of isoprenaline, which may have been 
related to disinhibition of a more potent effector system, as proposed by 
Liang et al. (2010). Various K+ channels have been reported to induce 
hyperpolarisation of VSM as a mechanism of E-AR-mediated vasodilatation. 
However, selective blockers of ATP-sensitive K+ channels (KATP), large-
conductance Ca2+-activated K+ channels (BKCa) and intermediate-
conductance Ca2+-activated K+ channels (IKCa) channels failed to alter E-
AR-mediated vasodilatation. Again, these negative results may have been 
associated with increased signalling via other pathways to compensate for 
K+ channel blockade. Attempts to study the effect of E-AR activation on K+ 
channels in smooth muscle cells using the patch-clamp technique were 
unsuccessful, due to difficulties in isolating healthy cells.   
 
E-ARs have been reported to signal via extracellular signal-regulated 
kinase (ERK), albeit in cultured cells (Baker et al., 2003; Friedman et al., 
2002), and ERK has been shown to contribute to contraction of VSM 
(Roberts, 2001; Xiao et al., 2004). However, the functional effects of E-AR-
mediated activation of ERK in blood vessels has not been studied. 
Therefore, the primary aim of this investigation was to reconcile the 
implication that E-AR activation, which causes VSM relaxation, may 
increase the activation of ERK, which promotes VSM contraction. It was 
subsequently shown that inhibition of ERK activation using specific MEK 
inhibitors significantly enhanced vasodilatation induced by isoprenaline, 
suggesting an inhibitory effect of ERK on this response. The use of 
subtype-selective E-AR agonists demonstrated that the phenomenon was 
specific to the E2-AR subtype. This finding may represent a physiological, 
negative-feedback regulatory mechanism of E2-AR-mediated vasodilatation 
and further adds to the complexity of this process.  
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In experiments designed to determine the mechanism by which ERK 
disrupts E-AR-mediated vasodilatation, the various elements of E-AR 
signalling were isolated prior to assessing the effects of MEK inhibition on 
the relaxation response. It was proposed that ERK may interact with a 
cAMP-independent pathway because forskolin-induced relaxations were 
unaffected by MEK inhibition. Inactivation of K+ channels, by using either 
the non-selective blocker tetraethylammonium (TEA) or high extracellular 
K+ concentrations, prevented the enhancement of E2-AR-mediated 
vasodilatation. E-ARs have been shown to activate K+ channels via cAMP-
dependent (White et al., 2000) and ±independent (Randall et al., 1995) 
routes. However, the finding in the current study that ERK interacts with 
K+ channels but not a cAMP-dependent pathway suggests that the K+ 
channel species involved in the enhancement phenomenon is/are activated 
via cAMP-independent routes. The nature of this activation may involve 
direct stimulation of the K+ channel by GDs, as has previously been 
demonstrated in PCA smooth muscle cells (Scornik et al., 1993). E2-AR-
mediated activation of ERK in HEK293 cells also required GDs but involved 
the AC-cAMP-PKA pathway (Friedman et al., 2002; Schmitt et al., 2000). 
Therefore, GDs may represent a commonality in E2-AR-mediated activation 
of K+ channels and ERK in PCA, with the latter but not the former also 
requiring the AC-cAMP-PKA pathway.  
 
Using an array of selective K+ channel blockers, it was found that the IKCa 
channel, but not the KATP or BKCa channel, was implicated in the MEK 
inhibitor-induced augmentation of E-AR-mediated vasodilatation. The 
expression of IKCa channels on endothelial cells has frequently been 
reported, underscoring its central role in the endothelium-derived 
hyperpolarising factor (EDHF) phenomenon. In VSM cells, however, IKCa 
channels may be relevant in proliferative phenotypes rather than 
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contractile phenotypes (McNeish et al., 2006; Tharp et al., 2009). This 
raises doubts over the possibility that the interaction between ERK and IKCa 
channels in PCA occurs at the level of the smooth muscle. Moreover, a 
previous study demonstrated that MEK inhibitors enhanced bradykinin-
induced, EDHF-mediated vasodilatation of PCA (Brandes et al., 2002). The 
authors proposed that enhancement occurred via reversal of the inhibitory 
influence of ERK on gap junction communication, caused by 
phosphorylation of connexin 43. The activation of IKCa and SKCa channels 
appears to be a pre-requisite for EDHF-mediated relaxation, though IKCa 
channels alone may be sufficient in some arteries (McNeish et al., 2006). 
In any case, IKCa/SKCa activation precedes the conduction of 
hyperpolarisation from the endothelium to the smooth muscle layer, which 
may involve myo-endothelial gap junctions (Busse et al., 2002). Therefore, 
it is possible that the enhancement caused by MEK inhibitors in the current 
study was related to the effects of ERK on gap junction communication 
rather than on IKCa channels per se; indeed, TRAM-34 would still have 
been expected to reverse the enhancement in this scenario. Nonetheless, 
the IKCa channel may still represent a phosphorylation target for ERK. 
Previous studies have shown that ERK is able to regulate various K+ 
channels (Li et al., 2006; Ross et al., 2003), including the IKCa channel 
(Lhuillier et al., 2000). Future experimentation using 32P labelling and 
immunoprecipitation would allow examination of the effect of MEK 
inhibition on IKCa channel phosphorylation status.  
 
As proposed earlier, ERK may act as part of a physiological, negative-
feedback mechanism limiting the degree of E-AR-mediated vasodilatation. 
However, increases in ERK activation, which have been reported in various 
cardiovascular diseases, may result in dysregulation and impairment of this 
process. Markedly reduced E-AR-mediated vasodilatation was observed in 
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arteries of Zucker Diabetic Fatty (ZDF) rats and Zucker obese rats, models 
of Type II diabetes and obesity, respectively. U46619-stimulated ERK 
activation was significantly increased in superior mesenteric artery (SMA) 
of ZDF rats, suggesting that the impairment of relaxations was related to 
greater ERK activity in these animals. Furthermore, MEK inhibition partially 
reversed the impairment of relaxations in SMA. Similar deficits in 
relaxations to E-AR agonists and other vasodilators in ZDF rats and Zucker 
rats have frequently been reported and often involve endothelial 
dysfunction. However, endothelial function is preserved in these rats at the 
age used in the current study (12 weeks) (Oltman et al., 2006), suggesting 
that the impairment of E-AR-mediated relaxations by ERK in this artery 
may occur at the level of the smooth muscle. Additional experiments would 
be required to confirm this suggestion and to examine the effect of 
increased ERK activation on K+ channel function. Moreover, further 
investigations would also aim to determine whether ERK nonetheless 
contributes to the development and progression of endothelial dysfunction 
in Zucker rats.  
 
Several studies have reported impairments of E-AR-mediated 
vasodilatation in various rat models of hypertension (Arvola et al., 1993; 
Fujimoto et al., 1988; Soltis et al., 1991). Furthermore, similar findings 
have been noted in human hypertension (Naslund et al., 1990; van 
Brummelen et al., 1981). Increased vascular ERK activation has also been 
reported in rat models of hypertension, and appears to occur without 
parallel increases in non-cardiovascular tissues (Kim et al., 2000a; Kim et 
al., 1997; Kim et al., 2000b). However, the relationship between ERK 
activation and E-AR-mediated vasodilatation in hypertensive states has not 
been studied. Nonetheless, given the finding in the current investigation 
that inhibition of ERK activation somewhat restored E-AR function in rat 
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models of diabetes and obesity, which are also characterised by increased 
ERK activation, it is possible that similar observations would be made in 
corresponding studies of hypertension. Interestingly, isoprenaline-
stimulated activation of ERK was shown to be significantly attenuated in 
aortic smooth muscle of spontaneously hypertensive rats (SHR) in 
comparison with normotensive controls (Gros et al., 2006). In contrast, 
forskolin-stimulated ERK activation did not differ between the two groups, 
whilst the vasoconstrictor hormones vasopressin and angiotensin II, which 
signal via GDq, activated ERK to a greater degree in SHR. The authors 
propose that uncoupling of E-AR-GDs interactions occurs in the 
hypertensive state, whilst G-protein-coupled receptor (GPCR)-GDq coupling 
may be increased. Collectively, the consequences of these changes would 
be detrimental to vascular function for several reasons. The uncoupling of 
E-AR-GDs would impair, firstly, the recruitment of effector systems required 
to elicit vasodilatation and, secondly, the long-term modulation of vascular 
growth, as E-AR activation is known to inhibit proliferation of VSM cells 
(Nakaki et al., 1990). Furthermore, increased GPCR-GDq coupling would 
have equivalent functional consequences, given the role of these receptors 
in VSM contraction and proliferation. In the current investigation, ERK 
phosphorylation in PCA was increased by E-AR and thromboxane-
prostanoid (TP) receptor stimulation. It is not known whether E-AR-
stimulated ERK activation was reduced in ZDF rats versus lean controls; 
however, TP receptor-stimulated, GDq-dependent ERK activation was 
increased, consistent with findings presented by Gros et al. (2006). It is 
possible that this profile of altered ERK and E-AR function in blood vessels 
may be a common feature of cardiovascular disease and may contribute to 
the alterations in vascular reactivity and growth.  
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In summary, a novel role for ERK in the regulation of vascular tone is 
proposed. Specifically, as part of a physiological control mechanism, ERK 
inhibits E-AR-mediated vasodilatation by reducing IKCa channel activity. 
This proposal represents an additional means by which ERK participates in 
the short-term regulation of vascular reactivity; its role in mediating 
vasoconstriction is well described. Furthermore, the long-term regulation of 
vascular function by ERK, also well described, involves VSM cell 
proliferation. Increased ERK activation in these contexts would be injurious 
to cardiovascular health via three distinct routes. First, impaired 
vasodilatation would render the vasculature unable to adequately respond 
to the circulatory demands of organs and tissues. Second, augmented 
contractility would increase vascular resistance and, therefore, mean 
arterial pressure. Indeed, this in turn may further increase ERK levels, as 
has been demonstrated in rat models of hypertension (Kim et al., 1997). 
Finally, vascular growth associated with endothelial/VSM cell migration and 
proliferation would reduce lumen diameter, increase vessel stiffness and 
promote endothelial dysfunction. Thus, targeting ERK in cardiovascular 
disease represents a promising treatment strategy.  
 
A possible role for statins in this context was explored in this study as 
statins have been shown to inhibit ERK activation (Tristano et al., 2007). 
However, the potent inhibitory effect of statins on E-AR-mediated 
relaxations was likely related to the concentrations used (low micromolar 
range), which are significantly higher than those achieved in the clinical 
setting (low-to-mid nanomolar range). Nonetheless, the rationale for 
targeting ERK in this way is supported by studies attributing the 
cardiovascular benefits of statins to inhibition of ERK activation (Huang et 
al., 2010; Takayama et al., 2011).  
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1. Methods 
 
1.1. The effect of MEK inhibition on E-AR desensitisation 
 
To determine whether ERK alters E-AR-mediated relaxations via effects on 
receptor desensitisation, arteries were exposed to isoprenaline (1 PM) for 
60 mins and washed out (every 5 mins for 45 mins) prior to contraction 
with U46619 and relaxation with salbutamol. In similar experiments, 
arteries were exposed to isoprenaline (1 PM) for 10, 20 or 30 mins prior to 
washout, contraction using U46619 and relaxation with isoprenaline. 
 
 
1.2. The role of the endothelium in E-AR-mediated relaxation 
 
In experiments assessing the role of endothelial cells in isoprenaline-
induced vasorelaxation, the endothelium was removed from PCA ring 
segments before they were fitted to a Mulvany wire myograph. A 
preliminary experiment was carried out in order to determine the minimum 
amount of tissue manipulation required to abolish endothelium-dependent 
UHOD[DWLRQ(QGRWKHOLXPUHPRYDOZDVDFKLHYHGE\YHU\JHQWO\³UROOLQJ´WKH
neck of a pair of forceps inside the lumen of artery rings. To prevent the 
tissue segments from drying, this procedure was carried out on a paper 
towel thoroughly moistened with KH solution.  The lumina of three 
DGMDFHQW ULQJ VHJPHQWV IURP WKH VDPH DUWHU\ ZHUH ³UROOHG´ WR YDU\LQJ
degrees (10, 20 or 30 times). The endothelium of a fourth, control 
segment was left intact.  
 
The arteries were gently washed in KH solution before being fitted to a 
Mulvany wire myograph as described earlier. Pre-contraction using U46619 
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preceded the application of the endothelium-dependent vasorelaxant 
substance P (100 nM). It was observed that 20 revolutions of the forcep 
neck were sufficient to prevent relaxations to substance P, and this 
protocol was used in subsequent investigations. At the end of the 
experiment, isoprenaline (1PM) was applied to the arteries without 
washout of substance P.  
 
In a separate experiment, the combined effects of endothelium denudation 
and MEK inhibition on E-AR-mediated relaxation were investigated. Prior to 
the experiment, four ring segments from the same PCA were dissected. 
Where appropriate, endothelia were removed as described above. The 
rings were subsequently relaxed with cumulative concentrations of 
isoprenaline (1 nM ± 3 PM) following pre-contraction with U46619 in either 
the absence (0.05% (v/v) DMSO) or presence of PD98059 (50 PM; 45 min 
incubation). Thus, the four experimental conditions were as follows: 1. 
endothelium intact + DMSO; 2. endothelium intact + PD98059; 
endothelium denuded + DMSO; endothelium denuded + PD98059.  
 
1.3. The effect of p38 MAPK inhibition on E-AR-mediated 
vasodilatation 
 
In these experiments, the effects of p38 on E-AR-mediated vasodilatation 
were assessed. Arteries were incubated for 45 min in KH solution 
containing either the p38 inhibitor SB 203580 (10 PM) (Saklatvala et al., 
1996)  or 0.1% (v/v) DMSO (control). After incubation, U46619 was used 
to pre-contract arteries, which were subsequently relaxed with 
isoprenaline. 
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2. Results 
 
2.1. The effect of MEK inhibition on E-AR desensitisation 
 
Salbutamol-induced relaxations were unchanged following 60 min pre-
exposure to isoprenaline (1 PM; Figure A1). Likewise, relaxations to 
cumulative concentrations of isoprenaline were unaffected by pre-exposure 
to isoprenaline (10 ± 30 mins; Figure A2). Taken together, these data 
suggest desensitisation of the E-AR does not occur under the current 
experimental conditions.  
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Figure A1. The effect of pre-incubation with a E-AR agonist on E-AR-mediated 
vasodilatation (n=2). Relaxations to salbutamol observed following 60 min pre-
exposure to isoprenaline (1 PM) and washout were similar to relaxations observed 
under control conditions (no isoprenaline).  
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Figure A2. The effect of pre-incubation with isoprenaline on E-AR-mediated 
relaxations in PCA (n=2). Pre-incubation with 1 PM isoprenaline (10±30 min) did 
not alter subsequent relaxations to isoprenaline. 
 
 
2.2. The role of the endothelium in E-AR-mediated relaxation 
 
The aim of a preliminary experiment was to determine the minimum 
degree of luminal disruption required to abolish endothelial-dependent 
relaxations. The endothelium-dependent vasodilator actions of substance P 
have previously been described (Kuroiwa et al., 1995).  In the current 
study substance P (100 nM) elicited transient relaxation (10 min) of pre-
contracted PCA ring segments in an endothelium-dependent manner 
(Figure A3). The control artery ring (intact endothelium) relaxed to 40% of 
the level of pre-FRQWUDFWLRQHYRNHGE\87KHDUWHU\ULQJ³UROOHG´
times was relaxed by substance P to a similar degree, 38%. However, 
greater disruption of endothelial function abolished responses to substance 
P. Isoprenaline (1 PM) relaxed all arteries to approximately the same 
extent (124% - 147%).  
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Figure A3. The effect of endothelium disruption on relaxations to 100 nM 
substance P and 1 PM isoprenaline (n=1). Endothelia were agitated by gently 
³UROOLQJ´WKHQHFNof a pair of forceps inside the artery lumen for varying lengths of 
WLPH 7KH HQGRWKHOLXP RI WKH FRQWURO VHJPHQW µ¶ ZDV OHIW LQWDFW Isoprenaline 
produced a similar degree of relaxation in each ring, whereas substance P either 
produced incomplete relaxations or failed to induce relaxations. Further repeat 
experiments are required. 
 
In an experiment investigating the combined effect of PD98059 and 
endothelium denudation (Figure A4), isoprenaline relaxed control arteries 
by 146%, with a pEC50 value of 7.5. In endothelium-denuded arteries, the 
corresponding values were similar: 138% and 7.5, respectively. PD98059 
reduced the maximal response to isoprenaline in endothelium-intact 
arteries to 111% but increased the potency (pEC50 = 8.0). Similarly, in 
endothelium-denuded arteries exposed to PD98059, the maximal response 
was 107% whilst the pEC50 value was 7.8. 
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Figure A4. The effect of MEK inhibition on E-AR-mediated vasodilatation in 
endothelium-denuded PCA rings (n=1). Prior to incubation with 50 PM PD98059 
(controls received 0.05 % (v/v) DMSO), the endothelia of arteries were either 
denuded or left intact. Isoprenaline produced concentration-dependent relaxations. 
Further repeat experiments are warranted. 
 
2.3. The effect of p38 inhibition on E-AR-mediated vasodilatation 
 
Isoprenaline-induced vasodilatation of PCA ring segments was altered by 
p38 inhibition (Figure A5). pEC50 values were raised from 7.6 r 0.1 in 
controls to 8.1 r 0.1 in SB 203580-treated arteries (P<0.01). On the other 
hand, RMAX values were reduced, though the changes were not statistically 
significant (138 r 10% in controls versus 118 r 3% in SB 203580-treated 
arteries, P>0.05).  
 
 
 
 
 
216 
 
-10 -9 -8 -7 -6 -5
0
25
50
75
100
125
150 Control
SB 203580 (10 PM)
[Isoprenaline] (log M)
R
e
la
x
a
ti
o
n
(%
U
4
6
6
1
9
-
e
v
o
k
e
d
 c
o
n
tr
a
c
ti
o
n
)
 
Figure A5. Log concentration±response curves to isoprenaline in PCA. Relaxations, 
shown as means r SEM (n=5), are expressed as a percentage of the U46619-
evoked contraction. Recordings were made in either the absence (0.1% (v/v) 
DMSO) or presence of SB 203580 (10 PM). 
 
 
3. Discussion 
 
Desensitisation of E-ARs occurs in response to repeated or prolonged 
exposure to E-AR agonists, and causes a reduction in subsequent 
responses to E-AR agonists. In brief, phosphorylation of the E-AR by PKA or 
E-adrenoceptor kinase (E-ARK) promotes the binding of the receptor to E-
arrestin, which in turn sterically uncouples the receptor from the G-protein, 
allowing internalisation of the receptor. As discussed earlier, ERK appears 
to exert an inhibitory influence on E-AR-mediated relaxations, but the 
exact mechanism involved is unknown. It has been shown in HEK-293 cells 
that the E-AR is able to activate ERK via a E-ARK/E-arrestin-dependent 
pathway (Shenoy et al., 2006). Thus an interaction with the mechanics of 
desensitisation represents a means by which ERK may regulate E-AR-
mediated relaxations.  
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A comparable phenomenon was proposed by the authors of a previous 
study, in which it was shown that activation of protein kinase C (PKC) in 
bovine tracheal smooth muscle enhanced desensitisation of the E2-AR 
(Boterman et al., 2006). Inhibition of PKC in the same study enhanced 
isoprenaline-induced relaxations. Thus activation of ERK may promote 
receptor desensitisation such that when ERK is inhibited, there is less 
receptor desensitisation and hence a greater relaxation. It is possible that 
receptor desensitisation occurs over the duration of the construction of 
concentration-response curves to E-AR agonists (30-60 min). Therefore we 
investigated whether desensitisation could occur over this time period.  
 
Attempts to observe desensitisation of E-AR-mediated relaxations of PCA 
were unsuccessful despite pre-exposing arteries to 1 PM isoprenaline for up 
to 60 mins. It is possible that incubating higher concentrations of E-AR 
agonists for longer time periods than those used in this experiment may 
have resulted in receptor desensitisation. However, the data presented 
suggest that it is unlikely that the effects of inhibition of ERK activation are 
due to prevention of receptor desensitisation.  
 
A caveat is that resensitisation may have occurred during the washout 
period (arteries were rinsed with pre-gassed KH solution every 5 mins for 
45 mins), meaning that E-AR density and function could have been 
restored prior to the repeated agonist challenge. This represents an 
inherent difficulty in experiments investigating desensitisation. Excessive 
washout may reverse and therefore mask the effects of desensitisation, 
whilst insufficient washout would fail to remove residual agonist from the 
receptor population, which may confound subsequent recordings. It is also 
possible that E-AR agonists produce relaxations in PCA via mechanisms 
which possess significant reserve capacities. A large receptor reserve, for 
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instance, could explain why agonist-induced receptor internalisation would 
not necessarily lead to reduced functional responses on agonist re-
exposure. Likewise, signalling downstream of receptor activation may be 
amplified such that functional responses are identical despite fewer 
agonist-receptor interactions.  
 
A role for p38 in E-AR-mediated vasodilatation is suggested by the finding 
that SB 203580, a p38 inhibitor (Saklatvala et al., 1996), increased the 
potency of isoprenaline-induced relaxations. It is therefore possible that 
p38, like ERK, may somehow inhibit E-AR-mediated vasodilatation. 
However, the relevance of this finding should be considered in light of 
frequent reports of non-specific effects of SB 203580 (Clerk et al., 1998; 
Kalmes et al., 1999). 
 
The neuropeptide substance P has been described as an endothelial-
dependent vasorelaxant (Crossman et al., 1989; Kuroiwa et al., 1995). 
Consistent with this characterisation, substance P was unable to evoke 
relaxations in endothelium-denuded arteries in this experiment. In 
contrast, relaxation responses to isoprenaline did not appear to be altered 
by endothelium denudation, which is inconsistent with the finding that the 
NOS inhibitor L-NAME inhibited isoprenaline-induced relaxations. However, 
a greater number of experimental repeats are needed to fully ascertain the 
role of the endothelium in E-AR-mediated vasodilatation. The observation 
that the enhancement of the isoprenaline concentration curve caused by 
PD98059 persisted in endothelium-denuded arteries suggests that the 
enhancement does not involve endothelium-derived factors. Again, further 
repeat experiments would be required to test this proposal.  
 
